U.S. patent application number 15/272820 was filed with the patent office on 2017-03-30 for n-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-y- l)-1,3-thiazol-4-yl] amides.
This patent application is currently assigned to Pfizer Inc.. The applicant listed for this patent is Pfizer Inc.. Invention is credited to Michael Aaron Brodney, Christopher Ryan Butler, Brian Thomas O'Neill, Romelia del Carmen Salomon Ferrer, Patrick Robert Verhoest, Lei Zhang.
Application Number | 20170088547 15/272820 |
Document ID | / |
Family ID | 56979617 |
Filed Date | 2017-03-30 |
United States Patent
Application |
20170088547 |
Kind Code |
A1 |
Brodney; Michael Aaron ; et
al. |
March 30, 2017 |
N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-Y-
L)-1,3-THIAZOL-4-YL] AMIDES
Abstract
The present invention is directed to compounds, tautomers and
pharmaceutically acceptable salts of the compounds which are
disclosed, wherein the compounds have the structure of Formula I,
##STR00001## wherein the variables R.sup.1, R.sup.2 and R.sup.3 are
as defined in the specification. Corresponding pharmaceutical
compositions, methods of treatment, methods of synthesis, and
intermediates are also disclosed.
Inventors: |
Brodney; Michael Aaron;
(Newton, MA) ; Butler; Christopher Ryan; (Canton,
MA) ; Zhang; Lei; (Auburndale, MA) ; O'Neill;
Brian Thomas; (Haddam, CT) ; Verhoest; Patrick
Robert; (Newton, MA) ; Salomon Ferrer; Romelia del
Carmen; (San Deigo, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Pfizer Inc. |
New York |
NY |
US |
|
|
Assignee: |
Pfizer Inc.
New York
NY
|
Family ID: |
56979617 |
Appl. No.: |
15/272820 |
Filed: |
September 22, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62222986 |
Sep 24, 2015 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 25/28 20180101;
A61P 3/10 20180101; C07D 417/14 20130101; A61P 43/00 20180101 |
International
Class: |
C07D 417/14 20060101
C07D417/14 |
Claims
1. A compound of Formula I ##STR00042## wherein R.sup.1 is a 5- to
6-membered heteroaryl, having one to four heteroatoms independently
selected from N, O or S, wherein at least one of the heteroatoms is
N and wherein said N is optionally substituted with R.sup.5; and
wherein said 5- to 6-membered heteroaryl is optionally substituted
on carbon with one to three R.sup.4; R.sup.2 and R.sup.3 are each
independently hydrogen, C.sub.1-6alkyl, C.sub.3-6cycloalkyl or 3-
to 7-membered heterocycloalkyl; wherein the C.sub.1-6alkyl is
optionally substituted with a C.sub.1-3alkoxy or with one to three
fluoro; and the C.sub.3-6cycloalkyl and 3- to 7-membered
heterocycloalkyl are each optionally and independently substituted
with one to three fluoro, C.sub.1-3alkyl or C.sub.1-3alkoxy; or
R.sup.2 and R.sup.3, taken together with the carbon to which they
are attached, form a C.sub.3-6cycloalkyl ring or 3- to 7-membered
heterocycloalkyl ring, each of which is optionally and
independently substituted with one to three fluoro, C.sub.1-3alkyl
or C.sub.1-3alkoxy; R.sup.4 at each occurrence is independently
selected from the group consisting of halo, hydroxy, cyano,
C.sub.1-6alkyl, C.sub.1-6alkoxy, C.sub.3-6alkenyl,
C.sub.3-6alkenyloxy, C.sub.3-6alkynyl, C.sub.3-6alkynyloxy,
C.sub.1-6alkoxy-C.sub.1-6alkyl, C.sub.3-6cycloalkoxy,
C.sub.3-6cycloalkyl, C.sub.3-6cycloalkyl-C.sub.1-6alkyl,
C.sub.3-6cycloalkyl-C.sub.1-6alkoxy, 4- to 6-membered
heterocycloalkyl and 4- to 6-membered
heterocycloalkyl-C.sub.1-6alkyl; wherein said C.sub.1-6alkyl,
C.sub.1-6alkoxy, C.sub.3-6alkenyl, C.sub.3-6alkenyloxy,
C.sub.3-6alkynyl, C.sub.3-6alkynyloxy,
C.sub.1-6alkoxy-C.sub.1-6alkyl, C.sub.3-6cycloalkoxy,
C.sub.3-6cycloalkyl, C.sub.3-6cycloalkyl-C.sub.1-6alkyl,
C.sub.3-6cycloalkyl-C.sub.1-6alkoxy, 4- to 6-membered
heterocycloalkyl and 4- to 6-membered
heterocycloalkyl-C.sub.1-6alkyl are each optionally substituted
with one to three substituents independently selected from fluoro,
chloro, hydroxy, cyano, methyl, fluoromethyl, difluoromethyl,
trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy and
trifluoromethoxy; and R.sup.5 is hydrogen or C.sub.1-6alkyl
optionally substituted with one to three fluoro; or a tautomer
thereof or a pharmaceutically acceptable salt of said compound or
tautomer.
2. The compound of claim 1 of Formula Ia ##STR00043## or a tautomer
thereof or a pharmaceutically acceptable salt of said compound or
tautomer.
3. The compound of claim 1 of Formula Ib ##STR00044## or a tautomer
thereof or a pharmaceutically acceptable salt of said compound or
tautomer.
4. The compound of claim 1 wherein R.sup.1 is pyrazolyl substituted
with R.sup.5; or oxazolyl, pyridinyl or pyrazinyl substituted with
one or two R.sup.4; or a tautomer thereof or a pharmaceutically
acceptable salt of said compound or tautomer.
5. The compound of claim 4 wherein R.sup.4 at each occurrence is
independently selected from the group consisting of halo, cyano,
C.sub.1-3alkyl optionally substituted with one to three fluoro,
C.sub.1-3alkoxy optionally substituted with one to three fluoro,
and C.sub.3-4alkynyloxy; R.sup.5 is C.sub.1-3alkyl optionally
substituted with one to three fluoro; or a tautomer thereof or a
pharmaceutically acceptable salt of said compound or tautomer.
6. The compound of claim 5 wherein R.sup.1 is
1-(difluoromethyl)-1H-pyrazol-3-yl,
2-(fluoromethyl)-1,3-oxazol-4-yl, 5-(difluoromethoxy)-pyridin-2-yl,
5-(difluoromethoxy)-3-methylpyridin-2-yl,
3-chloro-5-(difluoromethoxy)pyridin-2-yl, 5-cyanopyridin-2-yl,
5-cyano-3-methylpyridin-2-yl, 3-chloro-5-cyanopyridin-2-yl,
5-(but-2-yn-1-yloxy)pyridin-2-yl, 5-fluoromethyl)pyrazin-2-yl,
5-(difluoromethyl)pyrazin-2-yl, 5-(2,2-difluoropropoxy)pyrazin-2-yl
or 5-(but-2-yn-1-yloxy)pyrazin-2-yl; or a tautomer thereof or a
pharmaceutically acceptable salt of said compound or tautomer.
7. The compound of claim 6 wherein R.sup.2 and R.sup.3 are each
hydrogen; or a tautomer thereof or a pharmaceutically acceptable
salt of said compound or tautomer.
8. The compound of claim 6 wherein R.sup.2 and R.sup.3 are each
methyl; or a tautomer thereof or a pharmaceutically acceptable salt
of said compound or tautomer.
9. The compound of claim 6 wherein one of R.sup.2 and R.sup.3 is
hydrogen and the other is methyl, ethyl, cyclopropyl,
1-methylcyclopropyl or 2,2-dimethylcyclopropyl; or a tautomer
thereof or a pharmaceutically acceptable salt of said compound or
tautomer.
10. The compound of claim 6 wherein R.sup.2 and R.sup.3, taken
together with the carbon to which they are attached, form a
cyclopropyl, cyclobutyl or cyclopentyl ring; or a tautomer thereof
or a pharmaceutically acceptable salt of said compound or
tautomer.
11. The compound of claim 1 wherein R.sup.2 and R.sup.3 are each
hydrogen; or a tautomer thereof or a pharmaceutically acceptable
salt of said compound or tautomer.
12. The compound of claim 1 wherein R.sup.2 and R.sup.3 are each
methyl; or a tautomer thereof or a pharmaceutically acceptable salt
of said compound or tautomer.
13. The compound of claim 1 wherein one of R.sup.2 and R.sup.3 is
hydrogen and the other is methyl, ethyl, cyclopropyl,
1-methylcyclopropyl or 2,2-dimethylcyclopropyl; or a tautomer
thereof or a pharmaceutically acceptable salt of said compound or
tautomer.
14. The compound of claim 1 wherein R.sup.2 and R.sup.3, taken
together with the carbon to which they are attached, form a
cyclopropyl, cyclobutyl or cyclopentyl ring; or a tautomer thereof
or a pharmaceutically acceptable salt of said compound or
tautomer.
15. The compound of claim 1 selected from the group consisting of
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide;
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-1-(difluoromethyl)-1H-pyrazole-3-carboxamide;
N-{2-[(5R,6S)-3-amino-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro--
2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2--
carboxamide;
N-{2-[(5S,6R)-3-amino-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro--
2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2--
carboxamide;
N-{2-[(5S,6S)-3-amino-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro--
2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2--
carboxamide;
N-[2-(3-amino-2,5,6,6-tetramethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadi-
azin-5-yl)-1,3-thiazol-4-yl]-5-(difluoromethoxy)pyridine-2-carboxamide;
N-{2-[(5R)-3-amino-2,5,6,6-tetramethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-t-
hiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamid-
e;
N-{2-[(5S)-3-amino-2,5,6,6-tetramethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-
-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxam-
ide;
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thia-
diazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)-3-methylpyridine-2-carb-
oxamide;
N-{2-[(5R,6S)-3-amino-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2H--
1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-car-
boxamide;
N-{2-[(5S,6R)-3-amino-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2H-
-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-ca-
rboxamide;
N-{2-[(5S,6S)-3-amino-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2-
H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-c-
arboxamide;
N-{2-[(5R,6R)-3-amino-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-th-
iadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide-
;
N-{2-[(5R,6S)-3-amino-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,-
2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carbo-
xamide;
N-{2-[(5S,6R)-3-amino-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro-
-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-
-carboxamide;
N-{2-[(5R,6R)-3-amino-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2-
,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carbox-
amide;
N-{2-[(5S,6S)-3-amino-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro--
2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2--
carboxamide;
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethyl)pyrazine-2-carboxamide;
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-chloropyridine-2-carboxamide;
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-2-(fluoromethyl)-1,3-oxazole-4-carboxamide;
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-(2,2-difluoropropoxy)pyrazine-2-carboxamide;
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-(but-2-yn-1-yloxy)pyrazine-2-carboxamide;
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-(but-2-yn-1-yloxy)pyridine-2-carboxamide;
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-3-chloro-5-(difluoromethoxy)pyridine-2-carboxam-
ide;
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thia-
diazin-5-yl]-1,3-thiazol-4-yl}-5-cyanopyridine-2-carboxamide;
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-cyano-3-methylpyridine-2-carboxamide;
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-3-chloro-5-cyanopyridine-2-carboxamide;
N-(2-{(5S,6R)-3-amino-6-[(1R)-2,2-dimethylcyclopropyl]-2,5-dimethyl-1,1-d-
ioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl}-1,3-thiazol-4-yl)-5-(difluoro-
methoxy)-3-methylpyridine-2-carboxamide;
N-{2-[(5S,6R)-3-amino-2,5-dimethyl-6-(1-methylcyclopropyl)-1,1-dioxido-5,-
6-dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)p-
yridine-2-carboxamide; N-{2-[(8S)-6-amino-5,
8-dimethyl-4,4-dioxido-4-thia-5,
7-diazaspiro[2.5]oct-6-en-8-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)
pyridine-2-carboxamide;
N-{2-[(9S)-7-amino-6,9-dimethyl-5,5-dioxido-5-thia-6,8-diazaspiro[3.5]non-
-7-en-9-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)
pyridine-2-carboxamide; and N-{2-[(1
OS)-8-amino-7,10-dimethyl-6,6-dioxido-6-thia-7,9-iazaspiro[4.5]dec-8-en-1-
0-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide;
or a tautomer thereof or a pharmaceutically acceptable salt of said
compound or tautomer.
16. The compound
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide;
or a tautomer thereof or a pharmaceutically acceptable salt of said
compound or tautomer.
17. The compound
N-{2-[(5S,6S)-3-amino-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro)-
pyridine-2-carboxamide; or a tautomer thereof or a pharmaceutically
acceptable salt of said compound or tautomer.
18. The compound
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)-3-methylpyridine-2-carboxam-
ide; or a tautomer thereof or a pharmaceutically acceptable salt of
said compound or tautomer.
19. A pharmaceutical composition comprising a therapeutically
effective amount of a compound according to claim 1, or a tautomer
thereof or a pharmaceutically acceptable salt of said compound or
tautomer together with a pharmaceutically acceptable carrier.
20. A method of inhibiting production of amyloid-p protein,
inhibiting beta-site amyloid precursor protein cleaving enzyme 1
(BACE1), treating Alzheimer's disease or treating er Type 2
diabetes in a patient, the method comprising administering a
therapeutically effective amount of a compound according to claim
1, or a tautomer thereof or a pharmaceutically acceptable salt of
said compound or tautomer, to a patient in need of inhibition of
production of amyloid-.beta. protein, inhibition of beta-site
amyloid precursor protein cleaving enzyme 1 (BACE1), treatment of
Alzheimer's disease or treatment of Type 2 diabetes.
21.-22. (canceled)
23. The method of claim 20 wherein Alzheimer's disease is
treated.
24. (canceled)
25. The method of claim 20 wherein Type 2 diabetes is treated.
26.-31. (canceled)
32. The method of claim 20 wherein production of amyloid-.beta.
protein is inhibited.
33. The method of claim 20 wherein beta-site amyloid precursor
protein cleaving enzyme 1 (BACE1) is inhibited.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to small molecule compounds
and pharmaceutically acceptable salts thereof that are inhibitors
of .beta.-site amyloid precursor protein (APP) Cleaving Enzyme 1
(BACE1) and inhibitors of BACE2. This invention relates to
inhibiting the production of A-beta peptides that can contribute to
the formation of neurological deposits of amyloid protein. The
present invention also relates to the treatment of Alzheimer's
disease (AD) and other neurodegenerative and/or neurological
disorders, as well as the treatment of diabetes in mammals,
including humans. More particularly, this invention relates to
cyclic sulfonyl guanidine compounds and pharmaceutically acceptable
salts thereof useful for the treatment of neurodegenerative and/or
neurological disorders, such as AD and Down's syndrome, related to
A-beta peptide production.
BACKGROUND OF THE INVENTION
[0002] Dementia results from a wide variety of distinctive
pathological processes. The most common pathological processes
causing dementia are Alzheimer's disease ("AD"), cerebral amyloid
angiopathy ("CM") and prion-mediated diseases (see, e.g., Haan et
al., Clin. Neurol. Neurosurg., 1990, 92(4):305-310; Glenner et al.,
J. Neurol. Sci., 1989, 94:1-28). AD is a progressive,
neurodegenerative disorder characterized by memory impairment and
cognitive dysfunction. AD affects nearly half of all people past
the age of 85, the most rapidly growing portion of the United
States population. As such, the number of AD patients in the United
States is expected to increase from about 4 million to about 14
million by 2050.
[0003] The accumulation of amyloid-.beta. (A.beta. peptides) is
believed to be one of the underlying causes of Alzheimer's disease
(AD), which is the most common cause of cognitive decline in the
elderly (Hardy & Allsop, Trends Pharmacol Sci., 1991;
12(10):383-8; Selkoe, Behav. Brain Res., 2008; 192(1):106-13).
A.beta., the major protein constituent of amyloid plaques, is
derived from sequential cleavage of the type I integral membrane
protein, amyloid precursor protein (APP) by two proteases, .beta.-
and .gamma.-secretase. Proteolytic cleavage of APP by the
.beta.-site APP cleaving enzymes (BACE1 and BACE2) generates a
soluble N-terminal ectodomain of APP (sAPP.beta.) and the
C-terminal fragment C99. Subsequent cleavage of the membrane-bound
C99 fragment by the .gamma.-secretase liberates the various A.beta.
peptide species, of which A.beta.40 and A.beta.42 are the most
predominant forms (Vassar et al., J. Neurosci., 2009;
29(41):12787-94; Marks & Berg, Neurochem. Res., 2010;
35:181-210). Therefore, limiting the generation of A.beta. directly
through inhibition of BACE1 is one of the most attractive
approaches for the treatment of AD, as BACE1 inhibitors could
effectively inhibit the formation of all predominant A.beta.
peptides.
[0004] In addition, it has been determined that BACE1 knock-out
mice had markedly enhanced clearance of axonal and myelin debris
from degenerated fibers, accelerated axonal regeneration, and
earlier reinnervation of neuromuscular junctions compared with
littermate controls. These data suggest BACE1 inhibition as a
therapeutic approach to accelerate regeneration and recovery after
peripheral nerve damage. (See Farah et al., J. Neurosci., 2011,
31(15): 5744-5754).
[0005] Insulin resistance and impaired glucose homeostasis are
important indicators of Type 2 diabetes and are early risk factors
of AD. In particular, there is a higher risk of sporadic AD in
patients with Type 2 diabetes and AD patients are more prone to
Type 2 diabetes (Butler, Diabetes, 53:474-481, 2004.). Recently, it
has also been proposed that AD should be reconsidered as Type 3
diabetes (de la Monte, J. Diabetes Sci. Technol., 2008;
2(6):1101-1113). Of special interest is the fact that AD and Type 2
diabetes share common pathogenic mechanisms and possibly treatments
(Park S. A., J. Clin. Neurol., 2011; 7:10-18; Raffa, Br. J. Clin.
Pharmacol 2011, 71(3):365-376). Elevated plasma levels of A.beta.,
the product of BACE activities, were recently associated with
hyperglycemia and obesity in humans (see Meakin et al., Biochem J.,
2012, 441(1):285-96.; Martins, Journal of Alzheimer's Disease, 8
(2005) 269-282). Moreover, increased A.beta. production prompts the
onset of glucose intolerance and insulin resistance in mice
(Cozar-Castellano, Am. J. Physiol. Endocrinol. Metab.,
302:E1373-E1380, 2012; Delibegovic, Diabetologia (2011)
54:2143-2151). Finally, it is also suggested that circulating
A.beta. could participate in the development of atherosclerosis in
both humans and mice (De Meyer, Atherosclerosis 216 (2011) 54-58;
Catapano, Atherosclerosis 210 (2010) 78-87; Roher, Biochimica et
Biophysica Acta 1812 (2011) 1508-1514).
[0006] Therefore, it is believed that BACE1 levels may play a
critical role in glucose and lipid homeostasis in conditions of
chronic nutrient excess. Specifically, BACE1 inhibitors may be
potentially useful for increasing insulin sensitivity in skeletal
muscle and liver as illustrated by the fact that reduction in BACE1
decreases body weight, protects against diet-induced obesity and
enhances insulin sensitivity in mice (see Meakin et al., Biochem.
J. 2012, 441(1):285-96). Of equal interest is the identification of
LRP1 as a BACE1 substrate and the potential link to atherosclerosis
(Strickland, Physiol. Rev., 88: 887-918, 2008; Hyman, J. Biol.
Chem., Vol. 280, No. 18, 17777-17785, 2005).
[0007] Likewise, inhibition of BACE2 is proposed as a treatment of
Type 2 diabetes with the potential to preserve and restore
.beta.-cell mass and stimulate insulin secretion in pre-diabetic
and diabetic patients (WO2011/020806). BACE2 is a .beta.-cell
enriched protease that regulates pancreatic .beta. cell function
and mass and is a close homologue of BACE1. Pharmacological
inhibition of BACE2 increases .beta.-cell mass and function,
leading to the stabilization of Tmem27. (See Esterhazy et al., Cell
Metabolism 2011, 14(3): 365-377). It is suggested that BACE2
inhibitors are useful in the treatment and/or prevention of
diseases associated with the inhibition of BACE2 (e.g., Type 2
diabetes, with the potential to preserve and restore .beta.-cell
mass and stimulate insulin secretion in pre-diabetic and diabetic
patients) (WO2011/020806).
[0008] Aminodihydrothiazine or thioamidine compounds are described
in US2009/0082560, WO 2009/091016 and WO 2010/038686 as useful
inhibitors of the .beta.-secretase enzyme. Fused heterocyclic
compounds useful as inhibitors of the .beta.-secretase enzyme are
also described in WO 2011071109 and corresponding US 2012245155.
Co-pending PCT application, PCT/IB2012/054198, filed by Pfizer Inc
on Aug. 17, 2012, also describes aminodihydrothiazine compounds
that are useful inhibitors of the .beta.-secretase enzyme. The
present invention is directed to novel cyclic sulfonyl guanidine
compounds and their use in the treatment of neurodegenerative
diseases, including AD, as well as the treatment of metabolic
diseases and conditions such as diabetes and obesity.
SUMMARY OF THE INVENTION
[0009] A first embodiment of a first aspect of the present
invention is a compound of Formula I
##STR00002##
wherein
[0010] R.sup.1 is a 5- to 6-membered heteroaryl, having one to four
heteroatoms independently selected from N, O or S, wherein at least
one of the heteroatoms is N and wherein said N is optionally
substituted with R.sup.5; and wherein said 5- to 6-membered
heteroaryl is optionally substituted on carbon with one to three
R.sup.4;
[0011] R.sup.2 and R.sup.3 are each independently hydrogen,
C.sub.1-6alkyl, C.sub.3-6cycloalkyl or 3- to 7-membered
heterocycloalkyl; wherein the C.sub.1-6alkyl is optionally
substituted with a C.sub.1-3alkoxy or with one to three fluoro; and
the C.sub.3-6cycloalkyl and 3- to 7-membered heterocycloalkyl are
each optionally and independently substituted with one to three
fluoro, C.sub.1-3alkyl or C.sub.1-3alkoxy;
[0012] or R.sup.2 and R.sup.3, taken together with the carbon to
which they are attached, form a C.sub.3-6cycloalkyl ring or 3- to
7-membered heterocycloalkyl ring, each of which is optionally and
independently substituted with one to three fluoro, C.sub.1-3alkyl
or C.sub.1-3alkoxy;
[0013] R.sup.4 at each occurrence is independently selected from
the group consisting of halo, hydroxy, cyano, C.sub.1-6alkyl,
C.sub.1-6alkoxy, C.sub.3-6alkenyl, C.sub.3-6alkenyloxy,
C.sub.3-6alkynyl, C.sub.3-6alkynyloxy,
C.sub.1-6alkoxy-C.sub.1-6alkyl, C.sub.3-6cycloalkoxy,
C.sub.3-6cycloalkyl, C.sub.3-6cycloalkyl-C.sub.1-6alkyl,
C.sub.3-6cycloalkyl-C.sub.1-6alkoxy, 4- to 6-membered
heterocycloalkyl and 4- to 6-membered
heterocycloalkyl-C.sub.1-6alkyl; wherein said C.sub.1-6alkyl,
C.sub.1-6alkoxy, C.sub.3-6alkenyl, C.sub.3-6alkenyloxy,
C.sub.3-6alkynyl, C.sub.3-6alkynyloxy,
C.sub.1-6alkoxy-C.sub.1-6alkyl, C.sub.3-6cycloalkoxy,
C.sub.3-6cycloalkyl, C.sub.3-6cycloalkyl-C.sub.1-6alkyl,
C.sub.3-6cycloalkyl-C.sub.1-6alkoxy, 4- to 6-membered
heterocycloalkyl and 4- to 6-membered
heterocycloalkyl-C.sub.1-6alkyl are each optionally substituted
with one to three substituents independently selected from fluoro,
chloro, hydroxy, cyano, methyl, fluoromethyl, difluoromethyl,
trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy and
trifluoromethoxy; and
[0014] R.sup.5 is hydrogen or C.sub.1-6alkyl optionally substituted
with one to three fluoro;
[0015] or a tautomer thereof or a pharmaceutically acceptable salt
of said compound or tautomer.
[0016] Another embodiment of the present invention is a
pharmaceutical composition comprising compounds of Formula I, or a
tautomer thereof or a pharmaceutically acceptable salt of said
compound or tautomer, and a pharmaceutically acceptable vehicle,
diluent or carrier. The pharmaceutical compositions described
herein can be used for inhibiting production of amyloid-.beta.
protein and for inhibiting beta-site amyloid precursor protein
cleaving enzyme 1 (BACE1); for treating a neurodegenerative disease
and, in particular, Alzheimer's disease; for inhibiting BACE1
and/or BACE2 activity for the therapeutic and/or prophylactic
treatment of diseases and disorders characterized by elevated
.beta.-amyloid levels, including diabetes or Type 2 diabetes; for
increasing insulin sensitivity in skeletal muscle and liver in a
mammal, including humans; and for treating and/or preventing
obesity.
[0017] The present invention is also directed to methods of
treatment employing the compounds of Formula I such as:
[0018] (1) Methods of inhibiting BACE enzyme activity, by
administering a therapeutically effective amount of a compound of
any of the embodiments of Formula I or a pharmaceutically
acceptable salt thereof, and a pharmaceutically acceptable carrier,
to a mammal or a patient in need thereof.
[0019] (2) Methods for treating conditions or diseases of the
central nervous system and neurological disorders in which the
.beta.-secretase enzyme is involved (such as migraine; epilepsy;
Alzheimer's disease; Parkinson's disease; brain injury; stroke;
cerebrovascular diseases (including cerebral arteriosclerosis,
cerebral amyloid angiopathy, hereditary cerebral hemorrhage, and
brain hypoxia-ischemia); cognitive disorders (including amnesia,
senile dementia, HIV-associated dementia, Alzheimer's disease,
Huntington's disease, Lewy body dementia, vascular dementia,
drug-related dementia, tardive dyskinesia, myoclonus, dystonia,
delirium, Pick's disease, Creutzfeldt-Jacob disease, HIV disease,
Gilles de la Tourette's syndrome, epilepsy, muscular spasms and
disorders associated with muscular spasticity or weakness including
tremors, and mild cognitive impairment ("MCI"); mental deficiency
(including spasticity, Down syndrome and fragile X syndrome); sleep
disorders (including hypersomnia, circadian rhythm sleep disorder,
insomnia, parasomnia, and sleep deprivation) and psychiatric
disorders such as anxiety (including acute stress disorder,
generalized anxiety disorder, social anxiety disorder, panic
disorder, post-traumatic stress disorder, agoraphobia, and
obsessive-compulsive disorder); factitious disorder (including
acute hallucinatory mania); impulse control disorders (including
compulsive gambling and intermittent explosive disorder); mood
disorders (including bipolar I disorder, bipolar II disorder,
mania, mixed affective state, major depression, chronic depression,
seasonal depression, psychotic depression, seasonal depression,
premenstrual syndrome (PMS), premenstrual dysphoric disorder (PDD),
and postpartum depression); psychomotor disorder; psychotic
disorders (including schizophrenia, schizoaffective disorder,
schizophreniform, and delusional disorder); drug dependence
(including narcotic dependence, alcoholism, amphetamine dependence,
cocaine addiction, nicotine dependence, and drug withdrawal
syndrome); eating disorders (including anorexia, bulimia, binge
eating disorder, hyperphagia, obesity, compulsive eating disorders
and pagophagia); sexual dysfunction disorders; urinary
incontinence; neuronal damage disorders (including ocular damage,
retinopathy or macular degeneration of the eye, tinnitus, hearing
impairment and loss, and brain edema), nerve injury treatment
(including accelerating regeneration and recovery after peripheral
nerve damage) and pediatric psychiatric disorders (including
attention deficit disorder, attention deficit/hyperactive disorder,
conduct disorder, and autism) in a mammal, preferably a human,
comprising administering to said mammal a therapeutically effective
amount of a compound of Formula I or pharmaceutically acceptable
salt thereof. The compounds of Formula I may also be useful for
improving memory (both short-term and long-term) and learning
ability. The text revision of the fourth edition of the Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV-TR) (2000,
American Psychiatric Association, Washington, D.C.) provides a
diagnostic tool for identifying many of the disorders described
herein. The skilled artisan will recognize that there are
alternative nomenclatures, nosologies, and classification systems
for disorders described herein, including those as described in the
DMS-IV-TR, and that terminology and classification systems evolve
with medical scientific progress;
[0020] (3) Methods for treating a neurological disorder (such as
migraine; epilepsy; Alzheimer's disease; Parkinson's disease;
Niemann-Pick type C; brain injury; stroke; cerebrovascular disease;
cognitive disorder; sleep disorder) or a psychiatric disorder (such
as anxiety; factitious disorder; impulse control disorder; mood
disorder; psychomotor disorder; psychotic disorder; drug
dependence; eating disorder; and pediatric psychiatric disorder) in
a mammal, preferably a human, comprising administering to said
mammal a therapeutically effective amount of a compound of Formula
I or pharmaceutically acceptable salt thereof;
[0021] (4) Methods for the treatment (e.g., delaying the
progression or onset) of diabetes or diabetes-related disorders
including Type 1 and Type 2 diabetes, impaired glucose tolerance,
insulin resistance, hyperglycemia, and diabetic complications such
as atherosclerosis, coronary heart disease, stroke, peripheral
vascular disease, nephropathy, hypertension, neuropathy, and
retinopathy;
[0022] (5) Methods for the treatment of obesity co-morbidities,
such as metabolic syndrome. Metabolic syndrome includes diseases,
conditions or disorders such as dyslipidemia, hypertension, insulin
resistance, diabetes (e.g., Type 2 diabetes), coronary artery
disease and heart failure. For more detailed information on
metabolic syndrome, see, e.g., Zimmet, P. Z. et al., "The Metabolic
Syndrome: Perhaps an Etiologic Mystery but Far From a Myth--Where
Does the International Diabetes Federation Stand?," Medscape
Diabetes & Endocrinology, 7(2), (2005); and Alberti, K. G. et
al., "The Metabolic Syndrome--A New Worldwide Definition," Lancet,
366, 1059-62 (2005); and
[0023] (6) Methods for the treatment of nonalcoholic fatty liver
disease (NAFLD) and hepatic insulin resistance;
[0024] The present invention is also directed to combination
therapies wherein the compounds of this invention may also be used
in conjunction with other pharmaceutical agents for the treatment
of the diseases, conditions and/or disorders described herein.
Therefore, methods of treatment that include administering
compounds of the present invention in combination with other
pharmaceutical agents are also provided;
[0025] All patents, patent applications and references referred to
herein are hereby incorporated by reference in their entirety.
[0026] Other features and advantages of this invention will be
apparent from this specification and the appendant claims which
describe the invention. It is to be understood that both the
foregoing and the following detailed description are exemplary only
and are not restrictive of the invention as claimed.
DETAILED DESCRIPTION OF THE INVENTION
[0027] The present invention may be understood more readily by
reference to the following detailed description of exemplary
embodiments of the invention and the examples included therein. It
is to be understood that this invention is not limited to specific
methods of synthesis, which may of course vary. It is also to be
understood that the terminology used herein is for the purpose of
describing particular embodiments only and is not intended to be
limiting.
[0028] In this specification and in the claims that follow,
reference will be made to a number of terms that shall be defined
to have the following meanings:
[0029] As used herein, "eating disorders" refer to illnesses in
which the patient suffers disturbances in his/her eating behaviors
and related thoughts and emotions. Representative examples of
obesity-related eating disorders include overeating, bulimia,
binge-eating disorder, compulsive dieting, nocturnal sleep-related
eating disorder, pica, Prader-Willi syndrome, and night-eating
syndrome.
[0030] "Patient" refers to warm-blooded animals such as, for
example, guinea pigs, mice, rats, gerbils, cats, rabbits, dogs,
cattle, goats, sheep, horses, monkeys, chimpanzees, and humans.
[0031] The term "pharmaceutically acceptable" means the substance
or composition must be compatible, chemically and/or
toxicologically, with the other ingredients comprising a
formulation, and/or the mammal being treated therewith.
[0032] The term "therapeutically effective amount" means an amount
of a compound of the present invention that (i) treats or prevents
the particular disease, condition, or disorder, (ii) attenuates,
ameliorates, or eliminates one or more symptoms of the particular
disease, condition, or disorder, or (iii) prevents or delays the
onset of one or more symptoms of the particular disease, condition,
or disorder described herein.
[0033] The term "treating", as used herein, unless otherwise
indicated, means reversing, alleviating, inhibiting the progress
of, delaying the progression of, delaying the onset of, or
preventing the disorder or condition to which such term applies, or
one or more symptoms of such disorder or condition. The term
"treatment", as used herein, unless otherwise indicated, refers to
the act of treating as "treating" is defined immediately above. The
term "treating" also includes adjuvant and neo-adjuvant treatment
of a subject. For the avoidance of doubt, reference herein to
"treatment" includes reference to curative, palliative and
prophylactic treatment, and to the administration of a medicament
for use in such treatment.
[0034] The term "alkyl" refers to a linear or branched-chain
saturated hydrocarbyl substituent (i.e., a substituent obtained
from a hydrocarbon by removal of a hydrogen); in one embodiment
containing from one to six carbon atoms. Non-limiting examples of
such substituents include methyl, ethyl, propyl (including n-propyl
and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl and
tert-butyl), pentyl, isoamyl, hexyl and the like.
[0035] The term "alkoxy" refers to a linear or branched-chain
saturated hydrocarbyl substituent attached to an oxygen radical
(i.e., a substituent obtained from a hydrocarbon alcohol by removal
of the hydrogen from the OH); in one embodiment containing from one
to six carbon atoms. Non-limiting examples of such substituents
include methoxy, ethoxy, propoxy (including n-propoxy and
isopropoxy), butoxy (including n-butoxy, isobutoxy, sec-butoxy and
tert-butoxy), pentoxy, hexoxy and the like.
[0036] The term "alkenyl" refers to a linear or branched-chain
hydrocarbyl substituent (i.e., a substituent obtained from a
hydrocarbon by removal of a hydrogen) which contains at least one
carbon-carbon double bond; in one embodiment containing from three
to six carbon atoms. Non-limiting examples of such substituents
include allyl, propenyl, butenyl, isobutenyl, butadienyl, pentenyl,
pentadienyl, hexenyl, hexadienyl and the like. The term
"alkenyloxy" refers to an alkenyl group attached to an oxygen
radical.
[0037] The term "alkynyl" refers to a linear or branched-chain
hydrocarbyl substituent (i.e., a substituent obtained from a
hydrocarbon by removal of a hydrogen) which contains at least one
carbon-carbon triple bond; in one embodiment containing from three
to six carbon atoms. Non-limiting examples of such substituents
include propynyl, butynyl, isobutynyl, pentynyl, hexynyl and the
like. The term "alkynyloxy" refers to an alkynyl group attached to
an oxygen radical.
[0038] The term "alkylene" refers to an alkanediyl group (i.e. a
substituent obtained from a hydrocarbon by removal of two
hydrogens); in one embodiment containing from three to five
carbons. Non-limiting examples of such groups include propylene,
butylene and pentylene.
[0039] In some instances, the number of carbon atoms in a
hydrocarbyl substituent (i.e., alkyl, cycloalkyl, etc.) is
indicated by the prefix "C.sub.x-C.sub.y-" or "C.sub.x-y", wherein
x is the minimum and y is the maximum number of carbon atoms in the
substituent. Thus, for example, "C.sub.1-C.sub.6-alkyl" or
"C.sub.1-6 alkyl" refers to an alkyl substituent containing from 1
to 6 carbon atoms. Illustrating further, C.sub.3-C.sub.6cycloalkyl
or C.sub.3-6-cycloalkyl refers to saturated cycloalkyl group
containing from 3 to 6 carbon ring atoms.
[0040] The term "cycloalkyl" refers to a carbocyclic substituent
obtained by removing a hydrogen from a saturated carbocyclic
molecule, for example one having three to six carbon atoms or
having three to nine carbon atoms. The term "cycloalkyl" includes
mono-, bi- and tricyclic saturated carbocycles, as well as bridged
and fused ring carbocycles and also spiro-fused carbocyclic ring
systems. The term "C.sub.3-9cycloalkyl" means a radical of a three-
to nine-membered ring system, which includes the groups
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
cyclooctyl, cyclononyl, bicyclopentyl, bicyclohexyl, bicycloheptyl,
bicyclooctyl, bicyclononyl, spiropentyl, spirohexyl, spiroheptyl,
spirooctyl and spirononyl. The term "C.sub.3-6cycloalkyl" means a
radical of a three- to six-membered ring system, which includes the
groups cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
bicyclopentyl, bicyclohexyl, spiropentyl and spirohexyl. The term
"C.sub.3-6cycloalkoxy" refers to a three- to six-membered
cycloalkyl group attached to an oxygen radical. Examples include
cyclopropoxy, cyclobutoxy, cyclopentoxy and cyclohexoxy.
[0041] In some instances, the number of atoms in a cyclic
substituent containing one or more heteroatoms (i.e., heteroaryl or
heterocycloalkyl) is indicated by the prefix "x- to y-membered",
wherein x is the minimum and y is the maximum number of atoms
forming the cyclic moiety of the substituent. Thus, for example,
"4- to 6-membered heterocycloalkyl" refers to a heterocycloalkyl
containing from 4 to 6 atoms, including one to three heteroatoms,
in the cyclic moiety of the heterocycloalkyl. Likewise the phrase
"5- to 6-membered heteroaryl" refers to a heteroaryl containing
from 5 to 6 atoms, and "5- to 10-membered heteroaryl" refers to a
heteroaryl containing from 5 to 10 atoms, each including one or
more heteroatoms, in the cyclic moiety of the heteroaryl.
Furthermore the phases "5-membered heteroaryl" and "6-membered
heteroaryl" refer to a five-membered heteroaromatic ring system and
a six-membered heteroaromatic ring system, respectively. The
heteroatoms present in these ring systems are selected from N, O
and S.
[0042] The term "hydroxy" or "hydroxyl" refers to --OH. When used
in combination with another term(s), the prefix "hydroxy" indicates
that the substituent to which the prefix is attached is substituted
with one or more hydroxy substituents. Compounds bearing a carbon
to which one or more hydroxy substituents include, for example,
alcohols, enols and phenol.
[0043] The term "halo" or "halogen" refers to fluorine (which may
be depicted as --F), chlorine (which may be depicted as --Cl),
bromine (which may be depicted as --Br), or iodine (which may be
depicted as --I).
[0044] The term "heterocycloalkyl" refers to a substituent obtained
by removing a hydrogen from a saturated or partially saturated ring
structure containing a total of the specified number of atoms, such
as 4 to 6 ring atoms, wherein at least one of the ring atoms is a
heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining
ring atoms being independently selected from the group consisting
of carbon, oxygen, nitrogen, and sulfur. In a group that has a
heterocycloalkyl substituent, the ring atom of the heterocycloalkyl
substituent that is bound to the group may be a nitrogen
heteroatom, or it may be a ring carbon atom. Similarly, if the
heterocycloalkyl substituent is in turn substituted with a group or
substituent, the group or substituent may be bound to a nitrogen
heteroatom, or it may be bound to a ring carbon atom.
[0045] The term "heteroaryl" refers to an aromatic ring structure
containing the specified number of ring atoms in which at least one
of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or
sulfur), with the remaining ring atoms being independently selected
from the group consisting of carbon, oxygen, nitrogen, and sulfur.
Examples of heteroaryl substituents include 6-membered heteroaryl
substituents such as pyridyl, pyrazyl, pyrimidinyl, and
pyridazinyl; and 5-membered heteroaryl substituents such as
triazolyl, imidazolyl, furanyl, thiophenyl, pyrazolyl, pyrrolyl,
oxazolyl, isoxazolyl, thiazolyl, 1,2,3-, 1,2,4-, 1,2,5-, or
1,3,4-oxadiazolyl and isothiazolyl. The heteroaryl group can also
be a bicyclic heteroaromatic group such as indolyl, benzofuranyl,
benzothienyl, benzimidazolyl, benzothiazolyl, benzoxazolyl,
benzoisoxazolyl, oxazolopyridinyl, imidazopyridinyl,
imidazopyrimidinyl and the like. In a group that has a heteroaryl
substituent, the ring atom of the heteroaryl substituent that is
bound to the group may be a ring nitrogen atom, or it may be a ring
carbon atom. Similarly, if the heteroaryl substituent is in turn
substituted with a group or substituent, the group or substituent
may be bound to a ring nitrogen atom, or it may be bound to a ring
carbon atom. The term "heteroaryl" also includes pyridyl N-oxides
and groups containing a pyridine N-oxide ring. In addition, the
heteroaryl group may contain an oxo group such as the one present
in a pyridone group. Further examples include furyl, thienyl,
oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl,
isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl,
pyridazinyl, pyrimidinyl, pyrazinyl, pyridin-2(1H)-onyl,
pyridazin-2(1H)-onyl, pyrimidin-2(1H)-onyl, pyrazin-2(1H)-onyl,
imidazo[1,2-a]pyridinyl, and pyrazolo[1,5-a]pyridinyl. The
heteroaryl can be further substituted as defined herein.
[0046] Examples of single-ring heteroaryls and heterocycloalkyls
include furanyl, dihydrofuranyl, tetrahydrofuranyl, thiophenyl,
dihydrothiophenyl, tetrahydrothiophenyl, pyrrolyl, isopyrrolyl,
pyrrolinyl, pyrrolidinyl, imidazolyl, isoimidazolyl, imidazolinyl,
imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, triazolyl,
tetrazolyl, dithiolyl, oxathiolyl, oxazolyl, isoxazolyl, thiazolyl,
isothiazolyl, thiazolinyl, isothiazolinyl, thiazolidinyl,
isothiazolidinyl, thiaoxadiazolyl, oxathiazolyl, oxadiazolyl
(including oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, or
1,3,4-oxadiazolyl), pyranyl (including 1,2-pyranyl or 1,4-pyranyl),
dihydropyranyl, pyridinyl, piperidinyl, diazinyl (including
pyridazinyl, pyrimidinyl, piperazinyl, triazinyl (including
s-triazinyl, as-triazinyl and v-triazinyl), oxazinyl (including
2H-1,2-oxazinyl, 6H-1,3-oxazinyl, or 2H-1,4-oxazinyl), isoxazinyl
(including o-isoxazinyl or p-isoxazinyl), oxazolidinyl,
isoxazolidinyl, oxathiazinyl (including 1,2,5-oxathiazinyl or
1,2,6-oxathiazinyl), oxadiazinyl (including 2H-1,2,4-oxadiazinyl or
2H-1,2,5-oxadiazinyl), morpholinyl.
[0047] The term "heteroaryl" can also include, when specified as
such, ring systems having two rings wherein such rings may be fused
and wherein one ring is aromatic and the other ring is not fully
part of the conjugated aromatic system (i.e., the heteroaromatic
ring can be fused to a cycloalkyl or heterocycloalkyl ring).
Non-limiting examples of such ring systems include
5,6,7,8-tetrahydroisoquinolinyl, 5,6,7,8-tetrahydroquinolinyl,
6,7-dihydro-5H-cyclopenta[b]pyridinyl,
6,7-dihydro-5H-cyclopenta[c]pyridinyl,
1,4,5,6-tetrahydrocyclopenta[c]pyrazolyl,
2,4,5,6-tetrahydrocyclopenta[c]pyrazolyl,
5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl,
6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazolyl,
5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridinyl,
4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl,
4,5,6,7-tetrahydro-1H-indazolyl and
4,5,6,7-tetrahydro-2H-indazolyl. It is to be understood that if a
carbocyclic or heterocyclic moiety may be bonded or otherwise
attached to a designated substrate through differing ring atoms
without denoting a specific point of attachment, then all possible
points are intended, whether through a carbon atom or, for example,
a trivalent nitrogen atom. For example, the term "pyridyl" means
2-, 3- or 4-pyridyl, the term "thienyl" means 2- or 3-thienyl, and
so forth.
[0048] If substituents are described as "independently" having more
than one variable, each instance of a substituent is selected
independent of the other(s) from the list of variables available.
Each substituent therefore may be identical to or different from
the other substituent(s).
[0049] If substituents are described as being "independently
selected" from a group, each instance of a substituent is selected
independent of the other(s). Each substituent therefore may be
identical to or different from the other substituent(s).
[0050] As used herein, the term "Formula I" may be hereinafter
referred to as a "compound(s) of the invention," "the present
invention," and "compound of Formula I." Such terms are also
defined to include all forms of the compound of Formula I,
including hydrates, solvates, isomers, crystalline and
non-crystalline forms, isomorphs, polymorphs, and metabolites
thereof. For example, the compounds of the invention, or
pharmaceutically acceptable salts thereof, may exist in unsolvated
and solvated forms. When the solvent or water is tightly bound, the
complex will have a well-defined stoichiometry independent of
humidity. When, however, the solvent or water is weakly bound, as
in channel solvates and hygroscopic compounds, the water/solvent
content will be dependent on humidity and drying conditions. In
such cases, non-stoichiometry will be the norm.
[0051] The compounds of the invention may exist as clathrates or
other complexes. Included within the scope of the invention are
complexes such as clathrates, drug-host inclusion complexes wherein
the drug and host are present in stoichiometric or
non-stoichiometric amounts. Also included are complexes of the
compounds of the invention containing two or more organic and/or
inorganic components, which may be in stoichiometric or
non-stoichiometric amounts. The resulting complexes may be ionized,
partially ionized, or non-ionized. For a review of such complexes,
see J. Pharm. Sci., 64 (8), 1269-1288 by Haleblian (August
1975).
[0052] The compounds of the invention have asymmetric carbon atoms.
The carbon-carbon bonds of the compounds of the invention may be
depicted herein using a solid line (), a solid wedge (), or a
dotted wedge (). The use of a solid line to depict bonds to
asymmetric carbon atoms is meant to indicate that all possible
stereoisomers (e.g., specific enantiomers, racemic mixtures, etc.)
at that carbon atom are included. The use of either a solid or
dotted wedge to depict bonds to asymmetric carbon atoms is meant to
indicate that only the stereoisomer shown is meant to be included.
It is possible that compounds of Formula I may contain more than
one asymmetric carbon atom. In those compounds, the use of a solid
line to depict bonds to asymmetric carbon atoms is meant to
indicate that all possible stereoisomers are meant to be included.
For example, unless stated otherwise, it is intended that the
compounds of Formula I can exist as enantiomers and diastereomers
or as racemates and mixtures thereof. The use of a solid line to
depict bonds to one or more asymmetric carbon atoms in a compound
of Formula I and the use of a solid or dotted wedge to depict bonds
to other asymmetric carbon atoms in the same compound is meant to
indicate that a mixture of diastereomers is present.
[0053] Stereoisomers of Formula I include cis and trans isomers,
optical isomers such as R and S enantiomers, diastereomers,
geometric isomers, rotational isomers, conformational isomers, and
tautomers of the compounds of the invention, including compounds
exhibiting more than one type of isomerism; and mixtures thereof
(such as racemates and diastereomeric pairs). Also included are
acid addition or base addition salts wherein the counterion is
optically active, for example, D-lactate or L-lysine, or racemic,
for example, DL-tartrate or DL-arginine.
[0054] When any racemate crystallizes, crystals of two different
types are possible. The first type is the racemic compound (true
racemate) referred to above wherein one homogeneous form of crystal
is produced containing both enantiomers in equimolar amounts. The
second type is the racemic mixture or conglomerate wherein two
forms of crystal are produced in equimolar amounts each comprising
a single enantiomer.
[0055] The compounds of Formula I may exhibit the phenomenon of
tautomerism; such tautomers are also regarded as compounds of the
invention. For example, the compounds of Formula I may exist in
several tautomeric forms, including the
3-amino-2-methyl-5,6-dihydro-2H-1,2,4-thiadiazine 1,1-dioxide form
I, and the 3-imino-2-methyl-1,2,4-thiadiazinane 1,1-dioxide form
I'. All such tautomeric forms, and mixtures thereof, are included
within the scope of compounds of Formula I. Tautomers exist as
mixtures of a tautomeric set in solution. In solid form, usually
one tautomer predominates. Even though one tautomer may be
described, the present invention includes all tautomers of the
compounds of Formula I and salts thereof. Examples of tautomers are
described by the compounds of Formula I and I' and, collectively
and generically, are referred to as compounds of Formula I.
##STR00003##
[0056] The compounds of this invention may be used in the form of
salts derived from inorganic or organic acids. Depending on the
particular compound, a salt of the compound may be advantageous due
to one or more of the salt's physical properties, such as enhanced
pharmaceutical stability in differing temperatures and humidities,
or a desirable solubility in water or oil. In some instances, a
salt of a compound also may be used as an aid in the isolation,
purification, and/or resolution of the compound.
[0057] Where a salt is intended to be administered to a patient (as
opposed to, for example, being used in an in vitro context), the
salt preferably is pharmaceutically acceptable. The term
"pharmaceutically acceptable salt" refers to a salt prepared by
combining a compound of Formula I with an acid whose anion, or a
base whose cation, is generally considered suitable for human
consumption. Pharmaceutically acceptable salts are particularly
useful as products of the methods of the present invention because
of their greater aqueous solubility relative to the parent
compound. For use in medicine, the salts of the compounds of this
invention are non-toxic "pharmaceutically acceptable salts." Salts
encompassed within the term "pharmaceutically acceptable salts"
refer to non-toxic salts of the compounds of this invention which
are generally prepared by reacting the free base with a suitable
organic or inorganic acid.
[0058] Suitable pharmaceutically acceptable acid addition salts of
the compounds of the present invention, when possible, include
those derived from inorganic acids, such as hydrochloric,
hydrobromic, hydrofluoric, boric, fluoroboric, phosphoric,
metaphosphoric, nitric, carbonic, sulfonic, and sulfuric acids, and
organic acids such as acetic, benzenesulfonic, benzoic, citric,
ethanesulfonic, fumaric, gluconic, glycolic, isothionic, lactic,
lactobionic, maleic, malic, methanesulfonic,
trifluoromethanesulfonic, succinic, toluenesulfonic, tartaric, and
trifluoroacetic acids. Suitable organic acids generally include,
for example, aliphatic, cycloaliphatic, aromatic, araliphatic,
heterocyclic, carboxylic, and sulfonic classes of organic
acids.
[0059] Specific examples of suitable organic acids include acetate,
trifluoroacetate, formate, propionate, succinate, glycolate,
gluconate, digluconate, lactate, malate, tartaric acid, citrate,
ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate,
glutamate, benzoate, anthranilate, stearate, salicylate,
.beta.-hydroxybenzoate, phenylacetate, mandelate, embonate
(pamoate), methanesulfonate, ethanesulfonate, benzenesulfonate,
pantothenate, toluenesulfonate, 2-hydroxyethanesulfonate,
sufanilate, cyclohexylaminosulfonate, algenic acid,
.beta.-hydroxybutyric acid, galactarate, galacturonate, adipate,
alginate, butyrate, camphorate, camphorsulfonate,
cyclopentanepropionate, dodecylsulfate, glycoheptanoate,
glycerophosphate, heptanoate, hexanoate, nicotinate,
2-naphthalesulfonate, oxalate, palmoate, pectinate,
3-phenylpropionate, picrate, pivalate, thiocyanate, and
undecanoate.
[0060] Furthermore, where the compounds of the invention carry an
acidic moiety, suitable pharmaceutically acceptable salts thereof
may include the lighter alkali metal salts, i.e., sodium or
potassium salts; alkaline earth metal salts, e.g., calcium or
magnesium salts; and salts formed with suitable organic ligands,
e.g., quaternary ammonium salts. In another embodiment, base salts
are formed from bases which form non-toxic salts, including
aluminum, arginine, benzathine, choline, diethylamine, diolamine,
glycine, lysine, meglumine, olamine, tromethamine and zinc
salts.
[0061] Organic salts may be made from secondary, tertiary or
quaternary amine salts, such as tromethamine, diethylamine,
N,N'-dibenzylethylenediamine, chloroprocaine, choline,
diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and
procaine. Basic nitrogen-containing groups may be quaternized with
agents such as lower alkyl (C.sub.1-C.sub.6) halides (e.g., methyl,
ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl
sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates),
long chain halides (e.g., decyl, lauryl, myristyl, and stearyl
chlorides, bromides, and iodides), arylalkyl halides (e.g., benzyl
and phenethyl bromides), and others.
[0062] In one embodiment, hemisalts of acids and bases may also be
formed, for example, hemisulfate and hemicalcium salts.
[0063] Also within the scope of the present invention are so-called
"prodrugs" of the compound of the invention. Thus, certain
derivatives of the compound of the invention which may have little
or no pharmacological activity themselves can, when administered
into or onto the body, be converted into the compound of the
invention having the desired activity, for example, by hydrolytic
cleavage. Such derivatives are referred to as "prodrugs." Further
information on the use of prodrugs may be found in "Pro-drugs as
Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi
and V. Stella) and "Bioreversible Carriers in Drug Design,"
Pergamon Press, 1987 (ed. E. B. Roche, American Pharmaceutical
Association). Prodrugs in accordance with the invention can, for
example, be produced by replacing appropriate functionalities
present in the compounds of any of Formula I with certain moieties
known to those skilled in the art as "pro-moieties" as described,
for example, in "Design of Prodrugs" by H. Bundgaard (Elsevier,
1985).
[0064] The present invention also includes isotopically labeled
compounds, which are identical to those recited in Formula I, but
for the fact that one or more atoms are replaced by an atom having
an atomic mass or mass number different from the atomic mass or
mass number usually found in nature. Examples of isotopes that can
be incorporated into compounds of the present invention include
isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine
and chlorine, such as .sup.2H, .sup.3H, .sup.13C, .sup.11C,
.sup.14C, .sup.15N, .sup.18O, .sup.17O, .sup.32P, .sup.35S,
.sup.18F, and .sup.36Cl, respectively. Compounds of the present
invention, prodrugs thereof, and pharmaceutically acceptable salts
of said compounds or of said prodrugs that contain the
aforementioned isotopes and/or other isotopes of other atoms are
within the scope of this invention. Certain isotopically labeled
compounds of the present invention, for example those into which
radioactive isotopes such as .sup.3H and .sup.14C are incorporated,
are useful in drug and/or substrate tissue distribution assays.
Tritiated, i.e., .sup.3H, and carbon-14, i.e., .sup.14C, isotopes
are particularly preferred for their ease of preparation and
detectability. Further, substitution with heavier isotopes such as
deuterium, i.e., .sup.2H, can afford certain therapeutic advantages
resulting from greater metabolic stability, for example increased
in vivo half-life or reduced dosage requirements and, hence, may be
preferred in some circumstances. Isotopically labeled compounds of
Formula I of this invention and prodrugs thereof can generally be
prepared by carrying out the procedures disclosed in the Schemes
and/or in the Examples and Preparations below, by substituting a
readily available isotopically labeled reagent for a
non-isotopically labeled reagent.
[0065] A second embodiment of a first aspect of the present
invention is the compound of the first embodiment of the first
aspect of Formula Ia
##STR00004##
or a tautomer thereof or a pharmaceutically acceptable salt of said
compound or tautomer.
[0066] A third embodiment of a first aspect of the present
invention is the compound of the first embodiment of the first
aspect of Formula Ib
##STR00005##
or a tautomer thereof or a pharmaceutically acceptable salt of said
compound or tautomer.
[0067] A fourth embodiment of a first aspect of the present
invention is the compound of any one of the first through third
embodiments of the first aspect wherein R.sup.1 is pyrazolyl
substituted with R.sup.5; or oxazolyl, pyridinyl or pyrazinyl
substituted with one or two R.sup.4; or a tautomer thereof or a
pharmaceutically acceptable salt of said compound or tautomer.
[0068] A fifth embodiment of the first aspect of the present
invention is the compound of the fourth embodiment of the first
aspect wherein R.sup.4 at each occurrence is independently selected
from the group consisting of halo, cyano, C.sub.1-3alkyl optionally
substituted with one to three fluoro, C.sub.1-3alkoxy optionally
substituted with one to three fluoro, and C.sub.3-4alkynyloxy;
R.sup.5 is C.sub.1-3alkyl optionally substituted with one to three
fluoro; or a tautomer thereof or a pharmaceutically acceptable salt
of said compound or tautomer.
[0069] A sixth embodiment of the first aspect of the present
invention is the compound of the fifth embodiment of the first
aspect wherein R.sup.1 is 1-(difluoromethyl)-1H-pyrazol-3-yl,
2-(fluoromethyl)-1,3-oxazol-4-yl, 5-(difluoromethoxy)-pyridin-2-yl,
5-(difluoromethoxy)-3-methylpyridin-2-yl,
3-chloro-5-(difluoromethoxy)pyridin-2-yl, 5-cyanopyridin-2-yl,
5-cyano-3-methylpyridin-2-yl, 3-chloro-5-cyanopyridin-2-yl,
5-(but-2-yn-1-yloxy)pyridin-2-yl, 5-(fluoromethyl)pyrazin-2-yl,
5-(difluoromethyl)pyrazin-2-yl, 5-(2,2-difluoropropoxy)pyrazin-2-yl
or 5-(but-2-yn-1-yloxy)pyrazin-2-yl; or a tautomer thereof or a
pharmaceutically acceptable salt of said compound or tautomer.
[0070] A seventh embodiment of a first aspect of the present
invention is the compound of the sixth embodiment of the first
aspect wherein R.sup.2 and R.sup.3 are each hydrogen; or a tautomer
thereof or a pharmaceutically acceptable salt of said compound or
tautomer.
[0071] An eighth embodiment of a first aspect of the present
invention is the compound of the sixth embodiment wherein R.sup.2
and R.sup.3 are each methyl; or a tautomer thereof or a
pharmaceutically acceptable salt of said compound or tautomer.
[0072] A ninth embodiment of a first aspect of the present
invention is the compound of the sixth embodiment of the first
aspect wherein one of R.sup.2 and R.sup.3 is hydrogen and the other
is methyl, ethyl, cyclopropyl, 1-methylcyclopropyl or
2,2-dimethylcyclopropyl; or a tautomer thereof or a
pharmaceutically acceptable salt of said compound or tautomer.
[0073] A tenth embodiment of a first aspect of the present
invention is the compound of the sixth embodiment of the first
aspect wherein R.sup.2 and R.sup.3, taken together with the carbon
to which they are attached, form a cyclopropyl, cyclobutyl or
cyclopentyl ring; or a tautomer thereof or a pharmaceutically
acceptable salt of said compound or tautomer.
[0074] An eleventh embodiment of a first aspect of the present
invention is the compound of any one of the first through third
embodiments of the first embodiment wherein R.sup.2 and R.sup.3 are
each hydrogen; or a tautomer thereof or a pharmaceutically
acceptable salt of said compound or tautomer.
[0075] A twelfth embodiment of a first aspect of the present
invention is the compound of any one of the first through third
embodiments of the first aspect wherein R.sup.2 and R.sup.3 are
each methyl; or a tautomer thereof or a pharmaceutically acceptable
salt of said compound or tautomer.
[0076] A thirteenth embodiment of a first aspect of the present
invention is the compound of any one of the first through third
embodiments of the first aspect wherein one of R.sup.2 and R.sup.3
is hydrogen and the other is methyl, ethyl, cyclopropyl,
1-methylcyclopropyl or 2,2-dimethylcyclopropyl; or a tautomer
thereof or a pharmaceutically acceptable salt of said compound or
tautomer.
[0077] A fourteenth embodiment of a first aspect of the present
invention is the compound of any one of the first through third
embodiments of the first aspect wherein R.sup.2 and R.sup.3, taken
together with the carbon to which they are attached, form a
cyclopropyl, cyclobutyl or cyclopentyl ring; or a tautomer thereof
or a pharmaceutically acceptable salt of said compound or
tautomer.
[0078] A fifteenth embodiment of a first aspect of the present
invention is the compound of the first embodiment of the first
aspect selected from the group consisting of [0079]
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide;
[0080]
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-t-
hiadiazin-5-yl]-1,3-thiazol-4-yl}-1-(difluoromethyl)-1H-pyrazole-3-carboxa-
mide; [0081]
N-{2-[(5R,6S)-3-amino-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro--
2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2--
carboxamide; [0082]
N-{2-[(5S,6R)-3-amino-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro--
2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2--
carboxamide; [0083]
N-{2-[(5S,6S)-3-amino-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro--
2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2--
carboxamide; [0084]
N-[2-(3-amino-2,5,6,6-tetramethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadi-
azin-5-yl)-1,3-thiazol-4-yl]-5-(difluoromethoxy)pyridine-2-carboxamide;
[0085]
N-{2-[(5R)-3-amino-2,5,6,6-tetramethyl-1,1-dioxido-5,6-dihydro-2H--
1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-car-
boxamide; [0086]
N-{2-[(5S)-3-amino-2,5,6,6-tetramethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-t-
hiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamid-
e; [0087]
N-{2-[(5S)-3-amino-2,5-dimethyl-1-dioxido-5,6-dihydro-2H-1,2,4-t-
hiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)-3-methylpyridine-2-c-
arboxamide; [0088]
N-{2-[(5R,6S)-3-amino-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-th-
iadiazin-5-yl]-1,
3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide; [0089]
N-{2-[(5S,6R)-3-amino-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-th-
iadiazin-5-yl]-1,
3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide; [0090]
N-{2-[(5S,6S)-3-amino-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-th-
iadiazin-5-yl]-1,
3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide; [0091]
N-{2-[(5R,6R)-3-amino-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-th-
iadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide-
; [0092]
N-{2-[(5R,6S)-3-amino-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihydr-
o-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine--
2-carboxamide; [0093]
N-{2-[(5S,6R)-3-amino-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2-
,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carbox-
amide; [0094]
N-{2-[(5R,6R)-3-amino-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2-
,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carbox-
amide; [0095]
N-{2-[(5S,6S)-3-amino-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2-
,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carbox-
amide; [0096]
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethyl)pyrazine-2-carboxamide;
[0097]
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-t-
hiadiazin-5-yl]-1,3-thiazol-4-yl}-5-chloropyridine-2-carboxamide;
[0098]
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-2-(fluoromethyl)-1,3-oxazole-4-carboxamide;
[0099]
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-t-
hiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(2,2-difluoropropoxy)pyrazine-2-carbox-
amide; [0100]
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-(but-2-yn-1-yloxy)pyrazine-2-carboxamide;
[0101]
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-t-
hiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(but-2-yn-1-yloxy)pyridine-2-carboxami-
de; [0102]
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,-
4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-3-chloro-5-(difluoromethoxy)pyridine--
2-carboxamide; [0103]
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-cyanopyridine-2-carboxamide; [0104]
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-cyano-3-methylpyridine-2-carboxamide;
[0105]
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-3-chloro-5-cyanopyridine-2-carboxamide;
or a tautomer thereof or a pharmaceutically acceptable salt of said
compound or tautomer.
[0106] A sixteenth embodiment of a first aspect of the present
invention is the compound
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide;
or a tautomer thereof or a pharmaceutically acceptable salt of said
compound or tautomer.
[0107] A seventeenth embodiment of a first aspect of the present
invention is the compound
N-{2-[(5S,6S)-3-amino-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro)-
pyridine-2-carboxamide; or a tautomer thereof or a pharmaceutically
acceptable salt of said compound or tautomer.
[0108] An eighteenth embodiment of a first aspect of the present
invention is the compound
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)-3-methylpyridine-2-carboxam-
ide; or a tautomer thereof or a pharmaceutically acceptable salt of
said compound or tautomer.
[0109] A first embodiment of a second aspect of the present
invention is a pharmaceutical composition comprising a
therapeutically effective amount of a compound according to any one
of the first through eighteenth embodiments of the first aspect, or
a tautomer thereof or a pharmaceutically acceptable salt of said
compound or tautomer together with a pharmaceutically acceptable
carrier.
[0110] Further embodiments of the present invention include methods
of treatment employing the compounds of the present invention.
[0111] A first embodiment of a third aspect of the present
invention is a method of inhibiting production of amyloid-.beta.
protein in a patient, the method comprising administering a
therapeutically effective amount of a compound according to any one
of the first through eighteenth embodiments of the first aspect, or
a tautomer thereof or a pharmaceutically acceptable salt of said
compound or tautomer, to a patient in need of inhibition of
production of amyloid-.beta. protein.
[0112] A second embodiment of a third aspect of the present
invention is a method of inhibiting beta-site amyloid precursor
protein cleaving enzyme 1 (BACE1) in a patient, the method
comprising administering a therapeutically effective amount of a
compound according to any one of the first through eighteenth
embodiments of the first aspect, or a tautomer thereof or a
pharmaceutically acceptable salt of said compound or tautomer, to a
patient in need of inhibition of beta-site amyloid precursor
protein cleaving enzyme 1 (BACE1).
[0113] A third embodiment of a third aspect of the present
invention is a method for treating a neurodegenerative disease in a
patient, the method comprising administering a therapeutically
effective amount of a compound according to any one of the first
through eighteenth embodiments of the first aspect, or a tautomer
thereof or a pharmaceutically acceptable salt of said compound or
tautomer, to a patient in need of treatment thereof.
[0114] A fourth embodiment of a third aspect of the present
invention is the method of the third embodiment of the third aspect
wherein the neurodegenerative disease is Alzheimer's disease.
[0115] A fifth embodiment of a third aspect of the present
invention is a method of treating or preventing diabetes in a
patient, the method comprising administering a therapeutically
effective amount of a compound according to any one of the first
through eighteenth embodiments of the first aspect, or a tautomer
thereof or a pharmaceutically acceptable salt of said compound or
tautomer, to a patient in need of treatment or prevention
thereof.
[0116] A sixth embodiment of a third aspect of the present
invention is the method of the fifth embodiment of the third aspect
wherein the diabetes is Type 2 diabetes.
[0117] Further embodiments of the present invention include the use
of a compound according to any one of first through eighteenth
embodiments of the first aspect of the present invention in the
preparation of a medicament useful for treating the conditions,
diseases and disorders as described herein.
[0118] Typically, a compound of the invention is administered in an
amount effective to treat a condition as described herein. The
compounds of the invention are administered by any suitable route
in the form of a pharmaceutical composition adapted to such a
route, and in a dose effective for the treatment intended.
Therapeutically effective doses of the compounds required to treat
the progress of the medical condition are readily ascertained by
one of ordinary skill in the art using preclinical and clinical
approaches familiar to the medicinal arts.
[0119] The compounds of the invention may be administered orally.
Oral administration may involve swallowing, so that the compound
enters the gastrointestinal tract, or buccal or sublingual
administration may be employed, by which the compound enters the
blood stream directly from the mouth.
[0120] In another embodiment, the compounds of the invention may
also be administered directly into the blood stream, into muscle,
or into an internal organ. Suitable means for parenteral
administration include intravenous, intraarterial, intraperitoneal,
intrathecal, intraventricular, intraurethral, intrasternal,
intracranial, intramuscular and subcutaneous. Suitable devices for
parenteral administration include needle (including microneedle)
injectors, needle-free injectors and infusion techniques.
[0121] In another embodiment, the compounds of the invention may
also be administered topically to the skin or mucosa, that is,
dermally or transdermally. In another embodiment, the compounds of
the invention can also be administered intranasally or by
inhalation. In another embodiment, the compounds of the invention
may be administered rectally or vaginally. In another embodiment,
the compounds of the invention may also be administered directly to
the eye or ear.
[0122] The dosage regimen for the compounds and/or compositions
containing the compounds is based on a variety of factors,
including the type, age, weight, sex and medical condition of the
patient; the severity of the condition; the route of
administration; and the activity of the particular compound
employed. Thus the dosage regimen may vary widely. Dosage levels of
the order from about 0.01 mg to about 100 mg per kilogram of body
weight per day are useful in the treatment of the above-indicated
conditions. In one embodiment, the total daily dose of a compound
of the invention (administered in single or divided doses) is
typically from about 0.01 to about 100 mg/kg. In another
embodiment, total daily dose of the compound of the invention is
from about 0.1 to about 50 mg/kg, and in another embodiment, from
about 0.5 to about 30 mg/kg (i.e., mg compound of the invention per
kg body weight). In one embodiment, dosing is from 0.01 to 10
mg/kg/day. In another embodiment, dosing is from 0.1 to 1.0
mg/kg/day. Dosage unit compositions may contain such amounts or
submultiples thereof to make up the daily dose. In many instances,
the administration of the compound will be repeated a plurality of
times in a day (typically no greater than 4 times). Multiple doses
per day typically may be used to increase the total daily dose, if
desired.
[0123] For oral administration, the compositions may be provided in
the form of tablets containing from about 0.01 mg to about 500 mg
of the active ingredient, or in another embodiment, from about 1 mg
to about 100 mg of active ingredient. Intravenously, doses may
range from about 0.1 to about 10 mg/kg/minute during a constant
rate infusion.
[0124] Suitable subjects according to the present invention include
mammalian subjects. Mammals according to the present invention
include, but are not limited to, canine, feline, bovine, caprine,
equine, ovine, porcine, rodents, lagomorphs, primates, and the
like, and encompass mammals in utero. In one embodiment, humans are
suitable subjects. Human subjects may be of either gender and at
any stage of development.
[0125] In another embodiment, the invention comprises the use of
one or more compounds of the invention for the preparation of a
medicament for the treatment of the conditions recited herein.
[0126] For the treatment of the conditions referred to above, the
compound of the invention can be administered as compound per se.
Alternatively, pharmaceutically acceptable salts are suitable for
medical applications because of their greater aqueous solubility
relative to the parent compound.
[0127] In another embodiment, the present invention comprises
pharmaceutical compositions. Such pharmaceutical compositions
comprise a compound of the invention presented with a
pharmaceutically acceptable carrier. The carrier can be a solid, a
liquid, or both, and may be formulated with the compound as a
unit-dose composition, for example, a tablet, which can contain
from 0.05% to 95% by weight of the active compounds. A compound of
the invention may be coupled with suitable polymers as targetable
drug carriers. Other pharmacologically active substances can also
be present.
[0128] The compounds of the present invention may be administered
by any suitable route, preferably in the form of a pharmaceutical
composition adapted to such a route, and in a dose effective for
the treatment intended. The active compounds and compositions, for
example, may be administered orally, rectally, parenterally, or
topically.
[0129] Oral administration of a solid dose form may be, for
example, presented in discrete units, such as hard or soft
capsules, pills, cachets, lozenges, or tablets, each containing a
predetermined amount of at least one compound of the present
invention. In another embodiment, the oral administration may be in
a powder or granule form. In another embodiment, the oral dose form
is sub-lingual, such as, for example, a lozenge. In such solid
dosage forms, the compounds of Formula I are ordinarily combined
with one or more adjuvants. Such capsules or tablets may contain a
controlled-release formulation. In the case of capsules, tablets,
and pills, the dosage forms also may comprise buffering agents or
may be prepared with enteric coatings.
[0130] In another embodiment, oral administration may be in a
liquid dose form. Liquid dosage forms for oral administration
include, for example, pharmaceutically acceptable emulsions,
solutions, suspensions, syrups, and elixirs containing inert
diluents commonly used in the art (e.g., water). Such compositions
also may comprise adjuvants, such as wetting, emulsifying,
suspending, flavoring (e.g., sweetening), and/or perfuming
agents.
[0131] In another embodiment, the present invention comprises a
parenteral dose form. "Parenteral administration" includes, for
example, subcutaneous injections, intravenous injections,
intraperitoneal injections, intramuscular injections, intrasternal
injections, and infusion. Injectable preparations (e.g., sterile
injectable aqueous or oleaginous suspensions) may be formulated
according to the known art using suitable dispersing, wetting
agents, and/or suspending agents.
[0132] In another embodiment, the present invention comprises a
topical dose form. "Topical administration" includes, for example,
transdermal administration, such as via transdermal patches or
iontophoresis devices, intraocular administration, or intranasal or
inhalation administration. Compositions for topical administration
also include, for example, topical gels, sprays, ointments, and
creams. A topical formulation may include a compound which enhances
absorption or penetration of the active ingredient through the skin
or other affected areas. When the compounds of this invention are
administered by a transdermal device, administration will be
accomplished using a patch either of the reservoir and porous
membrane type or of a solid matrix variety. Typical formulations
for this purpose include gels, hydrogels, lotions, solutions,
creams, ointments, dusting powders, dressings, foams, films, skin
patches, wafers, implants, sponges, fibers, bandages and
microemulsions. Liposomes may also be used. Typical carriers
include alcohol, water, mineral oil, liquid petrolatum, white
petrolatum, glycerin, polyethylene glycol and propylene glycol.
Penetration enhancers may be incorporated; see, for example, J.
Pharm. Sci., 88 (10), 955-958, by Finnin and Morgan (October
1999).
[0133] Formulations suitable for topical administration to the eye
include, for example, eye drops wherein the compound of this
invention is dissolved or suspended in a suitable carrier. A
typical formulation suitable for ocular or aural administration may
be in the form of drops of a micronized suspension or solution in
isotonic, pH-adjusted, sterile saline. Other formulations suitable
for ocular and aural administration include ointments,
biodegradable (e.g., absorbable gel sponges, collagen) and
non-biodegradable (e.g., silicone) implants, wafers, lenses and
particulate or vesicular systems, such as niosomes or liposomes. A
polymer such as cross-linked polyacrylic acid, polyvinyl alcohol,
hyaluronic acid, a cellulosic polymer, for example,
hydroxypropylmethyl cellulose, hydroxyethyl cellulose, or methyl
cellulose, or a heteropolysaccharide polymer, for example, gelan
gum, may be incorporated together with a preservative, such as
benzalkonium chloride. Such formulations may also be delivered by
iontophoresis.
[0134] For intranasal administration or administration by
inhalation, the active compounds of the invention are conveniently
delivered in the form of a solution or suspension from a pump spray
container that is squeezed or pumped by the patient or as an
aerosol spray presentation from a pressurized container or a
nebulizer, with the use of a suitable propellant. Formulations
suitable for intranasal administration are typically administered
in the form of a dry powder (either alone, as a mixture, for
example, in a dry blend with lactose, or as a mixed component
particle, for example, mixed with phospholipids, such as
phosphatidylcholine) from a dry powder inhaler or as an aerosol
spray from a pressurized container, pump, spray, atomizer
(preferably an atomizer using electrohydrodynamics to produce a
fine mist), or nebulizer, with or without the use of a suitable
propellant, such as 1,1,1,2-tetrafluoroethane or
1,1,1,2,3,3,3-heptafluoropropane. For intranasal use, the powder
may comprise a bioadhesive agent, for example, chitosan or
cyclodextrin.
[0135] In another embodiment, the present invention comprises a
rectal dose form. Such rectal dose form may be in the form of, for
example, a suppository. Cocoa butter is a traditional suppository
base, but various alternatives may be used as appropriate.
[0136] Other carrier materials and modes of administration known in
the pharmaceutical art may also be used. Pharmaceutical
compositions of the invention may be prepared by any of the
well-known techniques of pharmacy, such as effective formulation
and administration procedures. The above considerations in regard
to effective formulations and administration procedures are well
known in the art and are described in standard textbooks.
Formulation of drugs is discussed in, for example, Hoover, John E.,
Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton,
Pa., 1975; Liberman et al., Eds., Pharmaceutical Dosage Forms,
Marcel Decker, New York, N.Y., 1980; and Kibbe et al., Eds.,
Handbook of Pharmaceutical Excipients (3.sup.rd Ed.), American
Pharmaceutical Association, Washington, 1999.
[0137] The compounds of the present invention can be used, alone or
in combination with other therapeutic agents, in the treatment of
various conditions or disease states. The compound(s) of the
present invention and other therapeutic agent(s) may be may be
administered simultaneously (either in the same dosage form or in
separate dosage forms) or sequentially.
[0138] Two or more compounds may be administered simultaneously,
concurrently or sequentially. Additionally, simultaneous
administration may be carried out by mixing the compounds prior to
administration or by administering the compounds at the same point
in time but at different anatomic sites or using different routes
of administration.
[0139] The phrases "concurrent administration,"
"co-administration," "simultaneous administration," and
"administered simultaneously" mean that the compounds are
administered in combination.
[0140] The present invention includes the use of a combination of a
BACE inhibitor compound as provided in Formula I and one or more
additional pharmaceutically active agent(s). If a combination of
active agents is administered, then they may be administered
sequentially or simultaneously, in separate dosage forms or
combined in a single dosage form. Accordingly, the present
invention also includes pharmaceutical compositions comprising an
amount of: (a) a first agent comprising a compound of Formula I or
a pharmaceutically acceptable salt of the compound; (b) a second
pharmaceutically active agent; and (c) a pharmaceutically
acceptable carrier, vehicle or diluent.
[0141] The compounds of this invention may also be used in
conjunction with other pharmaceutical agents for the treatment of
the diseases, conditions and/or disorders described herein.
Therefore, methods of treatment that include administering
compounds of the present invention in combination with other
pharmaceutical agents are also provided. Suitable pharmaceutical
agents that may be used in combination with the compounds of the
present invention include, without limitation: [0142] (i)
anti-obesity agents (including appetite suppressants), include
gut-selective MTP inhibitors (e.g., dirlotapide, mitratapide and
implitapide, CCKa agonists (e.g.,
N-benzyl-2-[4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-2,3,6,10b--
tetraaza-benzo[e]azulen-6-yl]-N-isopropyl-acetamide described in
PCT Publication No. WO 2005/116034 or US Publication No.
2005-0267100 A1), 5HT2c agonists (e.g., lorcaserin), MCR4 agonists
(e.g., compounds described in U.S. Pat. No. 6,818,658), lipase
inhibitors (e.g., Cetilistat), PYY.sub.3-36 (as used herein
"PYY.sub.3-36" includes analogs, such as peglated PYY.sub.3-36,
e.g., those described in US Publication 2006/0178501), opioid
antagonists (e.g., naltrexone), oleoyl-estrone (CAS No.
180003-17-2), obinepitide (TM30338), pramlintide (Symlin.RTM.),
tesofensine (NS2330), leptin, bromocriptine, orlistat, AOD-9604
(CAS No. 221231-10-3) and sibutramine. [0143] (ii) anti-diabetic
agents, such as an acetyl-CoA carboxylase (ACC) inhibitor as
described in WO2009144554, WO2003072197, WO2009144555 and
WO2008065508, a diacylglycerol O-acyltransferase 1 (DGAT-1)
inhibitor, such as those described in WO09016462 or WO2010086820,
AZD7687 or LCQ908, a diacylglycerol O-acyltransferase 2 (DGAT-2)
inhibitor, a monoacylglycerol O-acyltransferase inhibitor, a
phosphodiesterase (PDE)-10 inhibitor, an AMPK activator, a
sulfonylurea (e.g., acetohexamide, chlorpropamide, diabinese,
glibenclamide, glipizide, glyburide, glimepiride, gliclazide,
glipentide, gliquidone, glisolamide, tolazamide, and tolbutamide),
a meglitinide, an .alpha.-amylase inhibitor (e.g., tendamistat,
trestatin and AL-3688), an .alpha.-glucoside hydrolase inhibitor
(e.g., acarbose), an .alpha.-glucosidase inhibitor (e.g.,
adiposine, camiglibose, emiglitate, miglitol, voglibose,
pradimicin-Q, and salbostatin), a PPAR .gamma. agonist (e.g.,
balaglitazone, ciglitazone, darglitazone, englitazone,
isaglitazone, pioglitazone and rosiglitazone), a PPAR
.alpha./.gamma. agonist (e.g., CLX-0940, GW-1536, GW-1929, GW-2433,
KRP-297, L-796449, LR-90, MK-0767 and SB-219994), a biguanide
(e.g., metformin), a glucagon-like peptide 1 (GLP-1) modulator such
as an agonist (e.g., exendin-3 and exendin-4), liraglutide,
albiglutide, exenatide (Byetta.RTM.), albiglutide, taspoglutide,
lixisenatide, dulaglutide, semaglutide, NN-9924, TTP-054, a protein
tyrosine phosphatase-1B (PTP-1B) inhibitor (e.g., trodusquemine,
hyrtiosal extract, and compounds disclosed by Zhang, S. et al.,
Drug Discovery Today, 12(9/10), 373-381 (2007)), a SIRT-1 inhibitor
(e.g., resveratrol, GSK2245840 or GSK184072), a dipeptidyl
peptidase IV (DPP-IV) inhibitor (e.g., those in WO2005116014,
sitagliptin, vildagliptin, alogliptin, dutogliptin, linagliptin and
saxagliptin), an insulin secretagogue, a fatty acid oxidation
inhibitor, an A2 antagonist, a c-jun amino-terminal kinase (JNK)
inhibitor, a glucokinase activator (GKa) such as those described in
WO2010103437, WO2010103438, WO2010013161, WO2007122482, TTP-399,
TTP-355, TTP-547, AZD1656, ARRY403, MK-0599, TAK-329, AZD5658 or
GKM-001, insulin, an insulin mimetic, a glycogen phosphorylase
inhibitor (e.g., GSK1362885), a VPAC2 receptor agonist, an SGLT2
inhibitor, such as those described in E. C. Chao et al., Nature
Reviews Drug Discovery 9, 551-559 (July 2010) including
dapagliflozin, canagliflozin, BI-10733, tofogliflozin (CSG452),
ASP-1941, THR1474, TS-071, ISIS388626 and LX4211 as well as those
in WO2010023594, a glucagon receptor modulator such as those
described in Demong, D. E. et al., Annual Reports in Medicinal
Chemistry 2008, 43, 119-137, a GPR119 modulator, particularly an
agonist, such as those described in WO2010140092, WO2010128425,
WO2010128414, WO2010106457, Jones, R. M. et al., in Medicinal
Chemistry 2009, 44, 149-170 (e.g., MBX-2982, GSK1292263, APD597 and
PSN821), an FGF21 derivative or an analog such as those described
in Kharitonenkov, A. et al., Current Opinion in Investigational
Drugs 2009, 10(4), 359-364, TGR5 (also termed GPBAR1) receptor
modulators, particularly agonists, such as those described in
Zhong, M., Current Topics in Medicinal Chemistry, 2010, 10(4),
386-396 and INT777, a GPR40 agonist, such as those described in
Medina, J. C., Annual Reports in Medicinal Chemistry, 2008, 43,
75-85, including but not limited to TAK-875, a GPR120 modulator,
particularly an agonist, a high-affinity nicotinic acid receptor
(HM74A) activator, and an SGLT1 inhibitor, such as GSK1614235. A
further representative listing of anti-diabetic agents that can be
combined with the compounds of the present invention can be found,
for example, at page 28, line 35 through page 30, line 19 of
WO2011005611. Preferred anti-diabetic agents are metformin and
DPP-IV inhibitors (e.g., sitagliptin, vildagliptin, alogliptin,
dutogliptin, linagliptin and saxagliptin). Other antidiabetic
agents could include inhibitors or modulators of carnitine
palmitoyl transferase enzymes, inhibitors of fructose
1,6-diphosphatase, inhibitors of aldose reductase,
mineralocorticoid receptor inhibitors, inhibitors of TORC2,
inhibitors of CCR2 and/or CCR5, inhibitors of PKC isoforms (e.g.,
PKCa, PKCb, PKCg), inhibitors of fatty acid synthetase, inhibitors
of serine palmitoyl transferase, modulators of GPR81, GPR39, GPR43,
GPR41, GPR105, Kv1.3, retinol binding protein 4, glucocorticoid
receptor, somatostain receptors (e.g., SSTR1, SSTR2, SSTR3 and
SSTR5), inhibitors or modulators of PDHK2 or PDHK4, inhibitors of
MAP4K4, modulators of IL1 family including IL1beta, and modulators
of RXRalpha. In addition, suitable anti-diabetic agents include
mechanisms listed by Carpino, P. A., Goodwin, B. Expert Opin. Ther.
Pat, 2010, 20(12), 1627-51; [0144] (iii) anti-hyperglycemic agents,
for example, those described at page 31, line 31 through page 32,
line 18 of WO 2011005611; [0145] (iv) lipid lowering agents (for
example, those described at page 30, line 20 through page 31, line
30 of WO 2011005611), and anti-hypertensive agents (for example,
those described at page 31, line 31 through page 32, line 18 of WO
2011005611); [0146] (v) acetylcholinesterase inhibitors, such as
donepezil hydrochloride (ARICEPT.RTM., MEMAC), physostigmine
salicylate (ANTILIRIUM.RTM.), physostigmine sulfate (ESERINE),
ganstigmine, rivastigmine (EXELON.RTM.), ladostigil, NP-0361,
galantamine hydrobromide (RAZADYNE.RTM., REMINYL.RTM.,
NIVALIN.RTM.), tacrine (COGNEX.RTM.), tolserine, memoquin,
huperzine A (HUP-A; Neuro-Hitech), phenserine, bisnorcymserine
(also known as BNC), and INM-176; [0147] (vi) amyloid-.beta. (or
fragments thereof), such as A.beta..sub.1-15 conjugated to pan HLA
DR-binding epitope (PADRE.RTM.), ACC-001 (Elan/Wyeth), and
Affitope; [0148] (vii) antibodies to amyloid-.beta. (or fragments
thereof), such as ponezumab, solanezumab, bapineuzumab (also known
as AAB-001), AAB-002 (Wyeth/Elan), Gantenerumab, intravenous Ig
(GAMMAGARD.RTM.), LY2062430 (humanized m266; Lilly), and those
disclosed in International Patent Publication Nos WO04/032868,
WO05/025616, WO006/036291, WO006/069081, WO006/118959, in US Patent
Publication Nos US2003/0073655, US2004/0192898, US2005/0048049,
US2005/0019328, in European Patent Publication Nos EP0994728 and
1257584, and in U.S. Pat. No. 5,750,349; [0149] (viii)
amyloid-lowering or -inhibiting agents (including those that reduce
amyloid production, accumulation and fibrillization) such as
eprodisate (KIACTA.RTM.), celecoxib, lovastatin, anapsos,
colostrinin, pioglitazone, clioquinol (also known as PBT1), PBT2
(Prana Biotechnology), flurbiprofen (ANSAID.RTM., FROBEN.RTM.) and
its R-enantiomer tarenflurbil (FLURIZAN.RTM.), nitroflurbiprofen,
fenoprofen (FENOPRON, NALFON.RTM.), ibuprofen (ADVIL.RTM.,
MOTRIN.RTM., NUROFEN.RTM.), ibuprofen lysinate, meclofenamic acid,
meclofenamate sodium (MECLOMEN.RTM.), indomethacin (INDOCIN.RTM.),
diclofenac sodium (VOLTAREN.RTM.), diclofenac potassium, sulindac
(CLINORIL.RTM.), sulindac sulfide, diflunisal (DOLOBID.RTM.),
naproxen (NAPROSYN.RTM.), naproxen sodium (ANAPROX.RTM.,
ALEVE.RTM.), insulin-degrading enzyme (also known as insulysin),
the gingko biloba extract EGb-761 (ROKAN.RTM., TEBONIN.RTM.),
tramiprosate (CEREBRIL.RTM., ALZHEMED.RTM.), neprilysin (also known
as neutral endopeptidase (NEP)), scyllo-inositol (also known as
scyllitol), atorvastatin (LIPITOR.RTM.), simvastatin (ZOCOR.RTM.),
ibutamoren mesylate, BACE inhibitors such as LY450139 (Lilly),
BMS-782450, and GSK-188909; gamma secretase modulators and
inhibitors such as ELND-007, BMS-708163 (Avagacestat), and DSP8658
(Dainippon); and RAGE (receptor for advanced glycation
end-products) inhibitors, such as TTP488 (Transtech) and TTP4000
(Transtech), and those disclosed in U.S. Pat. No. 7,285,293,
including PTI-777; [0150] (ix) alpha-adrenergic receptor agonists,
and beta-adrenergic receptor blocking agents (beta blockers);
anticholinergics; anticonvulsants; antipsychotics; calcium channel
blockers; catechol O-methyltransferase (COMT) inhibitors; central
nervous system stimulants; corticosteroids; dopamine receptor
agonists and antagonists; dopamine reuptake inhibitors;
gamma-aminobutyric acid (GABA) receptor agonists;
immunosuppressants; interferons; muscarinic receptor agonists;
neuroprotective drugs; nicotinic receptor agonists; norepinephrine
(noradrenaline) reuptake inhibitors; quinolines; and trophic
factors; [0151] (x) histamine 3 (H3) antagonists, such as
PF-3654746 and those disclosed in US Patent Publication Nos
US2005-0043354, US2005-0267095, US2005-0256135, US2008-0096955,
US2007-1079175, and US2008-0176925; International Patent
Publication Nos WO2006/136924, WO2007/063385, WO2007/069053,
WO2007/088450, WO2007/099423, WO2007/105053, WO2007/138431, and
WO2007/088462; and U.S. Pat. No. 7,115,600); [0152] (xi)
N-methyl-D-aspartate (NMDA) receptor antagonists, such as memantine
(NAMENDA, AXURA, EBIXA), amantadine (SYMMETREL), acamprosate
(CAMPRAL), besonprodil, ketamine (KETALAR), delucemine,
dexanabinol, dexefaroxan, dextromethorphan, dextrorphan,
traxoprodil, CP-283097, himantane, idantadol, ipenoxazone, L-701252
(Merck), lancicemine, levorphanol (DROMORAN), methadone,
(DOLOPHINE), neramexane, perzinfotel, phencyclidine, tianeptine
(STABLON), dizocilpine (also known as MK-801), ibogaine,
voacangine, tiletamine, riluzole (RILUTEK), aptiganel (CERESTAT),
gavestinel, and remacimide; [0153] (xii) monoamine oxidase (MAO)
inhibitors, such as selegiline (EMSAM), selegiline hydrochloride
(l-deprenyl, ELDEPRYL, ZELAPAR), dimethylselegiline, brofaromine,
phenelzine (NARDIL), tranylcypromine (PARNATE), moclobemide
(AURORIX, MANERIX), befloxatone, safinamide, isocarboxazid
(MARPLAN), nialamide (NIAMID), rasagiline (AZILECT), iproniazide
(MARSILID, IPROZID, IPRONID), iproclozide, toloxatone (HUMORYL,
PERENUM), bifemelane, desoxypeganine, harmine (also known as
telepathine or banasterine), harmaline, linezolid (ZYVOX, ZYVOXID),
and pargyline (EUDATIN, SUPIRDYL); [0154] (xiii) phosphodiesterase
(PDE) inhibitors, including (a) PDE1 inhibitors (b) PDE2 inhibitors
(c) PDE3 inhibitors (d) PDE4 inhibitors (e) PDE5 inhibitors (f)
PDE9 inhibitors (e.g., PF-04447943, BAY 73-6691 (Bayer AG) and
those disclosed in US Patent Publication Nos US2003/0195205,
US2004/0220186, US2006/0111372, US2006/0106035, and U.S. Ser. No.
12/118,062 (filed May 9, 2008)), and (g) PDE10 inhibitors such as
2-({4-[1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline
(PF-2545920); [0155] (xiv) serotonin (5-hydroxytryptamine) 1A
(5-HT.sub.1A) receptor antagonists, such as spiperone,
levo-pindolol, lecozotan; [0156] (xv) serotonin
(5-hydroxytryptamine) 2C (5-HT.sub.2c) receptor agonists, such as
vabicaserin, and zicronapine; serotonin (5-hydroxytryptamine) 4
(5-HT.sub.4) receptor agonists/antagonists, such as PRX-03140
(Epix) and PF-04995274; [0157] (xvi) serotonin
(5-hydroxytryptamine) 3C (5-HT.sub.3c) receptor antagonists, such
as Ondansetron (Zofran); [0158] (xvii) serotonin
(5-hydroxytryptamine) 6 (5-HT.sub.6) receptor antagonists, such as
mianserin (TOLVON, BOLVIDON, NORVAL), methiothepin (also known as
metitepine), ritanserin, SB-271046, SB-742457 (GlaxoSmithKline), Lu
AE58054 (Lundbeck A/S), SAM-760, and PRX-07034 (Epix); [0159]
(xviii) serotonin (5-HT) reuptake inhibitors such as alaproclate,
citalopram (CELEXA, CIPRAMIL), escitalopram (LEXAPRO, CIPRALEX),
clomipramine (ANAFRANIL), duloxetine (CYMBALTA), femoxetine
(MALEXIL), fenfluramine (PONDIMIN), norfenfluramine, fluoxetine
(PROZAC), fluvoxamine (LUVOX), indalpine, milnacipran (IXEL),
paroxetine (PAXIL, SEROXAT), sertraline (ZOLOFT, LUSTRAL),
trazodone (DESYREL, MOLIPAXIN), venlafaxine (EFFEXOR), zimelidine
(NORMUD, ZELMID), bicifadine, desvenlafaxine (PRISTIQ),
brasofensine, vilazodone, cariprazine and tesofensine; [0160] (xix)
Glycine transporter-1 inhibitors such as paliflutine, ORG-25935,
and ORG-26041; and mGluR modulators such as AFQ-059 and amantidine;
[0161] (xx) AMPA-type glutamate receptor modulators such as
perampanel, mibampator, selurampanel, GSK-729327, and
N-{(3S,4S)-4-[4-(5-cyanothiophen-2-yl)phenoxy]tetrahydrofuran-3-yl}propan-
e-2-sulfonamide; [0162] (xxi) P450 inhibitors, such as ritonavir;
[0163] (xxii) tau therapy targets, such as davunetide; [0164] and
the like.
[0165] The present invention further comprises kits that are
suitable for use in performing the methods of treatment described
above. In one embodiment, the kit contains a first dosage form
comprising one or more of the compounds of the present invention
and a container for the dosage, in quantities sufficient to carry
out the methods of the present invention.
[0166] In another embodiment, the kit of the present invention
comprises one or more compounds of the invention.
General Synthetic Schemes
[0167] The compounds of Formula I may be prepared by the methods
described below, together with synthetic methods known in the art
of organic chemistry, or modifications and transformations that are
familiar to those of ordinary skill in the art. The starting
materials used herein are commercially available or may be prepared
by routine methods known in the art [such as those methods
disclosed in standard reference books such as the Compendium of
Organic Synthetic Methods, Vol. I-XII (published by
Wiley-Interscience)]. Preferred methods include, but are not
limited to, those described below.
[0168] During any of the following synthetic sequences it may be
necessary and/or desirable to protect sensitive or reactive groups
on any of the molecules concerned. This can be achieved by means of
conventional protecting groups, such as those described in T. W.
Greene, Protective Groups in Organic Chemistry, John Wiley &
Sons, 1981; T. W. Greene and P. G. M. Wuts, Protective Groups in
Organic Chemistry, John Wiley & Sons, 1991; and T. W. Greene
and P. G. M. Wuts, Protective Groups in Organic Chemistry, John
Wiley & Sons, 1999, which are hereby incorporated by
reference.
[0169] Compounds of Formula I, or their pharmaceutically acceptable
salts, can be prepared according to the reaction Schemes discussed
herein below. Unless otherwise indicated, the substituents in the
Schemes are defined as above. Isolation and purification of the
products is accomplished by standard procedures, which are known to
a chemist of ordinary skill.
[0170] It will be understood by one skilled in the art that the
various symbols, superscripts and subscripts used in the schemes,
methods and examples are used for convenience of representation
and/or to reflect the order in which they are introduced in the
schemes, and are not intended to necessarily correspond to the
symbols, superscripts or subscripts in the appended claims.
Additionally, one skilled in the art will recognize that in many
cases, these compounds will be mixtures and enantiomers that may be
separated at various stages of the synthetic schemes using
conventional techniques, such as, but not limited to,
crystallization, normal-phase chromatography, reversed phase
chromatography and chiral chromatography, to afford single
enantiomers. The schemes are representative of methods useful in
synthesizing the compounds of the present invention. They are not
to constrain the scope of the invention in any way.
[0171] Scheme 1 refers to the preparation of compounds of Formula
I, la and Ib. Referring to Scheme 1, the compound of Formula III,
III' or III'' can be prepared from the compound of Formula II, II'
or II'' via a standard peptide coupling with a carboxylic acid and
a suitable coupling reagent, for example, but not limited to,
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (HATU) or
2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide in
ethyl acetate (T3P). A compound of Formula I, Ia or Ib can then be
prepared through removal of protecting group P.sup.1. P.sup.1 in
this case refers to groups well known to those skilled in the art
for amine protection. For example, P.sup.1 may be a benzoyl group
(Bz), which can be cleaved via basic conditions, including but not
limited to treatment with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)
in methanol. Alternatively P.sup.1 may be one of many other
protecting groups suitable for amines, including
9-fluorenylmethoxycarbonyl (Fmoc) or tert-butoxy carbonyl (BOC) and
can be cleaved under standard conditions known in the art.
##STR00006##
[0172] Scheme 2 refers to the preparation of compounds II' wherein
P.sup.1 is Bz or Boc. Sulfinimines of Formula V are transformed to
adducts of Formula VI via the addition of an appropriately
metallated sulfonamide IV (generated, for example, through
treatment with n-butyllithium). Sulfonamides of Formula VII are
prepared through the deprotection of compound VI with a appropriate
agent, such as, but not limited to, trifluoroacetic acid in
1,3-dimethoxybenzene. Compounds of Formula IX are then prepared via
treatment with the appropriate isothiocyanate (such as benzoyl
isothiocyanate), and subsequent ring closure of VIII using an
appropriate alkylating agent such as methyl iodide with a base such
as potassium carbonate. Conversion of the bromothiazole of Formula
IX to the corresponding amine can be effected via a transition
metal-catalyzed coupling reaction, such as a palladium-mediated
amination. An example includes using a protected ammonia source,
such as, but not limited to 1-(2,4-dimethoxyphenyl)methanamine and
a suitable catalyst and ligand choice, for example,
tris(dibenzylideneacetone)dipalladium(0) and
di-tert-butyl[2',4',6'-tri(propan-2-yl)biphenyl-2-yl]phosphane or
biphenyl-2-yl(di-tert-butyl)phosphane (John Phos). Alternatively,
one can utilize a copper-mediated azide coupling method. One
skilled in the art will recognize that the requisite protected
ammonia source will need to be deprotected to afford compounds of
Formula II'. In the example utilizing
1-(2,4-dimethoxyphenyl)methanamine, said deprotection can be
effected via acidic hydrolysis, such as treatment with concentrated
hydrochloric acid. Compound II' can be converted into a compound of
Formula Ia according to the methods of Scheme 1. It is to be
understood by one skilled in the art that the compounds of Formula
I and Ib can be prepared in an analogous manner.
##STR00007##
[0173] Scheme 3 refers to the preparation of compounds IX. The
alkylation of compounds of Formula X may be accomplished in a
variety of ways known to those skilled in the art. As an example,
compounds of the Formula X may be treated with a suitable strong
base including but not limited to lithium bis(trimethylsilyl)amide
or sodium bis(trimethylsilyl)amide, followed by treatment with an
alkylating agent such as but not limited to methyl, ethyl or other
alkyl iodides. Additionally, the stereochemistry of the initial
product may alternatively be adjusted by further treatment with
base followed by protonation with an agent such as water or aqueous
ammonium chloride. Additional bases that have utility include
lithium diisopropylamide or potassium tert-butoxide. Alternatively,
the introduction of a group such as R.sup.2 or R.sup.3 wherein one
of R.sup.2 and R.sup.3 is hydrogen may be initiated by a suitable
olefination of X using a suitable base as described above and a
reagent such as dimethylmethylideneammonium iodide (Eschenmoser's
salt). The resulting dimethylamine adduct may be eliminated
directly with base or may be treated with methyl iodide or an
oxidizing agent such as perbenzoic acid or tert-butyl hydroperoxide
and subjected to treatment with a base such as described above,
with the formation of a methylene group. The resulting exo-olefin
may be reduced by catalytic hydrogenation over a catalyst
consisting of supported or unsupported palladium, nickel or
platinum. Alternatively, the exo-olefin group may be reduced
through conjugate hydride addition with, for instance, lithium
tri-sec-butylborohydride or lithium aluminum hydride, followed by
protonation of the resulting anion as described above. A compound
of Formula IX can be then be transformed into a compound of Formula
II' according to the methods described above for Scheme 2. It will
be understood by one skilled in the art that the compounds of
Formula II or II'' can be prepared in an analogous manner.
##STR00008##
[0174] The following are abbreviations which may be used in the
description of the experimental section:
[0175] AlMe.sub.3=trimethylaluminum; br=broad;
Bu.sub.4NNO.sub.3=tetrabutylammonium nitrate; CaCl.sub.2=calcium
chloride; CDCl.sub.3=deutero-chloroform;
CD.sub.3OD=deutero-methanol; (CF.sub.3CO.sub.2)O=trifluoroacetic
anhydride; d=doublet, dd=doublet of doublets; DBU=1,8-diazabicyclo
[5.4.0] undec-7-ene; DCM=dichloromethane;
DMF=N,N-dimethylformamide; EDC or
EDCI=1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride;
EtOAc=ethyl acetate; EtOH=ethanol; Fe=iron; g=gram; h=hour;
HATU=O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate; HCl=hydrochloric acid; H.sub.2O=water;
HPLC=high performance liquid chromatography; Hz=hertz;
K.sub.2CO.sub.3=potassium carbonate; L=liter; LCMS=liquid
chromatography mass spectroscopy; LiOH=lithium hydroxide;
m=multiplet; M=molar; Mel=methyl iodide; MeOH=methanol;
mg=milligram; MHz=megahertz; min=minute; .mu.L=microliter;
mL=milliliter, .mu.mol=micromole; mmol=millimole; mol=mole;
N=normal; NaH=sodium hydride; n-BuLi=n-butyllithium;
NEt.sub.3=triethylamine; NH.sub.4Cl=ammonium chloride;
NaHCO.sub.3=sodium bicarbonate; NaOAc=sodium acetate; NaOCl=sodium
hypochlorite; NaOH=sodium hydroxide; NaOMe=sodium methoxide;
NaOtBu=sodium tert-butoxide; Na.sub.2SO.sub.4=sodium sulfate;
NH.sub.2OH.HCl=hydroxylamine hydrochloride; NMR=nuclear magnetic
resonance; NOE=Nuclear Overhauser effect;
Pd.sub.2(dba).sub.3=tris(dibenzylideneacetone)dipalladium(0);
Pd(dppf)Cl.sub.2=[1,1'-bis(diphenylphosphino)
ferrocene]dichloropalladium(II); PPh.sub.3=triphenylphosphine;
q=quartet; rt=room temperature; s=singlet; t=triplet;
TBAF=tetrabutylammonium fluoride;
t-ButylXPhos=di-tert-butyl[2',4',6'-tri(propan-2-yl)biphenyl-2--
yl]phosphane; TFA or CF.sub.3CO.sub.2H=trifluoroacetic acid;
THF=tetrahydrofuran; TLC=thin layer chromatography;
Zn(CN).sub.2=zinc cyanide.
Experimental Procedures
[0176] The following illustrate the synthesis of various compounds
of the present invention. Additional compounds within the scope of
this invention may be prepared using the methods illustrated in
these Examples, either alone or in combination with techniques
generally known in the art.
[0177] Experiments were generally carried out under inert
atmosphere (nitrogen or argon), particularly in cases where oxygen-
or moisture-sensitive reagents or intermediates were employed.
Commercial solvents and reagents were generally used without
further purification. Anhydrous solvents were employed where
appropriate, generally AcroSeal.RTM. products from Acros Organics
or DriSolv.RTM. products from EMD Chemicals. In other cases,
commercial solvents were passed through columns packed with 4 .ANG.
molecular sieves, until the following QC standards for water were
attained: a) <100 ppm for dichloromethane, toluene,
N,N-dimethylformamide and tetrahydrofuran; b) <180 ppm for
methanol, ethanol, 1,4-dioxane and diisopropylamine. For very
sensitive reactions, solvents were further treated with metallic
sodium, calcium hydride or molecular sieves, and distilled just
prior to use. Products were generally dried under vacuum before
being carried on to further reactions or submitted for biological
testing. Mass spectrometry data is reported from either liquid
chromatography-mass spectrometry (LCMS), atmospheric pressure
chemical ionization (APCI) or gas chromatography-mass spectrometry
(GCMS) instrumentation. Chemical shifts for nuclear magnetic
resonance (NMR) data are expressed in parts per million (ppm,
.delta.) referenced to residual peaks from the deuterated solvents
employed. In some examples, chiral separations were carried out to
separate enantiomers of certain compounds of the invention (in some
examples, the separated enantiomers are designated as ENT-1 and
ENT-2, according to their order of elution). In some examples, the
optical rotation of an enantiomer was measured using a polarimeter.
According to its observed rotation data (or its specific rotation
data), an enantiomer with a clockwise rotation was designated as
the (+)-enantiomer and an enantiomer with a counter-clockwise
rotation was designated as the (-)-enantiomer. Racemic compounds
are indicated by the presence of (+/-) adjacent to the structure;
in these cases, indicated stereochemistry represents the relative
(rather than absolute) configuration of the compound's
substituents.
[0178] Reactions proceeding through detectable intermediates were
generally followed by LCMS, and allowed to proceed to full
conversion prior to addition of subsequent reagents. For syntheses
referencing procedures in other Examples or Methods, reaction
conditions (reaction time and temperature) may vary. In general,
reactions were followed by thin-layer chromatography or mass
spectrometry, and subjected to work-up when appropriate.
Purifications may vary between experiments: in general, solvents
and the solvent ratios used for eluents/gradients were chosen to
provide appropriate R.sub.fs or retention times. All starting
materials in these Preparations and Examples are either
commercially available or can be prepared by methods known in the
art or as described herein.
Preparation P1
tert-Butyl
[(5S)-5-(4-amino-1,3-thiazol-2-yl)-2,5-dimethyl-1,1-dioxido-5,6-
-dihydro-2H-1,2,4-thiadiazin-3-yl]carbamate (P1)
##STR00009##
[0179] Step 1. Synthesis of
N-(4-methoxybenzyl)-N-methylmethanesulfonamide (C1)
[0180] This experiment was carried out in two identical batches.
Sodium hydride (60% in mineral oil, 53.3 g, 1.33 mol) was added in
portions to a 0.degree. C. solution of
N-(4-methoxybenzyl)methanesulfonamide (205 g, 952 mmol) in
tetrahydrofuran (2.5 L), and the reaction mixture was stirred at
0.degree. C. for 30 minutes. Iodomethane (245 g, 1.73 mol) was then
added drop-wise over 30 minutes at 0.degree. C., whereupon the
reaction mixture was stirred at room temperature (.about.18.degree.
C.) for 1 hour, then poured into ice water (2 L). The resulting
mixture was extracted with ethyl acetate (3.times.1 L), and the
combined organic layers were washed with saturated aqueous sodium
chloride solution (3.times.1 L), dried over sodium sulfate,
filtered, and concentrated in vacuo. The two batches of crude
product were combined, diluted with petroleum ether (2 L) and
stirred at room temperature (.about.20.degree. C.) for 30 minutes;
the resulting solid was isolated via filtration to afford the
product as a yellow solid. Yield: 392 g, 1.71 mol, 90%. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 7.28 (br d, J=8.5 Hz, 2H), 6.90 (br
d, J=8.5 Hz, 2H), 4.26 (s, 2H), 3.82 (s, 3H), 2.81 (s, 3H), 2.76
(s, 3H).
Step 2. Synthesis of
N-[1-(4-bromo-1,3-thiazol-2-yl)ethylidene]-(R)-2-methylpropane-2-sulfinam-
ide (C2)
[0181] This experiment was carried out in two identical batches.
Titanium(IV) ethoxide (321 g, 1.41 mol) was added in one portion to
a room temperature (.about.15.degree. C.) solution of
1-(4-bromo-1,3-thiazol-2-yl)ethanone (145 g, 704 mmol) and
(R)-2-methylpropane-2-sulfinamide (128 g, 1.06 mol) in
tetrahydrofuran (2.0 L), and the reaction mixture was heated at
75.degree. C. for 16 hours. It was then cooled to room temperature
(.about.15.degree. C.), quenched with water (500 mL), and filtered.
The filter cake was washed with ethyl acetate (4.times.500 mL), and
the combined filtrates were concentrated in vacuo. The residues
from the two batches were combined and purified via silica gel
chromatography (Gradient: 5% to 25% ethyl acetate in petroleum
ether), providing the product as a yellow solid. Yield: 340 g, 1.10
mol, 78%. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.42 (s, 1H),
2.85 (s, 3H), 1.32 (s, 9H).
Step 3. Synthesis of
(2S)-2-(4-bromo-1,3-thiazol-2-yl)-2-{[(R)-tert-butylsulfinyl]amino}-N-(4--
methoxybenzyl)-N-methylpropane-1-sulfonamide (C3)
[0182] This experiment was carried out in two identical batches.
n-Butyllithium (2.5 M solution in hexanes, 165 mL, 412 mmol) was
added in a drop-wise manner over 1 hour to a -70.degree. C.
solution of C1 (98.0 g, 427 mmol) in tetrahydrofuran (1.5 L). After
the reaction mixture had stirred at -70.degree. C. for 1 hour, a
solution of C2 (85 g, 275 mmol) in tetrahydrofuran (600 mL) was
added drop-wise over 30 minutes, and stirring was then continued at
-70.degree. C. for 1 hour. Saturated aqueous ammonium chloride
solution (1.0 L) was added at -70.degree. C.; the aqueous layer was
extracted with ethyl acetate (2.times.1 L), and the combined
organic layers were dried over sodium sulfate, filtered, and
concentrated in vacuo. The two reaction products were combined and
purified via silica gel chromatography (Gradient: 10% to 80% ethyl
acetate in petroleum ether) to afford a white solid (145 g). This
material was treated with tert-butyl methyl ether (1.4 L) and
stirred at room temperature (.about.15.degree. C.) for 2 hours,
whereupon the solid was collected via filtration to afford the
product as a white solid. The indicated absolute stereochemistry is
that expected from this transformation (see J. A. Ellman et al.,
Chem. Rev. 2010, 110, 3600-3740); single-crystal X-ray structural
analysis on 9 (see below), which was synthesized from P1, confirmed
this absolute stereochemistry. Yield: 135 g, 251 mmol, 46%. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 7.21 (br d, J=8.5 Hz, 2H), 7.20
(s, 1H), 6.86 (br d, J=8.5 Hz, 2H), 6.32 (s, 1H), 4.06 (AB quartet,
J.sub.AB=14.6 Hz, .DELTA..nu..sub.AB=66.7 Hz, 2H), 4.00 (d, J=13.6
Hz, 1H), 3.80 (s, 3H), 3.70 (d, J=14.0 Hz, 1H), 2.61 (s, 3H), 1.97
(s, 3H), 1.36 (s, 9H).
Step 4. Synthesis of
(2S)-2-amino-2-(4-bromo-1,3-thiazol-2-yl)-N-(4-methoxybenzyl)-N-methylpro-
pane-1-sulfonamide, hydrochloride salt (C4)
[0183] A solution of hydrogen chloride in 1,4-dioxane (4 M, 400 mL,
1.6 mol) was added drop-wise to a solution of C3 (175 g, 325 mmol)
in dichloromethane (1.2 L) and methanol (600 mL) at room
temperature (.about.13.degree. C.), and the reaction mixture was
stirred at room temperature (.about.13.degree. C.) for 2 hours.
Removal of solvents in vacuo afforded the product (180 g) as a
colorless oil, which was used in the next step without further
purification. LCMS m/z 457.8 [M+Na.sup.+] (bromine isotope pattern
observed).
Step 5. Synthesis of
(2S)-2-amino-2-(4-bromo-1,3-thiazol-2-yl)-N-methylpropane-1-sulfonamide
(C5)
[0184] To a solution of C4 (from the previous step, 180 g, 5325
mmol) in chloroform (1.2 L) were added trifluoroacetic acid (900
mL) and 1,3-dimethoxybenzene (400 g, 2.89 mol) at room temperature
(.about.13.degree. C.). The reaction mixture was stirred at room
temperature (.about.13.degree. C.) for 16 hours, whereupon it was
concentrated in vacuo and diluted with aqueous hydrochloric acid (1
M, 1.0 L). The resulting mixture was washed with tert-butyl methyl
ether (2.times.800 mL), and the aqueous layer was basified to pH 8
with saturated aqueous sodium bicarbonate solution, then extracted
with ethyl acetate (3.times.600 mL). The combined ethyl acetate
layers were washed with saturated aqueous sodium chloride solution
(500 mL), dried over sodium sulfate, filtered, and concentrated
under reduced pressure to afford a yellow oil. This material was
combined with the corresponding product obtained from a similar
two-step reaction sequence carried out on C3 (125 g, 232 mmol) to
provide the product as a yellow oil. Yield: 174 g, 554 mmol, 99%
over 2 steps. LCMS m/z 313.6, 315.6 [M+H].sup.+. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 7.20 (s, 1H), 3.94 (d, J=14.6 Hz, 1H),
3.94-3.86 (m, 1H), 3.42 (d, J=14.6 Hz, 1H), 2.72 (d, J=5.0 Hz, 3H),
2.58-2.42 (br s, 2H), 1.66 (s, 3H).
Step 6. Synthesis of
N-{[(2S)-2-(4-bromo-1,3-thiazol-2-yl)-1-(methylsulfamoyl)propan-2-yl]carb-
amothioyl}benzamide (C6)
[0185] This experiment was carried out in two identical batches.
Benzoyl isothiocyanate (63.9 g, 392 mmol) was added in one portion
to a room temperature (.about.13.degree. C.) solution of C5 (82 g,
261 mmol) in dichloromethane (1.8 L). The reaction mixture was
stirred at room temperature (.about.13.degree. C.) for 16 hours,
whereupon it was concentrated in vacuo and the two batches were
combined. Chromatography on silica gel (Gradient: 10% to 80% ethyl
acetate in petroleum ether) afforded the product as an off-white
foam. Yield: 226 g, 473 mmol, 91%. LCMS m/z 478.7 [M+H].sup.+
(bromine isotope pattern observed). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 11.64 (s, 1H), 9.00 (s, 1H), 7.87 (br d, J=8
Hz, 2H), 7.65 (br t, J=7.4 Hz, 1H), 7.53 (br dd, J=8.0, 7.5 Hz,
2H), 7.26 (s, 1H), 5.18 (d, J=14.8 Hz, 1H), 4.59 (br q, J=5 Hz,
1H), 4.13 (d, J=14.6 Hz, 1H), 2.86 (d, J=5.3 Hz, 3H), 2.13 (s,
3H).
Step 7. Synthesis of
N-[(5S)-5-(4-bromo-1,3-thiazol-2-yl)-2,5-dimethyl-1,1-dioxido-5,6-dihydro-
-2H-1,2,4-thiadiazin-3-yl]benzamide (C7)
[0186] Iodomethane (61.5 g, 433 mmol) was added drop-wise to a room
temperature (.about.13.degree. C.) mixture of C6 (110 g, 230 mmol)
and potassium carbonate (63.7 g, 461 mmol) in acetonitrile (1.5 L).
The reaction mixture was stirred at room temperature
(.about.13.degree. C.) for 16 hours, whereupon it was diluted with
saturated aqueous ammonium chloride solution (1.0 L) and extracted
with ethyl acetate (3.times.800 mL). The combined organic layers
were washed with saturated aqueous sodium chloride solution (800
mL), dried over sodium sulfate, filtered, and concentrated in vacuo
to a volume of approximately 200 mL. After addition of petroleum
ether (1.0 L), the mixture was stirred at room temperature
(.about.13.degree. C.) for 30 minutes, whereupon the precipitate
was collected via filtration to afford the product as a white
solid. Yield: 94 g, 210 mmol, 91%. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 12.44 (s, 1H), 8.27-8.22 (m, 2H), 7.59-7.53 (m,
1H), 7.46 (br dd, J=7.8, 7.3 Hz, 2H), 7.22 (s, 1H), 4.49 (d, J=13.8
Hz, 1H), 3.72 (d, J=13.8 Hz, 1H), 3.47 (s, 3H), 1.99 (s, 3H).
Step 8. Synthesis of
(5S)-5-(4-bromo-1,3-thiazol-2-yl)-2,5-dimethyl-5,6-dihydro-2H-1,2,4-thiad-
iazin-3-amine 1,1-dioxide (C8)
[0187] 1,8-Diazabicyclo[5.4.0]undec-7-ene (25.8 g, 169 mmol) was
added in one portion to a room temperature (13.degree. C.)
suspension of C7 (75.0 g, 169 mmol) in methanol (1.5 L). The
reaction mixture was refluxed for 16 hours, whereupon it was cooled
and concentrated in vacuo. After the residue had been dissolved in
ethyl acetate (2.0 L), it was washed with saturated aqueous sodium
chloride solution (600 mL), dried over sodium sulfate, filtered,
and concentrated under reduced pressure to provide the product (76
g) as a yellow oil, which was used directly in the following
step.
Step 9. Synthesis of tert-butyl
[(5S)-5-(4-bromo-1,3-thiazol-2-yl)-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2-
H-1,2,4-thiadiazin-3-yl]carbamate (C9)
[0188] Di-tert-butyl dicarbonate (92.2 g, 422 mmol) and
triethylamine (59.9 g, 592 mmol) were added to a room temperature
(.about.13.degree. C.) solution of C8 (from the previous step, 76
g, .ltoreq.169 mmol) in dichloromethane (1.5 L), and the reaction
mixture was stirred at 35.degree. C. for 36 hours, whereupon it was
cooled and concentrated in vacuo to afford a yellow oil. This was
combined with two similar crude products from two-step reaction
sequences carried out on C7 (94.0 g, 212 mmol, and 33.8 g, 76.2
mmol), and the resulting material was purified via silica gel
chromatography (Gradient: 3% to 20% ethyl acetate in petroleum
ether). The fractions containing product were concentrated until
approximately 50 mL of solvent remained, and then diluted with
petroleum ether (1 L); this mixture was stirred at room temperature
(.about.13.degree. C.) for 30 minutes. The resulting solid was
collected via filtration to afford the product (90 g) as a white
solid. The mother liquor was concentrated under reduced pressure,
and the residue was chromatographed on silica gel (Gradient: 3% to
20% ethyl acetate in petroleum ether) to provide additional product
as a white solid (4.1 g). Combined yield: 94.1 g, 214 mmol, 47%
over 2 steps. LCMS m/z 440.6 [M+H].sup.+ (bromine isotope pattern
observed). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.93 (br s,
1H), 7.22 (s, 1H), 4.42 (d, J=14.0 Hz, 1H), 3.66 (d, J=13.8 Hz,
1H), 3.28 (s, 3H), 1.94 (s, 3H), 1.54 (s, 9H).
Step 10. Synthesis of tert-butyl
[(5S)-5-{4-[(diphenylmethylidene)amino]-1,3-thiazol-2-yl}-2,5-dimethyl-1,-
1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-3-yl]carbamate (C10)
[0189] A mixture of C9 (44.25 g, 100.7 mmol),
tris(dibenzylideneacetone)dipalladium(0) (8.38 g, 9.15 mmol),
biphenyl-2-yl(di-tert-butyl)phosphane (John Phos; 6.37 g, 21.3
mmol), sodium tert-butoxide (32.2 g, 335 mmol), and
1,1-diphenylmethanimine (20.4 mL, 122 mmol) in toluene (640 mL) was
evacuated and charged with nitrogen. This evacuation cycle was
repeated twice, whereupon the reaction mixture was stirred at
60.degree. C. for 1 hour. It was then filtered through diatomaceous
earth, and the filtrate was concentrated in vacuo to provide the
product as an amber oil. This material was taken directly to the
following step.
Step 11. Synthesis of tert-butyl
[(5S)-5-(4-amino-1,3-thiazol-2-yl)-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2-
H-1,2,4-thiadiazin-3-yl]carbamate (P1)
[0190] A solution of C10 (from the previous step, .ltoreq.100.7
mmol) in methanol (1.34 L) was treated with hydroxylamine
hydrochloride (14.0 g, 201 mmol) and sodium acetate (16.5 g, 201
mmol). The reaction mixture was stirred at room temperature for 1
hour, whereupon saturated aqueous sodium bicarbonate solution was
added. The resulting mixture was extracted twice with ethyl
acetate; the combined organic layers were washed with saturated
aqueous sodium chloride solution, dried over sodium sulfate,
filtered, and concentrated in vacuo. Silica gel chromatography
(Gradient: 0% to 100% ethyl acetate in heptane) afforded the
product as an amber solid. Yield: 31.3 g, 83.4 mmol, 83% over 2
steps. LCMS m/z 374.1 [M-H.sup.+]. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 6.02 (s, 1H), 4.44 (d, J=13.9 Hz, 1H), 4.09 (d,
J=14 Hz, 1H), 3.17 (s, 3H), 1.85 (br s, 3H), 1.50 (s, 9H).
Preparation P2
N-[(5S)-5-(4-Amino-1,3-thiazol-2-yl)-2,5-dimethyl-1,1-dioxido-5,6-dihydro--
2H-1,2,4-thiadiazin-3-yl]benzamide (P2)
##STR00010##
[0191] Step 1. Synthesis of
N-[(5S)-5-{4-[(2,4-dimethoxybenzyl)amino]-1,3-thiazol-2-yl}-2,5-dimethyl--
1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-3-yl]benzamide
(C11)
[0192] A mixture of tris(dibenzylideneacetone)dipalladium(0) (87.9
mg, 95.9 .mu.mol),
di-tert-butyl[2',4',6'-tri(propan-2-yl)biphenyl-2-yl]phosphane
(95%, 125 mg, 0.279 mmol), and sodium tert-butoxide (406 mg, 4.22
mmol) in 1,4-dioxane (5 mL, which had been sparged with argon) was
stirred at 70.degree. C. for 10 minutes, whereupon a solution of C7
(826 mg, 1.86 mmol) and 1-(2,4-dimethoxyphenyl)methanamine (561 mg,
3.36 mmol) in 1,4-dioxane (5 mL, which had been spared w/argon) was
added. Stirring was continued at 70.degree. C. for 15 minutes, at
which time the reaction mixture was allowed to cool to room
temperature. It was then poured into aqueous sodium bicarbonate
solution (30 mL) and extracted with ethyl acetate (3.times.30 mL).
The combined ethyl acetate layers were dried over sodium sulfate,
filtered, and concentrated in vacuo. Chromatography on silica gel
(Gradient: 0% to 100% ethyl acetate in heptane) afforded the
product as an orange-white solid. Yield: 925 mg, 1.75 mmol, 94%.
LCMS m/z 530.2 [M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.26-8.21 (m, 2H), 7.57-7.51 (m, 1H), 7.48-7.42 (m, 2H),
7.18 (d, J=8.2 Hz, 1H), 6.47 (d, half of AB quartet, J=2.3 Hz, 1H),
6.43 (dd, half of ABX pattern, J=8.2, 2.4 Hz, 1H), 6.06 (br s, 1H),
4.40 (d, J=13.8 Hz, 1H), 4.28 (s, 2H), 3.85 (s, 3H), 3.80 (s, 3H),
3.70 (d, J=13.8 Hz, 1H), 3.46 (s, 3H), 1.97 (s, 3H).
Step 2. Synthesis of
N-[(5S)-5-(4-amino-1,3-thiazol-2-yl)-2,5-dimethyl-1,1-dioxido-5,6-dihydro-
-2H-1,2,4-thiadiazin-3-yl]benzamide (P2)
[0193] Trifluoroacetic acid (2.0 mL) was added drop-wise to a
0.degree. C. solution of C11 (922 mg. 1.74 mmol) in dichloromethane
(15 mL). The reaction mixture was stirred at 0.degree. C. for 1
hour, whereupon it was concentrated in vacuo; the residue was
partitioned between saturated aqueous sodium bicarbonate solution
(30 mL) and ethyl acetate (30 mL), and the aqueous layer was
extracted with ethyl acetate (2.times.30 mL). The combined organic
layers were dried over sodium sulfate, filtered, and concentrated
under reduced pressure. Chromatography on silica gel (Gradient: 0%
to 100% ethyl acetate in heptane) provided the product as a
yellow-orange-white solid. Yield: 475 mg, 1.25 mmol, 72%. LCMS m/z
380.1 [M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.27-8.21 (m, 2H), 7.57-7.51 (m, 1H), 7.45 (br dd, J=8, 7.3 Hz,
2H), 6.19 (s, 1H), 4.44 (d, J=13.8 Hz, 1H), 3.71 (d, J=13.8 Hz,
1H), 3.46 (s, 3H), 1.98 (s, 3H).
Preparation P3
N-(6-Cyclopropyl-5-{4-[(2,4-dimethoxybenzyl)amino]-1,3-thiazol-2-yl}-2,5-d-
imethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-3-yl)benzamide
(P3)
##STR00011##
[0194] Step 1. Synthesis of
1-cyclopropyl-N-(4-methoxybenzyl)-N-methylmethanesulfonamide
(C12)
[0195] Triethylamine (4.51 mL, 32.3 mmol) was added to a
-20.degree. C. solution of 1-(4-methoxyphenyl)-N-methylmethanamine
(5.38 g, 35.6 mmol) in dichloromethane (132 mL). After drop-wise
addition of cyclopropylmethanesulfonyl chloride (5.00 g, 32.3
mmol), the reaction mixture was allowed to warm to room temperature
over a period of 6 hours and was then stirred for an additional 16
hours. It was then partitioned between water (200 mL) and
dichloromethane (250 mL) and the aqueous layer was extracted with
dichloromethane (3.times.100 mL). The combined organic layers were
washed with saturated aqueous sodium chloride solution (50 mL),
dried over sodium sulfate, filtered, and concentrated in vacuo. The
residue was adsorbed onto silica gel as a solution in
dichloromethane; silica gel chromatography (Gradient: 0% to 70%
ethyl acetate in heptane, followed by ethyl acetate to elute
material that had precipitated on the column) afforded a brown
solid. This material was triturated with heptane (50 mL); the
resulting solid was isolated via filtration and washed with heptane
(3.times.15 mL) to provide the product as a white solid. Yield: 7.4
g, 27 mmol, 84%. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.29 (br
d, J=8.5 Hz, 2H), 6.90 (br d, J=8.7 Hz, 2H), 4.32 (s, 2H), 3.82 (s,
3H), 2.94 (d, J=7.1 Hz, 2H), 2.79 (s, 3H), 1.21-1.10 (m, 1H),
0.77-0.68 (m, 2H), 0.41-0.32 (m, 2H).
Step 2. Synthesis of
2-(4-bromo-1,3-thiazol-2-yl)-2-{[(R)-tert-butylsulfinyl]amino}-1-cyclopro-
pyl-N-(4-methoxybenzyl)-N-methypropane-1-sulfonamide (C13)
[0196] n-Butyllithium (2.5 M solution in hexanes; 1.29 mL, 3.23
mmol) was added in a drop-wise manner to a -78.degree. C. solution
of C12 (0.871 g, 3.23 mmol) in tetrahydrofuran (20 mL), at a rate
that kept the reaction temperature below -70.degree. C. This
reaction mixture was stirred at -78.degree. C. for 1 hour. In a
separate flask, trimethylaluminum (2.0 M solution in toluene; 0.808
mL, 1.62 mmol) was added drop-wise to a -78.degree. C. solution of
C2 (0.500 g, 1.62 mmol) in toluene (8 mL), and this reaction
mixture was allowed to stir at -78.degree. C. for 20 minutes. The
C12 reaction mixture was then added via cannula to the C2 reaction
mixture, and stirring was continued at -78.degree. C. for 3.5
hours, whereupon the reaction was quenched with water (50 mL) and
allowed to warm to room temperature. After extraction of the
aqueous layer with ethyl acetate (3.times.25 mL), the combined
organic layers were dried over sodium sulfate, filtered, and
concentrated in vacuo. The residue was adsorbed onto silica gel as
a solution in dichloromethane, and purified via chromatography on
silica gel (Gradient: 0% to 100% ethyl acetate in heptane) to
afford the product as a white solid. By .sup.1H NMR analysis, this
material consisted of an approximately 3:2 mixture of
diastereomers. Yield: 0.614 g, 1.06 mmol, 65%. .sup.1H NMR (400
MHz, CDCl.sub.3), characteristic peaks: .delta. 7.25-7.20 (m, 2H),
[7.20 (s) and 7.14 (s), total 1H], 6.88-6.82 (m, 2H), [3.79 (s) and
3.79 (s), total 3H], [3.38 (d, J=11.2 Hz) and 3.25 (d, J=11.0 Hz),
total 1H], [2.67 (s) and 2.65 (s), total 3H], [2.10 (s) and 2.06
(s), total 3H], [1.39 (s) and 1.34 (s), total 9H], 1.08-0.39 (m,
5H).
Step 3. Synthesis of
2-amino-2-(4-bromo-1,3-thiazol-2-yl)-1-cyclopropyl-N-methylpropane-1-sulf-
onamide (C14)
[0197] A solution of hydrogen chloride in 1,4-dioxane (4.0 M, 1.60
mL, 6.40 mmol) was added to a solution of C13 (0.614 g, 1.06 mmol)
in dichloromethane (10 mL) and methanol (2 mL). The reaction
mixture was stirred at room temperature for 2 hours, whereupon it
was concentrated in vacuo, and the residue was azeotroped with
toluene (2.times.50 mL). The resulting solid was dissolved in
chloroform (10 mL) and treated with 1,3-dimethoxybenzene (0.833 mL,
6.36 mmol) and trifluoroacetic acid (1.5 mL, 19 mmol). After
stirring at room temperature for 16 hours, the reaction mixture was
concentrated in vacuo, and the residue was treated with aqueous
hydrochloric acid (0.25 M, 60 mL) and washed with diethyl ether
(3.times.100 mL). These organic washes were discarded, and the
aqueous layer was basified to pH 9 via addition of solid sodium
bicarbonate. It was then extracted with ethyl acetate (3.times.100
mL), and the combined ethyl acetate layers were dried over sodium
sulfate, filtered, and concentrated under reduced pressure to
provide the product as a white solid. By .sup.1H NMR analysis, this
material consisted of an approximately 3:2 mixture of
diastereomers. Yield: 0.40 g, 1.1 mmol, quantitative. .sup.1H NMR
(400 MHz, CDCl.sub.3), characteristic peaks: .delta. [7.37 (s) and
7.36 (s), total 1H], [3.55 (d, J=10.9 Hz) and 3.52 (d, J=11.0 Hz),
total 1H], [2.91 (s) and 2.83 (s), total 3H], [2.17 (s) and 2.10
(s), total 3H], 1.0-0.48 (m, 4H).
Step 4. Synthesis of
N-{[2-(4-bromo-1,3-thiazol-2-yl)-1-cyclopropyl-1-(methylsulfamoyl)propan--
2-yl]carbamothioyl}benzamide (C15)
[0198] Benzoyl isothiocyanate (0.212 mL, 1.58 mmol) was added to a
solution of C14 (0.40 g, 1.1 mmol) in dichloromethane (15 mL), and
the reaction mixture was stirred at room temperature for 16 hours.
Removal of solvent in vacuo provided the crude product as a yellow
solid (0.60 g), which was used directly in the following step.
Step 5. Synthesis of
N-[5-(4-bromo-1,3-thiazol-2-yl)-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,-
6-dihydro-2H-1,2,4-thiadiazin-3-yl]benzamide (C16)
[0199] To an acetonitrile (15 mL) solution of C15 (from the
previous step; 0.60 g, 51.1 mmol) was added potassium carbonate
(240 mg, 1.74 mmol), followed by iodomethane (0.108 mL, 1.73 mmol),
and the reaction mixture was allowed to stir at room temperature
for 16 hours. It was then diluted with saturated aqueous ammonium
chloride solution (50 mL) and water (20 mL), and the resulting
mixture was extracted with ethyl acetate (3.times.100 mL). The
combined organic layers were filtered and concentrated in vacuo;
the residue was adsorbed onto silica gel as a solution in
dichloromethane. Silica gel chromatography (Gradient: 0% to 60%
ethyl acetate in heptane) provided the product as a white solid. By
.sup.1H NMR analysis, this material consisted of an approximately
7:4 mixture of diastereomers. Four isomers were observed via chiral
supercritical fluid chromatography (Column: Phenomenex Lux
Cellulose-4, 5 .mu.m; Mobile phase A: carbon dioxide; Mobile phase
B: methanol containing 0.2% ammonium hydroxide; Gradient: 5% to 60%
B), in a ratio of 32:5:11:53. Yield: 0.284 g, 0.59 mmol, 54% over 2
steps. .sup.1H NMR (400 MHz, CDCl.sub.3), characteristic peaks:
.delta. 8.26-8.21 (m, 2H), 7.58-7.52 (m, 1H), 7.49-7.43 (m, 2H),
[7.25 (s) and 7.23 (s), total 1H], [3.58 (d, J=11.0 Hz) and 2.95
(d, J=10.8 Hz), total 1H], [3.50 (s) and 3.47 (s), total 3H], [2.09
(s) and 2.08 (s), total 3H], 1.13-0.80 (m, 3H), 0.53-0.34 (m,
1H).
Step 6. Synthesis of
N-(6-cyclopropyl-5-{4-[(2,4-dimethoxybenzyl)amino]-1,3-thiazol-2-yl}-2,5--
dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-3-yl)benzamide
(P3)
[0200] A mixture of sodium tert-butoxide (97%, 0.117 g, 1.18 mmol),
tris(dibenzylideneacetone)dipalladium(0) (97%, 25.4 mg, 26.9
.mu.mol), and
di-tert-butyl[2',4',6'-tri(propan-2-yl)biphenyl-2-yl]phosphane
(95%, 36.1 mg, 80.8 .mu.mol) was stirred under nitrogen, and then
purged in three cycles of evacuation followed by nitrogen fill.
1,4-Dioxane (5 mL) was added, and the resulting mixture was stirred
at 70.degree. C. for 10 minutes, whereupon a solution of C16 (0.26
g, 0.54 mmol) and 1-(2,4-dimethoxyphenyl)methanamine (0.145 mL,
0.965 mmol) in 1,4-dioxane (5 mL) was added to the 70.degree. C.
mixture. Stirring was continued at 70.degree. C. for 20 minutes;
the reaction mixture was then cooled to room temperature and poured
into saturated aqueous sodium bicarbonate solution (100 mL). The
mixture was extracted with ethyl acetate (3.times.100 mL), and the
combined organic layers were dried over sodium sulfate, filtered,
and concentrated under reduced pressure. The residue was adsorbed
onto silica gel as a solution in dichloromethane and subjected to
chromatography on silica gel (Gradient: 0% to 70% ethyl acetate in
heptane), providing the product as a white solid. By .sup.1H NMR
analysis, this material consisted of an approximately 1:1 mixture
of diastereomers. Yield: 288 mg, 0.506 mmol, 94%. LCMS m/z 570.3
[M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3), characteristic
peaks: .delta. [12.09 (br s) and 11.96 (br s), total 1H], 8.27-8.19
(m, 2H), 7.56-7.49 (m, 1H), 7.48-7.40 (m, 2H), [7.19 (d, J=8.2 Hz)
and 7.18 (d, J=8.2 Hz), total 1H], 6.48-6.45 (m, 1H), 6.43 (dd,
half of ABX pattern, J=8.2, 2.4 Hz, 1H), [5.89 (br s) and 5.83 (br
s), total 1H], [4.24 (s) and 4.23 (s), total 2H], 3.84 (s, 3H),
[3.80 (s) and 3.80 (s), total 3H], [3.49 (s) and 3.45 (s), total
3H], [2.07 (s) and 2.03 (s), total 3H].
Preparation P4
N-(5-{4-[(2,4-Dimethoxybenzyl)amino]-1,3-thiazol-2-yl}-2, 5, 6,
6-tetramethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-3-yl)benzamide
(P4)
##STR00012##
[0201] Step 1. Synthesis of
N-(4-methoxybenzyl)-N-methylpropane-2-sulfonamide (C17)
[0202] Triethylamine (4.50 mL, 32.3 mmol) was added to a
-20.degree. C. solution of 1-(4-methoxyphenyl)-N-methylmethanamine
(5.38 g, 35.6 mmol) in dichloromethane (130 mL). Propane-2-sulfonyl
chloride (4.61 g, 32.3 mmol) was introduced drop-wise; the reaction
mixture was then allowed to warm to room temperature over a period
of 6 hours and stir for an additional 16 hours. The reaction
mixture was partitioned between water (200 mL) and dichloromethane
(250 mL), and the aqueous layer was extracted with dichloromethane
(3.times.100 mL). The combined organic layers were washed with
saturated aqueous sodium chloride solution (50 mL), dried over
sodium sulfate, filtered, and concentrated in vacuo. The residue
was adsorbed onto silica gel as a solution in dichloromethane and
subjected to silica gel chromatography (Gradient: 0% to 70% ethyl
acetate in heptane); during this process, the product partially
precipitated on the chromatographic column, so the column was also
eluted with ethyl acetate. The material from the column was
obtained as a brown solid, which was then triturated with heptane
(50 mL) to afford a white solid. This material was washed with
heptane (3.times.15 mL), providing the product as a white solid.
Yield: 5.47 g, 21.3 mmol, 66%. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.28 (br d, J=8.8 Hz, 2H), 6.89 (br d, J=8.8 Hz, 2H), 4.33
(s, 2H), 3.82 (s, 3H), 3.28 (septet, J=6.8 Hz, 1H), 2.78 (s, 3H),
1.40 (d, J=6.8 Hz, 6H).
Step 2. Synthesis of
3-(4-bromo-1,3-thiazol-2-yl)-3-{[(R)-tert-butylsulfinyl]amino}-N-(4-metho-
xybenzyl)-N, 2-dimethylbutane-2-sulfonamide (C18)
[0203] Conversion of C17 to C18 was carried out using the method
described for synthesis of C13 from C12 in Preparation P3. The
product was obtained as an orange solid; by .sup.1H NMR analysis,
this material consisted of an approximately 3:2 mixture of
diastereomers. Yield: 528 mg, 0.932 mmol, 58%. .sup.1H NMR (400
MHz, CDCl.sub.3), characteristic peaks: .delta. 7.24-7.16 (m, 3H),
6.87-6.80 (m, 2H), [6.63 (br s) and 6.23 (br s), total 1H], [3.79
(s) and 3.78 (s), total 3H], 2.78-2.65 (m, 3H), 2.02 (s, 3H), [1.78
(s) and 1.68 (s), total 3H], [1.63 (s) and 1.55 (s), total 3H],
[1.36 (s) and 1.36 (s), total 9H].
Step 3. Synthesis of 3-amino-3-(4-bromo-1,3-thiazol-2-yl)-N,
2-dimethylbutane-2-sulfonamide (C19)
[0204] Conversion of C18 to C19 was carried out using the method
described for synthesis of C14 from C13 in Preparation P3, except
that the trifluoroacetic acid-mediated deprotection was effected
without added solvent. The product was isolated as a white solid.
Yield: 291 mg, 0.850 mmol, 91%. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.21 (s, 1H), 2.81 (s, 3H), 1.73 (s, 3H), 1.65 (s, 3H),
1.59 (s, 3H).
Step 4. Synthesis of
N-{[2-(4-bromo-1,3-thiazol-2-yl)-3-methyl-3-(methylsulfamoyl)butan-2-yl]c-
arbamothioyl}benzamide (C20)
[0205] Conversion of C19 (290 mg, 0.847 mmol) to C20 was effected
using the procedure described for synthesis of C15 from C14 in
Preparation P3. The product was obtained as a yellow solid, which
was taken directly into the following step. LCMS m/z 505.1, 507.1
[M+H].sup.+.
Step 5. Synthesis of
N-[5-(4-bromo-1,3-thiazol-2-yl)-2,5,6,6-tetramethyl-1,1-dioxido-5,6-dihyd-
ro-2H-1,2,4-thiadiazin-3-yl]benzamide (C21)
[0206] Conversion of C20 (from the previous reaction, <0.847
mmol) to C21 was carried out using the method described for
synthesis of C16 from C15 in Preparation P3. The product was
isolated as a white solid. Yield: 170 mg, 0.361 mmol, 43% over 2
steps. LCMS m/z 471.1, 473.1 [M+H].sup.+. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 12.45 (br s, 1H), 8.27-8.23 (m, 2H), 7.58-7.52
(m, 1H), 7.49-7.43 (m, 2H), 7.25 (s, 1H), 3.52 (s, 3H), 2.03 (s,
3H), 1.81 (s, 3H), 1.56 (s, 3H).
Step 6. Synthesis of
N-(5-{4-[(2,4-dimethoxybenzyl)amino]-1,3-thiazol-2-yl}-2, 5, 6,
6-tetramethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-3-yl)benzamide
(P4)
[0207] A mixture of sodium tert-butoxide (97%, 67.0 mg, 0.676
mmol), tris(dibenzylideneacetone)dipalladium(0) (97%, 14.5 mg, 15.4
.mu.mol), and
di-tert-butyl[2',4',6'-tri(propan-2-yl)biphenyl-2-yl]phosphane
(95%, 20.6 mg, 46.1 .mu.mol) was stirred under nitrogen, and then
purged in three cycles of evacuation followed by nitrogen fill.
1,4-Dioxane (10 mL) was added, and the solution was stirred at
70.degree. C. for 10 minutes, at which time a solution of C21
(0.145 g, 0.308 mmol) and 1-(2,4-dimethoxyphenyl)methanamine (92.6
mg, 0.554 mmol) in 1,4-dioxane (10 mL) was added to the hot
(70.degree. C.) reaction mixture. After being stirred at 70.degree.
C. for 80 minutes, the reaction mixture was allowed to cool to room
temperature, whereupon it was poured into saturated aqueous sodium
bicarbonate solution (100 mL). The resulting mixture was extracted
with ethyl acetate (3.times.100 mL), and the combined organic
layers were dried over sodium sulfate, filtered, and concentrated
under reduced pressure to provide an orange oil (195 mg), which
consisted of an approximately 1:1 mixture of C21 and P4 by LCMS
analysis. This material was resubjected to the same reaction
conditions using the following reagent quantities: sodium
tert-butoxide (97%, 41.3 mg, 0.417 mmol),
tris(dibenzylideneacetone)dipalladium(0) (97%, 8.94 mg, 9.47
.mu.mol),
di-tert-butyl[2',4',6'-tri(propan-2-yl)biphenyl-2-yl]phosphane
(95%, 12.7 mg, 28.4 .mu.mol), and
1-(2,4-dimethoxyphenyl)methanamine (57.0 mg, 0.341 mmol). In this
case, the reaction mixture was stirred at 70.degree. C. for 20
minutes. The crude product from this resubmission was adsorbed onto
silica gel as a solution in dichloromethane; silica gel
chromatography (Gradient: 0% to 70% ethyl acetate in heptane)
afforded the product as a white solid. Yield: 135 mg, 0.242 mmol,
79%. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 12.31 (br s, 1H),
8.27-8.23 (m, 2H), 7.55-7.50 (m, 1H), 7.47-7.41 (m, 2H), 7.20 (d,
J=8.2 Hz, 1H), 6.48 (d, half of AB quartet, J=2.4 Hz, 1H), 6.45
(dd, half of ABX pattern, J=8.3, 2.4 Hz, 1H), 5.75 (s, 1H),
4.75-4.68 (m, 1H), 4.26-4.21 (m, 2H), 3.85 (s, 3H), 3.82 (s, 3H),
3.51 (s, 3H), 2.03 (s, 3H), 1.82 (s, 3H), 1.42 (s, 3H).
Preparation P5
N-(5-{4-[(2,4-Dimethoxybenzyl)amino]-1,3-thiazol-2-yl}-2,5,6-trimethyl-1,1-
-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-3-yl)benzamide (P5)
##STR00013##
[0208] Step 1. Synthesis of
N-(4-methoxybenzyl)-N-methylethanesulfonamide (C22)
[0209] n-Butyllithium (2.5 M solution in hexanes; 3.66 mL, 9.15
mmol) was added drop-wise to a -72.degree. C. (internal reaction
temperature) solution of
N-(4-methoxybenzyl)-N-methylmethanesulfonamide (2.00 g, 8.72 mmol)
in tetrahydrofuran (35 mL), at a rate that maintained the internal
temperature at -70.degree. C. or below. After the reaction mixture
had stirred at -70.degree. C. for 1 hour, iodomethane (0.983 mL,
15.8 mmol) was added in a drop-wise manner, and stirring was
continued at -70.degree. C. for 4 hours. The reaction mixture was
then allowed to warm to room temperature over 16 hours, whereupon
it was diluted with saturated aqueous ammonium chloride solution
(150 mL) and water (120 mL). The resulting mixture was extracted
with ethyl acetate (3.times.100 mL), and the combined organic
layers were filtered and concentrated in vacuo. The residue was
adsorbed onto silica gel as a solution in dichloromethane and
subjected to silica gel chromatography (Gradient: 0% to 100% ethyl
acetate in heptane), providing the product as a white solid. Yield:
1.92 g, 7.89 mmol, 90%. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.30-7.25 (m, 2H, assumed; partially obscured by solvent peak),
6.90 (br d, J=8.5 Hz, 2H), 4.31 (s, 2H), 3.82 (s, 3H), 3.02 (q,
J=7.4 Hz, 2H), 2.77 (s, 3H), 1.39 (t, J=7.4 Hz, 3H).
Step 2. Synthesis of
3-(4-bromo-1,3-thiazol-2-yl)-3-{[(R)-tert-butylsulfinyl]amino}-N-(4-metho-
xybenzyl)-N-methylbutane-2-sulfonamide (C23)
[0210] Conversion of C22 to C23 was carried out using the method
described for synthesis of C13 from C12 in Preparation P3. The
product was isolated as a white solid. By .sup.1H NMR analysis,
this material consisted of at least three diastereomers, in a ratio
of approximately 5:4:3. Yield: 1.57 g, 2.84 mmol, 73%. .sup.1H NMR
(400 MHz, CDCl.sub.3), characteristic peaks: .delta. [7.24-7.17 (m)
and 6.89-6.83 (m), total 5H], [3.80 (s), 3.80 (s), and 3.80 (s),
total 3H], [2.73 (s), 2.68 (s), and 2.64 (s), total 3H], [2.07 (s),
2.00 (s), and 1.94 (s), total 3H], [1.75 (d, J=7.1 Hz), 1.54 (d,
J=7.1 Hz), and 1.53 (d, J=7.1 Hz), total 3H], [1.37 (s), 1.34 (s),
and 1.28 (s), total 9H].
Step 3. Synthesis of
3-amino-3-(4-bromo-1,3-thiazol-2-yl)-N-methylbutane-2-sulfonamide
(C24)
[0211] A solution of hydrogen chloride in 1,4-dioxane (4.0 M, 4.13
mL, 16.5 mmol) was added to a solution of C23 (1.52 g, 2.75 mmol)
in dichloromethane (30 mL) and methanol (6 mL), and the reaction
mixture was stirred at room temperature for 2 hours. After removal
of solvent in vacuo, the residue was azeotroped with toluene
(2.times.50 mL), and the resulting yellow solid was then dissolved
in a mixture of 1,3-dimethoxybenzene (5 mL) and trifluoroacetic
acid (10 mL). This reaction mixture was stirred at room temperature
for 16 hours, whereupon aqueous hydrochloric acid (0.25 M, 100 mL)
was added, and the mixture was washed with diethyl ether
(3.times.100 mL). The aqueous layer was basified to pH 9 by
addition of 1 M aqueous sodium hydroxide solution, and then
extracted with ethyl acetate (3.times.100 mL). The combined ethyl
acetate layers were dried over sodium sulfate, filtered, and
concentrated under reduced pressure to provide the product as a
colorless oil. By .sup.1H NMR analysis, this material consisted of
an approximately 3:2 mixture of diastereomers. Yield: 886 mg, 2.70
mmol, 98%. Major diastereomer: .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.17 (s, 1H), 4.18 (br q, J=5 Hz, 1H), 3.89 (q, J=7.1 Hz,
1H), 2.85 (d, J=5.2 Hz, 3H), 2.4-2.2 (brs, 2H), 1.82 (s, 3H), 1.33
(d, J=7.1 Hz, 3H). Minor diastereomer: .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.18 (s, 1H), 4.00 (q, J=7.2 Hz, 1H), 3.70 (br
q, J=5 Hz, 1H), 2.67 (d, J=5.3 Hz, 3H), 2.4-2.2 (br s, 2H), 1.57
(s, 3H), 1.53 (d, J=7.2 Hz, 3H).
Step 4. Synthesis of
N-{[2-(4-bromo-1,3-thiazol-2-yl)-3-(methylsulfamoyl)butan-2-yl]carbamothi-
oyl}benzamide (C25)
[0212] Conversion of C24 to C25 was effected using the method
described for synthesis of C15 from C14 in Preparation P3. The
product was obtained as a yellow solid, which was taken directly to
the following step.
Step 5. Synthesis of
N-[5-(4-bromo-1,3-thiazol-2-yl)-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2-
H-1,2,4-thiadiazin-3-yl]benzamide (C26)
[0213] Conversion of C25 to C26 was carried out using the procedure
described for synthesis of C16 from C15 in Preparation P3. The
product was isolated as a white solid that, by .sup.1H NMR
analysis, consisted of an approximately 3:2 mixture of
diastereomers. Yield: 390 mg, 0.853 mmol, 32% over 2 steps. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. [12.38 (br s) and 12.32 (br s),
total 1H], 8.27-8.21 (m, 2H), 7.58-7.52 (m, 1H), 7.49-7.42 (m, 2H),
[7.25 (s) and 7.24 (s), total 1H], [4.33 (q, J=7.1 Hz) and 3.78 (q,
J=7.1 Hz), total 1H], [3.51 (s) and 3.49 (s), total 3H], [2.03 (s)
and 1.93 (s), total 3H], [1.76 (d, J=7.1 Hz) and 1.65 (d, J=7.0
Hz), total 3H].
Step 6. Synthesis of
N-(5-{4-[(2,4-dimethoxybenzyl)amino]-1,3-thiazol-2-yl}-2,5,6-trimethyl-1,-
1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-3-yl)benzamide (P5)
[0214] Reaction of C26 with 1-(2,4-dimethoxyphenyl)methanamine was
carried out according to the procedure described for synthesis of
P3 from C16 in Preparation P3. The product was isolated as a yellow
solid; by .sup.1H NMR analysis, this material consisted of an
approximately 1:1 mixture of diastereomers. Yield: 457 mg, 0.840
mmol, 98%. .sup.1H NMR (400 MHz, CDCl.sub.3), characteristic peaks:
.delta. [12.24 (br s) and 12.05 (br s), total 1H], 8.28-8.18 (m,
2H), 7.56-7.49 (m, 1H), 7.47-7.40 (m, 2H), [7.21 (d, J=8.2 Hz) and
7.20 (d, J=8.2 Hz), total 1H], 6.50-6.42 (m, 2H), [5.75 (s) and
5.73 (s), total 1H], 4.26-4.19 (m, 2H), [3.85 (s), 3.84 (s), 3.81
(s), and 3.81 (s), total 6H], [3.50 (s) and 3.49 (s), total 3H],
[2.02 (s) and 1.93 (s), total 3H], [1.61 (d, J=7.0 Hz) and 1.59 (d,
J=7.0 Hz), total 3H].
Preparation P6
5-(Difluoromethoxy)pyridine-2-carboxylic acid (P6)
##STR00014##
[0215] Step 1. Synthesis of methyl
5-(difluoromethoxy)pyridine-2-carboxylate (C27)
[0216] Potassium carbonate (45.1 g, 326 mmol) was added to a
solution of methyl 5-hydroxypyridine-2-carboxylate (20 g, 130 mmol)
in N,N-dimethylformamide (500 mL), and the reaction mixture was
stirred at room temperature for 0.5 hours. Sodium
chloro(difluoro)acetate (63.7 g, 418 mmol) was introduced, and the
resulting mixture was heated at 100.degree. C. for 5 hours,
whereupon it was partitioned between saturated aqueous sodium
chloride solution (300 mL) and ethyl acetate (300 mL). The aqueous
layer was extracted with ethyl acetate (3.times.200 mL), and the
combined organic layers were washed with saturated aqueous sodium
chloride solution (2.times.200 mL), dried, filtered, and
concentrated in vacuo. Silica gel chromatography (Eluent: 5:1
petroleum ether/ethyl acetate) afforded the product as a pale
yellow oil. Yield: 17 g, 84 mmol, 65%. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.56 (s, 1H), 8.17 (d, J=8.7 Hz, 1H), 7.59 (br
d, J=8.7 Hz, 1H), 6.64 (t, J.sub.HF=71.9 Hz, 1H), 4.00 (s, 3H).
Step 2. Synthesis of 5-(difluoromethoxy)pyridine-2-carboxylic acid
(P6)
[0217] A solution of C27 (17 g, 84 mmol) in tetrahydrofuran (100
mL) and water (50 mL) was cooled to 0.degree. C. and treated with
lithium hydroxide (6.0 g, 250 mmol). After the reaction mixture had
stirred at room temperature for 2 hours, it was acidified to a pH
of 3 with 1 M aqueous hydrochloric acid. The aqueous layer was
extracted with ethyl acetate (3.times.100 mL), and the combined
organic layers were washed with saturated aqueous sodium chloride
solution (100 mL), dried, filtered, and concentrated under reduced
pressure to provide the product as a white solid. Yield: 13 g, 69
mmol, 82%. LCMS m/z 189.8 [M+H].sup.+. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.52 (d, J=2.4 Hz, 1H), 8.29 (d, J=8.5 Hz, 1H),
7.73 (dd, J=8.6, 2.4 Hz, 1H), 6.68 (t, J.sub.HF=71.5 Hz, 1H).
Preparation P7
5-(Difluoromethoxy)-3-methylpyridine-2-carboxylic acid (P7)
##STR00015##
[0218] Step 1. Synthesis of 3-methyl-5-nitropyridine-2-carbonitrile
(C28)
[0219] A mixture of 3-methylpyridine-2-carbonitrile (128 g, 1.08
mol) and tetrabutylammonium nitrate (363 g, 1.19 mol) in tert-butyl
methyl ether (1.3 L) was cooled to 4.degree. C. Trifluoroacetic
anhydride (171 mL, 1.21 mol) was added, and the reaction mixture
was allowed to stir at room temperature for 60 hours. It was then
adjusted to a pH of approximately 7 by addition of 20% aqueous
sodium hydroxide solution, and extracted with dichloromethane
(3.times.1 L). The combined organic layers were dried, filtered,
and concentrated in vacuo; purification via silica gel
chromatography (Gradient: 0% to 10% ethyl acetate in petroleum
ether) afforded the product as a yellow solid. Yield: 70 g, 0.43
mmol, 40%. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.36-9.31 (m,
1H), 8.52-8.47 (m, 1H), 2.74 (s, 3H).
Step 2. Synthesis of 5-amino-3-methylpyridine-2-carbonitrile
(C29)
[0220] To a solution of C28 (40.0 g, 245 mmol) in ethanol (630 mL)
and water (70 mL) was added calcium chloride (13.6 g, 123 mmol),
followed by iron powder (123 g, 2.20 mol), and the reaction mixture
was stirred overnight at room temperature. After filtration of the
reaction mixture, the filtrate was concentrated in vacuo, and the
residue was purified by chromatography on silica gel (Gradient: 10%
to 50% ethyl acetate in petroleum ether). The product was obtained
as a yellow solid. Yield: 20.0 g, 150 mmol, 61%. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 7.94 (d, J=2.5 Hz, 1H), 6.81 (d, J=2.5 Hz,
1H), 4.19-4.07 (br s, 2H), 2.45 (s, 3H).
Step 3. Synthesis of 5-hydroxy-3-methylpyridine-2-carbonitrile
(C30)
[0221] Sodium nitrite (1.6 M aqueous solution containing 10.3 g of
sodium nitrite, 149 mmol) was slowly added to a 0.degree. C.
solution of C29 (18.0 g, 135 mmol) in water (243 mL) and
concentrated sulfuric acid (67.5 mL). The reaction mixture was
warmed to room temperature and then stirred at 100.degree. C. for 3
hours, whereupon it was cooled and extracted with ethyl acetate
(3.times.75 mL). The combined organic layers were washed with water
(2.times.75 mL) and with saturated aqueous sodium chloride solution
(2.times.75 mL), dried, filtered, and concentrated under reduced
pressure to afford the product as a yellow solid. Yield: 16 g, 120
mmol, 89%. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.07 (br s,
1H), 8.08 (d, J=2.6 Hz, 1H), 7.20 (d, J=2.3 Hz, 1H), 2.40 (s,
3H).
Step 4. Synthesis of
5-(difluoromethoxy)-3-methylpyridine-2-carbonitrile (C31)
[0222] A mixture of C30 (5.70 g, 42.5 mmol), sodium
chlorodifluoroacetate (13.0 g, 85.3 mmol), and potassium carbonate
(17.6 g, 127 mmol) in N,N-dimethylformamide (175 mL) was stirred
for 30 minutes at 100.degree. C. The reaction mixture was then
diluted with ethyl acetate (400 mL), and sequentially washed with
saturated aqueous ammonium chloride solution (3.times.200 mL) and
saturated aqueous sodium chloride solution (3.times.200 mL). The
combined aqueous layers were extracted with ethyl acetate (200 mL),
and the combined organic layers were dried over sodium sulfate,
filtered, and concentrated in vacuo. Silica gel chromatography
(Gradient: 5% to 15% ethyl acetate in petroleum ether) provided the
product as a colorless oil. Yield: 3.9 g, 21 mmol, 49%. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 8.39 (br d, J=2.1 Hz, 1H), 7.47-7.43
(m, 1H), 6.64 (t, J.sub.HF=71.5 Hz, 1H), 2.59 (s, 3H).
Step 5. Synthesis of
5-(difluoromethoxy)-3-methylpyridine-2-carboxylic acid (P7)
[0223] Aqueous sodium hydroxide solution (1 M, 124 mL, 124 mmol)
was added to a solution of C31 (7.60 g, 41.3 mmol) in ethanol (200
mL), and the reaction mixture was stirred for 16 hours at
70.degree. C. It was then diluted with tert-butyl methyl ether (200
mL) and extracted with water (2.times.100 mL). The combined aqueous
layers were washed with tert-butyl methyl ether (100 mL), acidified
to pH 2 with 1 M aqueous hydrochloric acid, and extracted with
tert-butyl methyl ether (2.times.200 mL). The combined organic
extracts were dried over sodium sulfate, filtered, and concentrated
in vacuo to afford the product as a white solid. Yield: 6.6 g, 32
mmol, 77%. LCMS m/z 203.7 [M+H].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.32 (br d, J=2.1 Hz, 1H), 7.62-7.58 (m, 1H),
7.06 (t, J.sub.HF=72.7 Hz, 1H), 2.64 (s, 3H).
Preparation P8
3-Chloro-5-(difluoromethoxy)pyridine-2-carboxylic acid (P8)
##STR00016##
[0224] Step 1. Synthesis of 5,6-dichloropyridine-3-diazonium
tetrafluoroborate (C32)
[0225] To a 0.degree. C. solution of 5,6-dichloropyridin-3-amine
(15 g, 92 mmol) in tetrafluoroboric acid (.about.45% in water; 150
mL) was added a solution of sodium nitrite (6.67 g, 96.6 mmol) in
water (90 mL) in a drop-wise manner, during which time the
diazonium salt precipitated. After completion of the addition, the
reaction mixture was stirred at 0.degree. C. for 1 hour. It was
then filtered; the filter cake was washed with petroleum ether
(3.times.200 mL) to afford the product (25.8 g) as a pale red
solid. This material was used directly in the next step.
Step 2. Synthesis of 5,6-dichloropyridin-3-yl acetate (C33)
[0226] A solution of C32 (from the previous step; 25.8 g,
.ltoreq.92 mmol) was dissolved in acetic anhydride (75 mL) and
slowly warmed to 70.degree. C. When nitrogen evolution had ceased,
stirring was continued for 1 hour at 70.degree. C., whereupon the
solvent was evaporated. The residue was dissolved in tert-butyl
methyl ether (100 mL) and washed with water (4.times.40 mL). The
combined aqueous layers were extracted with additional tert-butyl
methyl ether (3.times.50 mL), and the combined organic layers were
washed with saturated aqueous sodium chloride solution (5.times.20
mL), dried over sodium sulfate, filtered, and concentrated in
vacuo. Silica gel chromatography (Gradient: 0% to 25% ethyl acetate
in petroleum ether) afforded the product as a yellow oil. Yield:
9.7 g, 47 mmol, 51% over 2 steps. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.33 (d, J=2.5 Hz, 1H), 8.18 (d, J=2.5 Hz,
1H), 2.32 (s, 3H).
Step 3. Synthesis of 3-chloro-5-hydroxypyridine-2-carbonitrile
(C34)
[0227] Zinc cyanide (2.6 g, 22 mmol), zinc dust (145 mg, 2.21
mmol), and
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1.72
g, 2.35 mmol) were added to a room temperature solution of C33 (9.7
g, 47 mmol) in N,N-dimethylformamide (60 mL). The reaction mixture
was stirred at 140.degree. C. for 13 hours, whereupon it was
diluted with tert-butyl methyl ether (200 mL) and water (150 mL)
and filtered through a pad of diatomaceous earth. The aqueous layer
of the filtrate was extracted with additional tert-butyl methyl
ether (3.times.50 mL), and the combined organic layers were washed
with saturated aqueous sodium chloride solution (8.times.50 mL),
dried over sodium sulfate, filtered, and concentrated in vacuo to
provide the product as a brown solid. Yield: 6.8 g, 44 mmol, 94%.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.16 (d, J=2.5 Hz, 1H),
7.38 (d, J=2.5 Hz, 1H).
Step 4. Synthesis of
3-chloro-5-(difluoromethoxy)pyridine-2-carbonitrile (C35)
[0228] A mixture of C34 (6.8 g, 44 mmol), sodium
chloro(difluoro)acetate (20 g, 180 mmol) and potassium carbonate
(36.5 g, 264 mmol) in N,N-dimethylformamide (70 mL) was stirred at
100.degree. C. for 40 minutes (until no gas evolution could be
seen). The reaction mixture was diluted with tert-butyl methyl
ether (200 mL) and water (150 mL), and the aqueous layer was
extracted with additional tert-butyl methyl ether (3.times.100 mL).
The combined organic layers were washed with saturated aqueous
sodium chloride solution (8.times.50 mL), dried over sodium
sulfate, filtered, and concentrated under reduced pressure.
Chromatography on silica gel (Gradient: 0% to 20% ethyl acetate in
petroleum ether) afforded the product as a yellow oil. Yield: 5.55
g, 27.1 mmol, 62%. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.52-8.45 (m, 1H), 7.73-7.65 (m, 1H), 6.68 (t, J.sub.HF=70.8 Hz,
1H).
Step 5. Synthesis of methyl
3-chloro-5-(difluoromethoxy)pyridine-2-carboxylate (C36)
[0229] Compound C35 (4.82 g, 23.6 mmol) was dissolved in a solution
of hydrogen chloride in methanol (4 M; 75 mL), and the reaction
mixture was stirred at 60.degree. C. for 13 hours. It was then
diluted with water (50 mL) and stirred at room temperature for 30
minutes. The mixture was concentrated under reduced pressure and
the residual aqueous phase was neutralized via addition of
saturated aqueous sodium bicarbonate solution (200 mL) and then
extracted with ethyl acetate (3.times.60 mL). The combined organic
layers were washed with saturated aqueous sodium chloride solution
(30 mL), dried over sodium sulfate, filtered, and concentrated in
vacuo. The resulting material was combined with the crude product
from a similar reaction carried out using C35 (500 mg, 2.4 mmol),
and the mixture was subjected to silica gel chromatography
(Gradient: 0% to 20% ethyl acetate in petroleum ether), providing
the product as a yellow oil, which solidified upon standing at room
temperature. Yield: 3.4 g, 14 mmol, 54%. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.50-8.43 (m, 1H), 7.68-7.62 (m, 1H), 6.64 (t,
J.sub.HF=71.3 Hz, 1H), 4.02 (s, 3H).
Step 6. Synthesis of
3-chloro-5-(difluoromethoxy)pyridine-2-carboxylic acid (P8)
[0230] Lithium hydroxide monohydrate (279 mg, 6.31 mmol) was added
to a solution of C36 (1.0 g, 4.2 mmol) in tetrahydrofuran (40 mL)
and water (20 mL). The reaction mixture was stirred at room
temperature for 3 hours, whereupon it was concentrated in vacuo,
and the residual aqueous phase was adjusted to a pH of 2-3 via
addition of 2 M aqueous hydrochloric acid. The resulting mixture
was extracted with ethyl acetate (7.times.20 mL), and the combined
organic layers were dried over sodium sulfate, filtered, and
concentrated under reduced pressure to afford the product as a pale
yellow solid. Yield: 720 mg, 3.22 mmol, 77%. LCMS m/z 222.0
[M-H.sup.+] (chlorine isotope pattern observed). .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 8.51 (d, J=2.0 Hz, 1H), 8.06 (d, J=2.0
Hz, 1H), 7.44 (t, J.sub.HF=72.8 Hz, 1H).
Preparation P9
2-(Fluoromethyl)-1,3-oxazole-4-carboxylic acid (P9)
##STR00017##
[0231] Step 1. Synthesis of methyl
2-(dichloromethyl)-4,5-dihydro-1,3-oxazole-4-carboxylate (C37)
[0232] A solution of dichloroacetonitrile (215 g, 1.96 mol) in
methanol (200 mL) was added drop-wise to a -5.degree. C. solution
of sodium methoxide (15.4 g, 0.285 mol) in methanol (500 mL). A
solution of methyl 2-amino-3-hydroxypropanoate, hydrochloride salt
(382 g, 2.45 mol) in methanol (300 mL) was then added to the
-5.degree. C. reaction mixture, which was subsequently allowed to
stir at room temperature for 16 hours. Dichloromethane (1 L) and
water (800 mL) were added, and the aqueous layer was extracted with
dichloromethane (1 L); the combined organic layers were
concentrated in vacuo to provide the product as a yellow oil, which
was used in the next step without further purification. Yield: 300
g, 1.4 mol, 71%. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 6.29 (s,
1H), 4.90 (dd, J=10.8, 8.3 Hz, 1H), 4.74 (dd, J=8.8, 8.3 Hz, 1H),
4.66 (dd, J=10.8, 8.9 Hz, 1H), 3.82 (s, 3H).
Step 2. Synthesis of methyl 2-(chloromethyl)-4-methoxy-4,
5-dihydro-1,3-oxazole-4-carboxylate (C38)
[0233] A solution of C37 (205 g, 0.967 mol) in methanol (700 mL)
was added drop-wise to a cooled solution of sodium methoxide (52.2
g, 0.966 mol) in methanol (300 mL), at a rate sufficient to
maintain the reaction temperature below 10.degree. C. The reaction
mixture was then stirred at room temperature for 16 hours,
whereupon it was diluted with dichloromethane (1 L) and water (800
mL). The aqueous layer was extracted with dichloromethane
(2.times.500 mL), and the combined organic layers were concentrated
in vacuo to afford the product as a yellow oil. This material was
used in the next step without additional purification. Yield: 200
g, 0.96 mol, 99%.
Step 3. Synthesis of methyl
2-(chloromethyl)-1,3-oxazole-4-carboxylate (C39)
[0234] (7,7-Dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic
acid (camphor-sulfonic acid, 45.9 g, 0.198 mol) was added to a
solution of C38 (193 g, 0.930 mol) in toluene (700 mL), and the
reaction mixture was heated at 70.degree. C. for 1 hour. Water (1
L) was added, and the mixture was extracted with ethyl acetate
(2.times.1 L); the combined organic layers were sequentially washed
with aqueous potassium carbonate solution (10%, 500 mL), water (800
mL), and saturated aqueous sodium chloride solution (0.8 L), dried,
and concentrated in vacuo. Silica gel chromatography (Gradient: 5%
to 25% ethyl acetate in petroleum ether) provided the product as a
white solid. Yield: 55 g, 0.31 mol, 33%. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.26 (s, 1H), 4.65 (s, 2H), 3.93 (s, 3H).
Step 4. Synthesis of methyl
2-(fluoromethyl)-1,3-oxazole-4-carboxylate (C40)
[0235] To a suspension of C39 (40 g, 0.23 mol) in acetonitrile (1
L) was added tetrabutylammonium fluoride (357 g, 1.36 mol), and the
reaction mixture was stirred at 25.degree. C. for 16 hours. After
removal of solvent in vacuo, the residue was diluted with water (1
L) and extracted with ethyl acetate (4.times.1 L). The combined
organic layers were dried over sodium sulfate, filtered, and
concentrated under reduced pressure. Chromatography on silica gel
(Gradient: 17% to 23% ethyl acetate in petroleum ether) afforded
the product as a yellow solid. Yield: 8.7 g, 55 mmol, 24%. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 8.31 (d, J=1.2 Hz, 1H), 5.43 (d,
J.sub.HF=47.2 Hz, 2H), 3.94 (s, 3H).
Step 5. Synthesis of 2-(fluoromethyl)-1,3-oxazole-4-carboxylic acid
(P9)
[0236] To a solution of C40 (18 g, 110 mmol) in tetrahydrofuran
(150 mL) was added a solution of lithium hydroxide (5.42 g, 226
mmol) in a mixture of methanol and water (1:1, 500 mL). The
reaction mixture was stirred at room temperature for 1 hour,
whereupon it was concentrated in vacuo. After the residue had been
dissolved in water (500 mL), it was acidified by addition of 2 M
aqueous hydrochloric acid until it reached a pH of 2. The aqueous
layer was then extracted with ethyl acetate (2.times.100 mL), and
the combined organic layers were dried over sodium sulfate,
filtered, and concentrated under reduced pressure, providing the
product as a yellow solid. Yield: 13 g, 90 mmol, 82%. LCMS m/z
144.0 [M-H.sup.+]. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.61
(s, 1H), 5.47 (d, J.sub.HF=47 Hz, 2H).
Preparation P10
5-(But-2-yn-1-yloxy)pyridine-2-carboxylic acid (P10)
##STR00018##
[0237] Step 1. Synthesis of methyl
5-(but-2-yn-1-yloxy)pyridine-2-carboxylate (C41)
[0238] To a 0.degree. C. solution of but-2-yn-1-ol (0.645 mL, 8.62
mmol) in tetrahydrofuran (30 mL) were added methyl
5-hydroxypyridine-2-carboxylate (1.30 g, 8.49 mmol),
triphenylphosphine (3.34 g, 12.7 mmol), and diisopropyl
azodicarboxylate (2.50 mL, 12.7 mmol). The reaction mixture was
then warmed to room temperature (18.degree. C.) and stirred for 48
hours, whereupon it was concentrated in vacuo. Silica gel
chromatography (Gradient: 15% to 50% ethyl acetate in petroleum
ether) afforded the product as a yellow solid. Yield: 1.1 g, 5.4
mmol, 64%. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.46 (d, J=2.9
Hz, 1H), 8.13 (d, J=8.8 Hz, 1H), 7.37 (dd, J=8.8, 2.9 Hz, 1H), 4.77
(q, J=2.3 Hz, 2H), 3.99 (s, 3H), 1.86 (t, J=2.3 Hz, 3H).
Step 2. Synthesis of 5-(but-2-yn-1-yloxy)pyridine-2-carboxylic acid
(P10)
[0239] A solution of lithium hydroxide monohydrate (975 mg, 23.2
mmol) in water (7 mL) was added drop-wise to a room temperature
(15.degree. C.) solution of C41 (1.59 g, 7.75 mmol) in
tetrahydrofuran (20 mL), and the reaction mixture was stirred at
room temperature for 1 hour. It was then acidified to pH 2 via
addition of 2 M aqueous hydrochloric acid, and extracted with ethyl
acetate (2.times.100 mL). The combined organic layers were washed
with saturated aqueous sodium chloride solution (2.times.100 mL),
dried over sodium sulfate, filtered, and concentrated under reduced
pressure to provide the product as a yellow solid. Yield: 1.0 g,
5.2 mmol, 67%. LCMS m/z 192.1 [M+H].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.35 (d, J=2.9 Hz, 1H), 8.14 (d, J=8.7 Hz, 1H),
7.57 (dd, J=8.7, 2.8 Hz, 1H), 4.87 (q, J=2.3 Hz, 2H), 1.84 (t,
J=2.3 Hz, 3H).
Example 1
N-{2-[(5S)-3-Amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazi-
n-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide
(1)
##STR00019##
[0240] Step 1. Synthesis of tert-butyl
{(5S)-5-[4-({[5-(difluoromethoxy)pyridin-2-yl]carbonyl)}amino)-1,3-thiazo-
l-2-yl]-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-3-yl}carb-
amate (C42)
[0241] Triethylamine (36.4 .mu.L, 0.261 mmol) and
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (HATU; 72.9 mg, 0.192 mmol) were added to a
solution of P1 (100 mg, 0.266 mmol) and P6 (36.3 mg, 0.192 mmol) in
dichloromethane (3.5 mL), and the reaction mixture was stirred at
room temperature for 1 hour. After being diluted with
dichloromethane, it was washed sequentially with water and with
saturated aqueous sodium chloride solution, dried over sodium
sulfate, filtered, and concentrated in vacuo. Silica gel
chromatography (Gradient: 0% to 50% ethyl acetate in heptane)
afforded the product as a white solid. Yield: 88.7 mg, 0.162 mmol,
84%. LCMS m/z 547.3 [M+H].sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.56 (dd, J=2.7, 0.4 Hz, 1H), 8.27 (dd, J=8.7, 0.5 Hz, 1H),
7.81 (br dd, J=8.7, 2.7 Hz, 1H), 7.78 (s, 1H), 7.08 (t,
J.sub.HF=72.6 Hz, 1H), 4.58 (d, J=13.9 Hz, 1H), 4.17 (d, J=14.0 Hz,
1H), 3.19 (s, 3H), 1.92 (s, 3H), 1.52 (s, 9H).
Step 2. Synthesis of
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiaz-
in-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide
(1)
[0242] A solution of C42 (88.7 mg, 0.162 mmol) in dichloromethane
(2.7 mL) was treated with trifluoroacetic acid (0.249 mL, 3.23
mmol), and the reaction mixture was stirred at room temperature for
1 hour. It was then diluted with dichloromethane, washed
sequentially with saturated aqueous sodium bicarbonate solution and
with saturated aqueous sodium chloride solution, dried over sodium
sulfate, filtered, and concentrated. Purification via
chromatography on silica gel (Gradient: 0% to 10% methanol in
dichloromethane) provided the product as a white solid. Yield: 67
mg, 0.15 mmol, 93%. LCMS m/z 447.2 [M+H].sup.+. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.56 (br dd, J=2.7, 0.5 Hz, 1H), 8.27 (dd,
J=8.7, 0.6 Hz, 1H), 7.81 (ddt, J=8.6, 2.7, 0.6 Hz, 1H), 7.64 (s,
1H), 7.08 (t, J.sub.HF=72.6 HZ, 1H), 4.16 (d, J=13.8 Hz, 1H), 3.76
(d, J=13.8 Hz, 1H), 3.19 (s, 3H), 1.70 (s, 3H).
Example 2
N-{2-[(5S)-3-Amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazi-
n-5-yl]-1,3-thiazol-4-yl}-1-(difluoromethyl)-1H-pyrazole-3-carboxamide
(2)
##STR00020##
[0243] Step 1. Synthesis of
N-{2-[(5S)-3-(benzoylamino)-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-
-thiadiazin-5-yl]-1,3-thiazol-4-yl}-1-(difluoromethyl)-1H-pyrazole-3-carbo-
xamide (C43)
[0244] A mixture of P2 (50 mg, 0.13 mmol) and
1-(difluoromethyl)-1H-pyrazole-3-carboxylic acid (25.6 mg, 0.158
mmol) in ethyl acetate (1 mL) was cooled to 0.degree. C.
Triethylamine (73 .mu.L, 0.52 mmol) and
2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide
(50% solution in ethyl acetate; 157 .mu.L, 0.264 mmol) were added,
and the reaction mixture was stirred for 2.5 hours at 0.degree. C.
It was then partitioned between saturated aqueous sodium
bicarbonate solution (7 mL) and ethyl acetate (7 mL); the aqueous
layer was extracted with ethyl acetate (3.times.7 mL), and the
combined organic layers were dried over sodium sulfate, filtered,
and concentrated in vacuo. Silica gel chromatography (Gradient: 0%
to 100% ethyl acetate in heptane) provided the product as an
off-white solid. Yield: 25.8 mg, 49.3 .mu.mol, 38%. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 12.52-12.26 (brs, 1H), 9.39 (brs,
1H), 8.25 (brd, J=8.2 Hz, 2H), 7.91 (d, J=2.6 Hz, 1H), 7.74 (s,
1H), 7.56 (br dd, J=7, 7 Hz, 1H), 7.46 (br dd, J=7.6, 7.5 Hz, 2H),
7.23 (t, J.sub.HF=60.4 Hz, 1H), 7.08 (d, J=2 Hz, 1H), 4.44 (d,
J=13.8 Hz, 1H), 3.75 (d, J=13.8 Hz, 1H), 3.48 (s, 3H), 2.00 (s,
3H).
Step 2. Synthesis of
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1, 2,
4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-1-(difluoromethyl)-1H-pyrazole-3-car-
boxamide (2)
[0245] A suspension of C43 (25.8 mg, 49.3 .mu.mol) and
1,8-diazabicyclo[5.4.0]undec-7-ene (2 drops) in methanol (1 mL) was
heated to 60.degree. C. overnight, whereupon it was allowed to cool
to room temperature and was concentrated in vacuo. Chromatography
on silica gel (Gradient: 40% to 100% ethyl acetate in heptane)
afforded the product as a white solid. Yield: 10.6 mg, 25.3
.mu.mol, 51%. LCMS m/z 420.1 [M+H].sup.+. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 9.34 (br s, 1H), 7.90 (d, J=2.7 Hz, 1H), 7.65
(s, 1H), 7.23 (t, J.sub.HF=60.5 Hz, 1H), 7.07 (d, J=2.7 Hz, 1H),
4.12 (d, J=14.0 Hz, 1H), 3.71 (d, J=14.0 Hz, 1H), 3.31 (s, 3H),
1.81 (s, 3H).
Examples 3, 4, and 5
N-{2-[(5R,6S)-3-Amino-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2-
H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-c-
arboxamide (3),
N-{2-[(5S,6R)-3-Amino-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro--
2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2--
carboxamide (4), and
N-{2-[(5S,6S)-3-Amino-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro--
2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2--
carboxamide (5)
##STR00021##
[0246] Step 1. Synthesis of
N-[5-(4-amino-1,3-thiazol-2-yl)-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,-
6-dihydro-2H-1,2,4-thiadiazin-3-yl]benzamide (C44)
[0247] Trifluoroacetic acid (0.7 mL) was added in a drop-wise
manner to a 0.degree. C. solution of P3 (0.288 g, 0.506 mmol) in
dichloromethane (5 mL). The reaction mixture was stirred at
0.degree. C. for 1 hour, whereupon it was partitioned between
dichloromethane (100 mL) and saturated aqueous sodium bicarbonate
solution (200 mL). The aqueous layer was extracted with
dichloromethane (2.times.50 mL), and the combined organic layers
were dried over sodium sulfate, filtered, and concentrated in vacuo
to provide the product as an orange solid (0.25 g). This material
was taken directly to the following step. LCMS showed two
close-running peaks of similar size, both with m/z 420.4
[M+H].sup.+.
Step 2. Synthesis of
N-{2-[3-(benzoylamino)-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro-
-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)
pyridine-2-carboxamide (C45)
[0248] A solution of C44 (from the previous step, 0.25 g,
.ltoreq.0.506 mmol) and P6 (0.135 g, 0.714 mmol) in ethyl acetate
(5 mL) was cooled to 0.degree. C. and treated with triethylamine
(0.332 mL, 2.38 mmol).
2,4,6-Tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide
(50% solution in ethyl acetate; 0.709 mL, 1.19 mmol) was added, and
stirring was continued for 2 hours at 0.degree. C. LCMS analysis at
this point revealed two close-running peaks in an approximately 1:1
ratio, both with m/z 591.3 [M+H].sup.+. Saturated aqueous sodium
bicarbonate solution (50 mL) was added, and the resulting mixture
was extracted with ethyl acetate (3.times.50 mL). The combined
organic layers were dried over sodium sulfate, filtered, and
concentrated in vacuo; the residue was adsorbed onto silica gel as
a solution in dichloromethane and subjected to silica gel
chromatography (Gradient: 0% to 100% ethyl acetate in heptane). The
product was isolated as a white solid, which by .sup.1H NMR
analysis consisted of an approximately 1:1 mixture of
diastereomers. Yield: 232 mg, 0.393 mmol, 78% over 2 steps. .sup.1H
NMR (400 MHz, CDCl.sub.3), characteristic peaks: .delta. [10.43 (br
s) and 10.40 (br s), total 1H], [8.50 (br d, J=2.6 Hz) and 8.47 (br
d, J=2.4 Hz), total 1H], 8.34-8.30 (m, 1H), 8.28-8.20 (m, 2H),
[7.84 (s) and 7.83 (s), total 1H], 7.70-7.66 (m, 1H), 7.58-7.51 (m,
1H), 7.49-7.42 (m, 2H), [6.66 (t, J.sub.HF=71.9 Hz) and 6.65 (t,
J.sub.HF=71.8 Hz), total 1H], [3.56 (d, J=10.9 Hz) and 2.98 (d,
J=10.9 Hz), total 1H], [3.52 (s) and 3.48 (s), total 3H), [2.13 (s)
and 2.09 (s), total 3H].
Step 3. Synthesis of
N-{2-[(5R,6S)-3-amino-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro--
2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2--
carboxamide (3),
N-{2-[(5S,6R)-3-amino-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro--
2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2--
carboxamide (4), and
N-{2-[(5S,6S)-3-amino-6-cyclopropyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro--
2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2--
carboxamide (5)
[0249] To a solution of C45 (232 mg, 0.393 mmol) in methanol (10
mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (59.3 .mu.L, 0.396
mmol), and the reaction mixture was heated to 60.degree. C. for 16
hours. Solvent was removed in vacuo, and the residue was adsorbed
onto silica gel as a solution in dichloromethane; silica gel
chromatography (Gradient: 20% to 100% ethyl acetate in heptane)
provided the products (138 mg, 0.284 mmol, 72% yield). The mixed
fractions from the column (115 mg, 0.236 mmol) were subjected to
supercritical fluid chromatography (Column: Phenomenex Lux
Cellulose-2, .mu.m; Mobile phase A: carbon dioxide; Mobile phase B:
1:1 acetonitrile/methanol; Gradient: 5% to 60% B) to separate the
individual enantiomers and diastereomers. Each of the three samples
isolated was then individually chromatographed on silica gel
(Gradient: 0% to 10% methanol in dichloromethane) to afford the
following, all of which were obtained as white solids.
[0250] The first-eluting isomer from the supercritical fluid
chromatography provided 3. Yield: 7.4 mg, 15 .mu.mol, 4%. LCMS m/z
487.3 [M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.38
(br s, 1H), 8.47 (br s, 1H), 8.31 (d, J=8.6 Hz, 1H), 7.71 (s, 1H),
7.67 (br d, J=8.6 Hz, 1H), 6.65 (t, J.sub.HF=72.1 Hz, 1H), 3.37 (d,
J=11.0 Hz, 1H), 3.29 (s, 3H), 1.85 (s, 3H), 1.10-0.99 (m, 1H),
0.95-0.69 (m, 3H), 0.27-0.18 (m, 1H).
[0251] The second-eluting isomer from the supercritical fluid
chromatography provided 4. Yield: 39.9 mg, 82.0 .mu.mol, 21%. LCMS
m/z 487.3 [M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
10.38 (br s, 1H), 8.47 (br d, J=2.4 Hz, 1H), 8.31 (br d, J=8.6 Hz,
1H), 7.73 (s, 1H), 7.67 (br dd, J=8.6, 2.7 Hz, 1H), 6.65 (t,
J.sub.HF=72.0, 1H), 3.45 (d, J=10.8 Hz, 1H), 3.31 (s, 3H), 1.91 (s,
3H), 1.12-1.00 (m, 1H), 0.96-0.85 (m, 1H), 0.85-0.72 (m, 2H),
0.29-0.19 (m, 1H).
[0252] The third-eluting isomer from the supercritical fluid
chromatography was obtained in a quantity too small to
characterize.
[0253] The fourth-eluting isomer from the supercritical fluid
chromatography provided 5. Yield: 20.2 mg, 41.5 .mu.mol, 11%. LCMS
m/z 487.3 [M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
10.38 (br s, 1H), 8.49 (br d, J=2.3 Hz, 1H), 8.32 (br d, J=8.6 Hz,
1H), 7.74 (s, 1H), 7.68 (br dd, J=8.6, 2.7 Hz, 1H), 6.65 (t,
J.sub.HF=72.0 Hz, 1H), 3.29 (s, 3H), 2.91 (d, J=10.9 Hz, 1H), 1.92
(s, 3H), 1.36-1.23 (m, 1H), 0.85-0.69 (m, 2H), 0.62-0.52 (m, 1H),
0.30-0.21 (m, 1H).
[0254] The indicated relative and absolute stereochemistries for
these compounds were assigned on the basis of NMR work and
biological activity. From the .sup.1H NMR spectra, 3 and 4 are
enantiomers of one another. NOE studies revealed that irradiation
of the quaternary methyl group of both 3 and 4 resulted in
enhancement of the methine proton of the cyclopropyl group, while
irradiation of the methine adjacent to the sulfonyl group in 5
provided a substantial enhancement in the signal for the quaternary
methyl group; these results established the relative
stereochemistry of the cyclopropyl and methyl groups. The potency
difference between 3 and 4, in relation to the potency of 9 (see
Table 7), indicated that 4 has the same absolute stereochemistry at
the quaternary center as does 9 (see X-ray structure determination
on 9 below).
Examples 6, 7, and 8
N-[2-(3-Amino-2, 5, 6,
6-tetramethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl)-1,3-thiaz-
ol-4-yl]-5-(difluoromethoxy)pyridine-2-carboxamide (6),
N-{2-[(5R)-3-amino-2,
5,6,6-tetramethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-t-
hiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide (7), and
N-{2-[(5S)-3-amino-2,5,6,6-tetramethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-t-
hiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamid-
e (8)
##STR00022##
[0255] Step 1. Synthesis of
N-[5-(4-amino-1,3-thiazol-2-yl)-2,5,6,6-tetramethyl-1,1-dioxido-5,6-dihyd-
ro-2H-1,2,4-thiadiazin-3-yl]benzamide (C46)
[0256] Conversion of P4 to C46 was carried out using the method
described for synthesis of C44 from P3 in Examples 3, 4, and 5. The
product was obtained as an orange solid, which was used directly in
the following step. LCMS m/z 408.2 [M+H].sup.+.
Step 2. Synthesis of
N-{2-[3-(benzoylamino)-2,5,6,6-tetramethyl-1,1-dioxido-5,6-dihydro-2H-1,2-
,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carbox-
amide (C47)
[0257] Reaction of C46 with P6 was effected using the procedure
described for synthesis of C45 from C44 in Examples 3, 4, and 5.
The product was isolated as a white solid. Yield: 80 mg, 0.14 mmol,
58%. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 12.45 (br s, 1H),
10.44 (br s, 1H), 8.51 (br d, J=2.6 Hz, 1H), 8.33 (dd, J=8.6, 0.6
Hz, 1H), 8.29-8.25 (m, 2H), 7.83 (s, 1H), 7.69 (br dd, J=8.7, 2.7
Hz, 1H), 7.57-7.52 (m, 1H), 7.49-7.43 (m, 2H), 6.66 (t,
J.sub.HF=71.9 Hz, 1H), 3.54 (s, 3H), 2.07 (s, 3H), 1.85 (s, 3H),
1.52 (s, 3H).
Step 3. Synthesis of N-[2-(3-amino-2, 5, 6,
6-tetramethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl)-1,3-thiaz-
ol-4-yl]-5-(difluoromethoxy)pyridine-2-carboxamide (6)
[0258] 1,8-Diazabicyclo[5.4.0]undec-7-ene (20.9 .mu.L, 0.140 mmol)
was added to a solution of C47 (80 mg, 0.14 mmol) in methanol (5
mL). The reaction mixture was heated to 60.degree. C. for 10 hours,
whereupon it was concentrated in vacuo and adsorbed onto silica gel
as a solution in dichloromethane. Silica gel chromatography
(Gradient: 20% to 100% ethyl acetate in heptane) afforded the
product as a white solid. Yield: 57 mg, 0.12 mmol, 86%. LCMS m/z
475.3 [M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.36
(br s, 1H), 8.50 (br d, J=2.7 Hz, 1H), 8.32 (dd, J=8.6, 0.6 Hz,
1H), 7.69 (s, 1H), 7.68 (br dd, J=8.6, 2.6 Hz, 1H), 6.66 (t,
J.sub.HF=72.0 Hz, 1H), 4.22-4.07 (br s, 2H), 3.29 (s, 3H), 1.95 (s,
3H), 1.85 (s, 3H), 1.17 (s, 3H).
Step 4. Isolation of
N-{2-[(5R)-3-amino-2,5,6,6-tetramethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-t-
hiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamid-
e (7) and
N-{2-[(5S)-3-amino-2,5,6,6-tetramethyl-1,1-dioxido-5,6-dihydro-2-
H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-c-
arboxamide (8)
[0259] Separation of 6 (57 mg) into its component enantiomers was
effected via supercritical fluid chromatography (Column: Phenomenex
Lux Cellulose-2, 5 .mu.m; Mobile phase A: carbon dioxide; Mobile
phase B: 1:1 acetonitrile/methanol; Gradient: 5% to 60% B). Each
enantiomer was then repurified using silica gel chromatography
(Gradient: 0% to 10% methanol in dichloromethane). The
first-eluting enantiomer from the supercritical fluid
chromatography was obtained as a white solid after silica gel
chromatography, and was assigned as 7. Yield: 6.3 mg, 11% for the
separation. LCMS m/z 475.3 [M+H].sup.+. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.37 (br s, 1H), 8.50 (d, J=2.6 Hz, 1H), 8.32
(d, J=8.6 Hz, 1H), 7.74 (s, 1H), 7.70-7.66 (m, 1H), 6.66 (t,
J.sub.HF=71.9 Hz, 1H), 3.35 (s, 3H), 1.92 (s, 3H), 1.90 (s, 3H),
1.27 (br s, 3H).
[0260] The second-eluting enantiomer from the supercritical fluid
chromatography was also obtained as a white solid after silica gel
chromatography, and was assigned as 8. Yield: 15 mg, 26% for the
separation. LCMS m/z 475.3 [M+H].sup.+. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 10.36 (br s, 1H), 8.50 (s, 1H), 8.32 (d, J=8.6
Hz, 1H), 7.71 (s, 1H), 7.70-7.65 (m, 1H), 6.65 (t, J.sub.HF=71.9
Hz, 1H), 3.32 (s, 3H), 1.93 (s, 3H), 1.87 (s, 3H), 1.21 (s,
3H).
[0261] The indicated absolute stereochemistries of 7 and 8 were
assigned on the basis of the difference in the biological activity
of these two compounds (see Table 7), in analogy with the
stereochemistries of 3 and 4.
Example 9
N-{2-[(5S)-3-Amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazi-
n-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)-3-methylpyridine-2-carboxami-
de, methanesulfonic acid salt (9)
##STR00023##
[0262] Step 1. Synthesis of tert-butyl
{(5S)-5-[4-({[5-(difluoromethoxy)-3-methylpyridin-2-yl]carbonyl}amino)-1,-
3-thiazol-2-yl]-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-3-
-yl}carbamate (C48)
[0263] A mixture of P1 (31.30 g, 83.36 mmol), P7 (30.5 g, 150
mmol), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (76.1 g, 200 mmol), and
N,N-diisopropylethylamine (116 mL, 666 mmol) in dichloromethane
(1.7 L) was stirred at room temperature for 30 minutes. The
reaction mixture was then diluted with dichloromethane, washed
sequentially with aqueous 5% citric acid solution, saturated
aqueous sodium bicarbonate solution, and saturated aqueous sodium
chloride solution, dried over sodium sulfate, filtered, and
concentrated in vacuo. Chromatography on silica gel (Gradient: 0%
to 100% ethyl acetate in heptane) afforded the product as a pale
yellow solid. Yield: 36.57 g, 65.23 mmol, 78%. LCMS m/z 559.3
[M-H+]. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.39-8.37 (m,
1H), 7.74 (s, 1H), 7.60-7.58 (m, 1H), 7.06 (t, J.sub.HF=72.8 Hz,
1H), 4.56 (d, J=13.9 Hz, 1H), 4.16 (d, J=14.0 Hz, 1H), 3.19 (s,
3H), 2.75 (s, 3H), 1.91 (br s, 3H), 1.52 (s, 9H).
Step 2. Synthesis of
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1, 2,
4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)-3-methylpyridine-
-2-carboxamide (C49)
[0264] Trifluoroacetic acid (100 mL) was added to a solution of C48
(36.57 g, 65.23 mmol) in dichloromethane (1.1 L). The reaction
mixture was stirred at room temperature for 45 minutes, whereupon
it was basified by addition of 1 M aqueous sodium hydroxide
solution. The aqueous layer was extracted twice with
dichloromethane, and the combined organic layers were washed with
saturated aqueous sodium chloride solution, dried over sodium
sulfate, filtered and concentrated under reduced pressure. Silica
gel chromatography (Gradient: 0% to 5% methanol in dichloromethane)
provided an off-white solid, which was triturated in heptane
containing a small amount of diethyl ether for approximately 30
minutes to afford the product as a white solid. Yield: 26.08 g,
56.64 mmol, 87%. LCMS m/z 461.3 [M+H].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.38 (br d, J=2.5 Hz, 1H), 7.60 (s, 1H), 7.58
(br d, J=2.5 Hz, 1H), 7.05 (t, J.sub.HF=72.8 Hz, 1H), 4.15 (d,
J=13.7 Hz, 1H), 3.75 (d, J=13.8 Hz, 1H), 3.19 (s, 3H), 2.75 (s,
3H), 1.70 (s, 3H).
Step 3. Synthesis of
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1, 2,
4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)-3-methylpyridine-
-2-carboxamide, methanesulfonic acid salt (9)
[0265] A mixture of C49 (32.62 g, 70.84 mmol) in methanol (316 mL)
was filtered through cotton, and then treated with a solution of
methanesulfonic acid (4.60 mL, 70.9 mmol) in methanol (38 mL). The
resulting mixture was stirred for 1 hour, whereupon it was
concentrated on a rotary evaporator until it became a very thick
slurry. At this point, diethyl ether (400 mL) was added, and the
mixture was stirred for 10 minutes and filtered. The filter cake
was thoroughly washed with diethyl ether, affording the product as
a white solid, which was found to be crystalline via powder X-ray
diffraction. Yield: 36.95 g, 66.39 mmol, 94%. LCMS m/z 461.3
[M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.87 (s,
1H), 10.40 (br s, 1H), 8.70-8.52 (br s, 2H), 8.44 (d, J=2.7 Hz,
1H), 7.78 (s, 1H), 7.75-7.73 (m, 1H), 7.45 (t, J.sub.HF=72.9 Hz,
1H), 4.66 (br AB quartet, J.sub.AB=13.9 Hz, .DELTA..nu..sub.AB=81
Hz, 2H), 3.23 (s, 3H), 2.65 (s, 3H), 2.35 (s, 3H), 1.84 (br s, 3H).
Recrystallization of a sample of 9 from methanol afforded a crystal
that was used for X-ray crystal structure analysis (see below);
this confirmed the absolute stereochemistry as that drawn.
Single-Crystal X-Ray Structure Determination on 9
[0266] Data collection was performed on a Bruker APEX
diffractometer at room temperature. Data collection consisted of
omega and phi scans. Resolution limited to 1.0 angstroms, data
collection cut short, thus data to parameter ratio near 3:1.
[0267] The structure was solved by direct methods using SHELX
software suite in the space group P2.sub.12.sub.12.sub.1. The
structure was subsequently refined by the full-matrix least squares
method. All non-hydrogen atoms were found and refined using
anisotropic displacement parameters.
[0268] The hydrogen atoms located on nitrogen were found from the
Fourier difference map and refined with distances restrained. The
remaining hydrogen atoms were placed in calculated positions and
were allowed to ride on their carrier atoms. The final refinement
included isotropic displacement parameters for all hydrogen
atoms.
[0269] Analysis of the absolute structure using likelihood methods
(Hooft, 2008) was performed using PLATON (Spek, 2010). The results
indicate that the absolute structure has been correctly assigned.
The method calculates that the probability that the structure is
correct is 100.0. The Hooft parameter is reported as 0.023 with an
esd of 0.07.
[0270] The final R-index was 3.0%. A final difference Fourier
revealed no missing or misplaced electron density.
[0271] Pertinent crystal, data collection and refinement
information is summarized in Table 1. Atomic coordinates, bond
lengths, bond angles, and displacement parameters are listed in
Tables 2-5.
[0272] Software and References [0273] SHELXTL, Version 5.1, Bruker
AXS, 1997. [0274] PLATON, A. L. Spek, J. Appl. Cryst. 2003, 36,
7-13. [0275] MERCURY, C. F. Macrae, P. R. Edington, P. McCabe, E.
Pidcock, G. P. Shields, R. Taylor, M. Towler, and J. van de Streek,
J. Appl. Cryst. 2006, 39, 453-457. [0276] OLEX2, O. V. Dolomanov,
L. J. Bourhis, R. J. Gildea, J. A. K. Howard, and H. Puschmann, J.
Appl. Cryst. 2009, 42, 339-341. [0277] R. W. W. Hooft, L. H.
Straver, and A. L. Spek, J. Appl. Cryst. 2008, 41, 96-103. [0278]
H. D. Flack, Acta Cryst. 1983, A39, 867-881.
TABLE-US-00001 [0278] TABLE 1 Crystal data and structure refinement
for 9. Empirical formula
C.sub.17H.sub.22F.sub.2N.sub.6O.sub.7S.sub.3 Formula weight 556.59
Temperature 298(2) K Wavelength 1.54178 .ANG. Crystal system
Orthorhombic Space group P2.sub.12.sub.12.sub.1 Unit cell
dimensions a = 6.6239(3) .ANG. .alpha. = 90.degree. b = 12.4160(6)
.ANG. .beta. = 90.degree. c = 28.8517(14) .ANG. .gamma. =
90.degree. Volume 2372.83(19) .ANG..sup.3 Z 4 Density (calculated)
1.558 Mg/m.sup.3 Absorption coefficient 3.475 mm.sup.-1 F(000) 1152
Crystal size 0.24 .times. 0.18 .times. 0.06 mm.sup.3 Theta range
for data collection 3.06 to 42.31.degree. Index ranges -5 <= h
<= 5, -10 <= k <= 10, -24 <= l <= 24 Reflections
collected 20417 Independent reflections 1639 [R(int) = 0.0469]
Completeness to theta = 99.2% 70.31.degree. Absorption correction
None Max. and min. transmission 0.8186 and 0.4893 Refinement method
Full-matrix least-squares on F.sup.2 Data/restraints/parameters
1639/6/336 Goodness-of-fit on F.sup.2 1.055 Final R indices [I >
2sigma(I)] R1 = 0.0304, wR2 = 0.0763 R indices (all data) R1 =
0.0324, wR2 = 0.0777 Absolute structure parameter 0.03(3) Largest
diff. peak and hole 0.375 and -0.217 e..ANG..sup.-3
TABLE-US-00002 TABLE 2 Atomic coordinates (.times.10.sup.4) and
equivalent isotropic displacement parameters (.ANG..sup.2 .times.
10.sup.3) for 9. U(eq) is defined as one-third of the trace of the
orthogonalized U.sup.ij tensor. x y z U(eq) C(1) 7487(9) 4467(4)
5085(2) 34(2) C(2) 12429(10) 4239(5) 4312(2) 51(2) C(3) 11467(11)
5313(6) 4995(3) 27(2) C(4) 8447(10) 4980(5) 5515(2) 31(2) C(5)
7074(9) 5896(5) 5681(2) 42(2) C(6) 8712(10) 4172(5) 5902(2) 29(2)
C(7) 9730(12) 3138(5) 6562(2) 45(2) C(8) 7770(13) 3031(6) 6442(2)
36(2) C(9) 6437(13) 1924(6) 7069(3) 40(2) C(10) 4615(14) 1238(6)
7160(3) 47(2) C(11) 4360(14) 742(6) 7599(3) 60(2) C(12) 5759(15)
826(7) 8013(3) 95(3) C(13) 2670(19) 152(8) 7645(3) 74(3) C(14)
1345(14) 23(6) 7296(4) 58(2) C(15) 1672(15) 538(7) 6865(3) 65(2)
C(16) -1085(14) -1301(11) 7086(4) 111(4) C(17) 4161(10) 8489(5)
6216(2) 65(2) N(1) 11059(7) 4493(4) 4700(2) 34(1) N(2) 12959(9)
5985(4) 4909(2) 35(1) N(3) 10396(8) 5457(4) 5384(2) 31(1) N(4)
7189(8) 3616(4) 6059(2) 34(1) N(5) 6287(10) 2384(5) 6637(2) 41(2)
N(6) 3322(12) 1129(5) 6819(2) 52(2) O(1) 8423(6) 3371(3) 4335(1)
52(1) O(2) 9836(6) 2761(3) 5076(1) 47(1) O(3) 7823(9) 2044(4)
7328(2) 74(2) O(5) 1628(7) 7046(3) 5993(1) 65(2) O(6) 3176(7)
8017(3) 5376(1) 63(1) O(7) 741(8) 8894(4) 5856(2) 73(1) O(4A)
-410(11) -563(6) 7375(2) 103(2) F(1) -2206(11) -639(7) 6794(2)
173(3) F(2) -2449(11) -1873(5) 7278(3) 179(4) S(1) 9156(2) 3614(1)
4784(1) 37(1) S(2) 10919(3) 4016(1) 6197(1) 48(1) S(3) 2270(3)
8084(1) 5832(1) 40(1)
TABLE-US-00003 TABLE 3 Bond lengths [.ANG.] and angles [.degree.]
for 9. C(1)-C(4) 1.533(7) C(1)-S(1) 1.759(6) C(1)-H(1A) 0.9700
C(1)-H(1B) 0.9700 C(2)-N(1) 1.475(7) C(2)-H(2A) 0.9600 C(2)-H(2B)
0.9600 C(2)-H(2C) 0.9600 C(3)-N(2) 1.317(7) C(3)-N(3) 1.340(7)
C(3)-N(1) 1.354(7) C(4)-N(3) 1.470(8) C(4)-C(6) 1.511(8) C(4)-C(5)
1.532(8) C(5)-H(5A) 0.9600 C(5)-H(5B) 0.9600 C(5)-H(5C) 0.9600
C(6)-N(4) 1.303(7) C(6)-S(2) 1.703(6) C(7)-C(8) 1.351(9) C(7)-S(2)
1.708(7) C(7)-H(7) 0.9300 C(8)-N(4) 1.377(7) C(8)-N(5) 1.389(8)
C(9)-O(3) 1.194(8) C(9)-N(5) 1.374(8) C(9)-C(10) 1.500(10)
C(10)-N(6) 1.312(8) C(10)-C(11) 1.419(9) C(11)-C(13) 1.344(11)
C(11)-C(12) 1.515(11) C(12)-H(12A) 0.9600 C(12)-H(12B) 0.9600
C(12)-H(12C) 0.9600 C(13)-C(14) 1.344(11) C(13)-H(13) 0.9300
C(14)-O(4A) 1.390(9) C(14)-C(15) 1.416(10) C(15)-N(6) 1.323(9)
C(15)-H(15) 0.9300 C(16)-F(2) 1.275(10) C(16)-O(4A) 1.318(11)
C(16)-F(1) 1.392(9) C(16)-H(16) 0.9800 C(17)-S(3) 1.745(6)
C(17)-H(17A) 0.9600 C(17)-H(17B) 0.9600 C(17)-H(17C) 0.9600
N(1)-S(1) 1.685(5) N(2)-H(222) 1.01(2) N(2)-H(223) 0.98(2)
N(3)-H(333) 0.99(2) N(5)-H(555) 0.97(2) O(1)-S(1) 1.416(4)
O(2)-S(1) 1.425(4) O(5)-S(3) 1.434(4) O(6)-S(3) 1.450(4) O(7)-S(3)
1.429(5) C(4)-C(1)-S(1) 112.9(4) C(4)-C(1)-H(1A) 109.0
S(1)-C(1)-H(1A) 109.0 C(4)-C(1)-H(1B) 109.0 S(1)-C(1)-H(1B) 109.0
H(1A)-C(1)-H(1B) 107.8 N(1)-C(2)-H(2A) 109.5 N(1)-C(2)-H(2B) 109.5
H(2A)-C(2)-H(2B) 109.5 N(1)-C(2)-H(2C) 109.5 H(2A)-C(2)-H(2C) 109.5
H(2B)-C(2)-H(2C) 109.5 N(2)-C(3)-N(3) 118.0(6) N(2)-C(3)-N(1)
120.5(6) N(3)-C(3)-N(1) 121.4(7) N(3)-C(4)-C(6) 110.8(5)
N(3)-C(4)-C(5) 107.6(5) C(6)-C(4)-C(5) 109.4(5) N(3)-C(4)-C(1)
108.8(5) C(6)-C(4)-C(1) 111.7(4) C(5)-C(4)-C(1) 108.4(5)
C(4)-C(5)-H(5A) 109.5 C(4)-C(5)-H(5B) 109.5 H(5A)-C(5)-H(5B) 109.5
C(4)-C(5)-H(5C) 109.5 H(5A)-C(5)-H(5C) 109.5 H(5B)-C(5)-H(5C) 109.5
N(4)-C(6)-C(4) 121.2(6) N(4)-C(6)-S(2) 115.5(4) C(4)-C(6)-S(2)
123.0(5) C(8)-C(7)-S(2) 110.3(6) C(8)-C(7)-H(7) 124.9
S(2)-C(7)-H(7) 124.9 C(7)-C(8)-N(4) 115.1(7) C(7)-C(8)-N(5)
129.2(7) N(4)-C(8)-N(5) 115.7(7) O(3)-C(9)-N(5) 124.9(7)
O(3)-C(9)-C(10) 125.3(8) N(5)-C(9)-C(10) 109.7(8) N(6)-C(10)-C(11)
123.1(8) N(6)-C(10)-C(9) 116.9(7) C(11)-C(10)-C(9) 120.0(9)
C(13)-C(11)-C(10) 115.0(8) C(13)-C(11)-C(12) 118.1(9)
C(10)-C(11)-C(12) 126.9(9) C(11)-C(12)-H(12A) 109.5
C(11)-C(12)-H(12B) 109.5 H(12A)-C(12)-H(12B) 109.5
C(11)-C(12)-H(12C) 109.5 H(12A)-C(12)-H(12C) 109.5
H(12B)-C(12)-H(12C) 109.5 C(11)-C(13)-C(14) 122.4(8)
C(11)-C(13)-H(13) 118.8 C(14)-C(13)-H(13) 118.8 C(13)-C(14)-O(4A)
119.1(10) C(13)-C(14)-C(15) 120.2(7) O(4A)-C(14)-C(15) 120.5(10)
N(6)-C(15)-C(14) 117.6(7) N(6)-C(15)-H(15) 121.2 C(14)-C(15)-H(15)
121.2 F(2)-C(16)-O(4A) 110.7(10) F(2)-C(16)-F(1) 102.3(7)
O(4A)-C(16)-F(1) 98.8(10) F(2)-C(16)-H(16) 114.5 O(4A)-C(16)-H(16)
114.5 F(1)-C(16)-H(16) 114.5 S(3)-C(17)-H(17A) 109.5
S(3)-C(17)-H(17B) 109.5 H(17A)-C(17)-H(17B) 109.5 S(3)-C(17)-H(17C)
109.5 H(17A)-C(17)-H(17C) 109.5 H(17B)-C(17)-H(17C) 109.5
C(3)-N(1)-C(2) 121.0(5) C(3)-N(1)-S(1) 123.1(5) C(2)-N(1)-S(1)
115.5(4) C(3)-N(2)-H(222) .sup. 121(3) C(3)-N(2)-H(223) .sup.
131(4) H(222)-N(2)-H(223) .sup. 107(5) C(3)-N(3)-C(4) 128.8(5)
C(3)-N(3)-H(333) .sup. 116(3) C(4)-N(3)-H(333) .sup. 114(4)
C(6)-N(4)-C(8) 109.9(6) C(9)-N(5)-C(8) 123.9(7) C(9)-N(5)-H(555)
.sup. 121(3) C(8)-N(5)-H(555) .sup. 115(3) C(10)-N(6)-C(15)
121.5(7) C(16)-O(4A)-C(14) 123.0(8) O(1)-S(1)-O(2) 119.3(2)
O(1)-S(1)-N(1) 105.2(2) O(2)-S(1)-N(1) 109.3(2) O(1)-S(1)-C(1)
111.3(3) O(2)-S(1)-C(1) 110.8(2) N(1)-S(1)-C(1) 98.7(3)
C(6)-S(2)-C(7) 89.2(4) O(7)-S(3)-O(5) 114.0(3) O(7)-S(3)-O(6)
112.1(3) O(5)-S(3)-O(6) 111.4(2) O(7)-S(3)-C(17) 106.0(3)
O(5)-S(3)-C(17) 105.5(3) O(6)-S(3)-C(17) 107.2(3)
[0279] Symmetry transformations used to generate equivalent
atoms.
TABLE-US-00004 TABLE 4 Anisotropic displacement parameters
(.ANG..sup.2 .times. 10.sup.3) for 9. The anisotropic displacement
factor exponent takes the form: -2.pi..sup.2[h.sup.2
a*.sup.2U.sup.11 + . . . + 2 h k a* b* U.sup.12]. U.sup.11 U.sup.22
U.sup.33 U.sup.23 U.sup.13 U.sup.12 C(1) 34(4) 30(4) 39(4) 5(3)
X7(4) 4(4) C(2) 54(5) 46(4) 53(4) -23(4) 13(5) -8(4) C(3) 24(5)
28(5) 30(5) 2(5) -3(4) 10(4) C(4) 33(5) 32(4) 28(4) -5(4) 3(4)
-5(4) C(5) 40(4) 37(4) 49(4) 0(3) 12(3) 7(4) C(6) 38(5) 27(4) 21(4)
1(4) 2(4) 6(4) C(7) 52(6) 44(5) 40(4) 18(4) -6(4) 4(4) C(8) 55(7)
27(4) 27(5) 3(4) 5(5) 1(5) C(9) 51(7) 25(4) 44(7) 8(5) 23(5) -4(5)
C(10) 77(7) 43(5) 20(5) 4(5) 14(6) 19(6) C(11) 51(6) 49(5) 79(9)
1(5) 18(6) -2(5) C(12) 101(7) 132(8) 52(5) 29(5) -3(6) -9(7) C(13)
82(8) 77(7) 64(7) 12(5) 4(8) 13(7) C(14) 51(7) 32(5) 91(8) 9(5)
38(7) -28(5) C(15) 67(7) 56(5) 72(7) -13(5) 15(5) -16(5) C(16)
35(6) 176(12) 122(9) -19(9) -41(7) 17(8) C(17) 56(5) 65(5) 74(5)
-11(4) -39(5) -7(4) N(1) 37(3) 33(3) 32(3) -15(3) 6(3) -9(3) N(2)
32(4) 27(3) 46(4) -5(3) 4(3) -15(3) N(3) 32(4) 28(3) 32(4) -5(3)
2(3) -4(3) N(4) 38(4) 36(3) 28(4) 4(3) 3(3) -5(4) N(5) 53(5) 43(4)
26(4) 12(4) 0(4) -15(4) N(6) 62(5) 45(4) 49(5) 4(3) 11(5) -12(4)
O(1) 66(3) 58(3) 31(3) -15(2) -4(2) -20(2) O(2) 56(3) 28(3) 57(3)
9(2) 2(2) 5(2) O(3) 75(4) 92(4) 53(4) 20(3) -22(3) -22(4) O(5)
100(4) 44(3) 51(3) -3(2) -4(3) -32(3) O(6) 92(4) 53(3) 44(3) -3(2)
6(3) -10(3) O(7) 69(3) 73(3) 78(3) -24(3) -30(3) 40(3) O(4A) 104(6)
99(5) 105(5) 7(4) 15(5) -34(5) F(1) 141(6) 251(8) 126(5) 20(5)
-11(5) -87(6) F(2) 98(5) 120(4) 320(9) 98(5) -26(6) -69(4) S(1)
38(1) 33(1) 40(1) -5(1) 3(1) -4(1) S(2) 41(1) 57(1) 47(1) 11(1)
-4(1) -4(1) S(3) 48(1) 34(1) 40(1) -3(1) -11(1) 0(1)
TABLE-US-00005 TABLE 5 Hydrogen coordinates (.times.10.sup.4) and
isotropic displacement parameters (.ANG..sup.2 .times. 10.sup.3)
for 9. x y z U(eq) H(1A) 7036 5033 4878 41 H(1B) 6311 4056 5179 41
H(2A) 12335 4793 4081 77 H(2B) 12052 3560 4178 77 H(2C) 13791 4197
4425 77 H(5A) 7663 6234 5948 63 H(5B) 5773 5610 5761 63 H(5C) 6925
6417 5438 63 H(7) 10345 2783 6809 55 H(12A) 5339 326 8248 142
H(12B) 5712 1545 8135 142 H(12C) 7114 661 7919 142 H(13) 2408 -179
7928 89 H(15) 760 463 6622 78 H(16) -26 -1717 6930 133 H(17A) 4482
9232 6162 97 H(17B) 5344 8056 6168 97 H(17C) 3697 8400 6529 97
H(222) 13170(80) 6640(30) 5110(15) 45(19) H(223) 13830(90) 6070(50)
4635(16) 90(30) H(333) 10840(90) 6060(30) 5587(15) 50(20) H(555)
5100(50) 2280(40) 6446(16) 40(20)
Examples 10, 11, 12, and 13
N-{2-[(5R,6S)-3-Amino-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thi-
adiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide
(10),
N-{2-[(5S,6R)-3-Amino-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2H-1,-
2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carbo-
xamide (11),
N-{2-[(5S,6S)-3-Amino-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-th-
iadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)
pyridine-2-carboxamide (12), and
N-{2-[(5R,6R)-3-Amino-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-th-
iadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide
(13)
##STR00024##
[0280] Step 1. Synthesis of
N-[5-(4-amino-1,3-thiazol-2-yl)-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2-
H-1,2,4-thiadiazin-3-yl]benzamide (C50)
[0281] Conversion of P5 to C50 was carried out using the procedure
described for synthesis of C44 from P3 in Examples 3, 4, and 5. The
product was isolated as an orange solid, which was taken directly
to the following step. Analysis of the reaction mixture by LCMS at
the conclusion of the experiment revealed two close-running
products in a 1:1 ratio, presumed to be the two diastereomers of
C50, with LCMS m/z 394.1 and 394.2 [M+H].sup.+.
Step 2. Synthesis of
N-{2-[3-(benzoylamino)-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-t-
hiadiazin-5-yl]-,
3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide (C51)
[0282] Reaction of C50 with P6 was carried out using the procedure
described for synthesis of C45 from C44 in Examples 3, 4, and 5.
The product was obtained as a white solid, which by .sup.1H NMR
analysis consisted of an approximately 1:1 mixture of
diastereomers. Yield: 207 mg, 0.367 mmol, 44%. .sup.1H NMR (400
MHz, CDCl.sub.3), characteristic peaks: .delta. [12.34 (br s) and
12.23 (br s), total 1H], [10.44 (br s) and 10.43 (br s), total 1H],
8.52-8.47 (m, 1H), 8.34-8.30 (m, 1H), 8.29-8.21 (m, 2H), [7.83 (s)
and 7.83 (s), total 1H], 7.71-7.66 (m, 1H), 7.58-7.51 (m, 1H),
7.49-7.42 (m, 2H), [6.66 (t, J.sub.HF=71.9 Hz) and 6.66 (t,
J.sub.HF=71.9 Hz), total 1H], 3.52 (s, 3H), [2.05 (s) and 1.98 (s),
total 3H], [1.73 (d, J=7.1 Hz) and 1.65 (d, J=7.0 Hz), total
3H].
Step 3. Synthesis of
N-{2-[(5R,6S)-3-amino-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-th-
iadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide
(10),
N-{2-[(5S,6R)-3-amino-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2H-1,
2,
4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-car-
boxamide (11),
N-{2-[(5S,6S)-3-amino-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-th-
iadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide
(12), and
N-{2-[(5R,6R)-3-amino-2,5,6-trimethyl-1,1-dioxido-5,6-dihydro-2-
H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-c-
arboxamide (13)
[0283] Conversion of C51 to a mixture of the products was carried
out according to the method described for conversion of C45 to a
mixture of 3, 4 and 5 in Examples 3, 4, and 5. The product mixture
was isolated as a white solid (120 mg, 0.260 mmol, 73%); this
material was separated into its component isomers via supercritical
fluid chromatography [Column: Phenomenex Lux Cellulose-2, 5 .mu.m;
Mobile phase: 3:1 carbon dioxide/(1:1 acetonitrile/methanol)]. Each
isomer was then subjected individually to chromatography on silica
gel (Gradient: 0% to 10% methanol in dichloromethane) to afford the
four products, each as a white solid.
[0284] The first-eluting isomer from the supercritical fluid
chromatography provided 10. Yield: 13.5 mg, 29.3 .mu.mol, 8%. LCMS
m/z 461.3 [M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
10.38 (br s, 1H), 8.48 (dd, J=2.6, 0.6 Hz, 1H), 8.31 (dd, J=8.6,
0.6 Hz, 1H), 7.71 (s, 1H), 7.67 (br dd, J=8.6, 2.7 Hz, 1H), 6.65
(t, J.sub.HF=72.0 Hz, 1H), 3.93 (q, J=7.1 Hz, 1H), 3.29 (s, 3H),
1.72 (s, 3H), 1.68 (d, J=7.0 Hz, 3H).
[0285] The second-eluting isomer from the supercritical fluid
chromatography provided 11. Yield: 39.5 mg, 85.8 .mu.mol, 24%. LCMS
m/z 461.3 [M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
10.38 (br s, 1H), 8.48 (br d, J=2.6 Hz, 1H), 8.31 (dd, J=8.6, 0.6
Hz, 1H), 7.71 (s, 1H), 7.67 (br dd, J=8.6, 2.6 Hz, 1H), 6.65 (t,
J.sub.HF=72.0 Hz, 1H), 3.93 (q, J=7.0 Hz, 1H), 3.29 (s, 3H), 1.72
(s, 3H), 1.68 (d, J=7.0 Hz, 3H).
[0286] The third-eluting isomer from the supercritical fluid
chromatography provided 12. Yield: 12.5 mg, 27.1 .mu.mol, 8%. LCMS
m/z 461.3 [M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
10.39 (br s, 1H), 8.49 (dd, J=2.7, 0.5 Hz, 1H), 8.31 (dd, J=8.6,
0.6 Hz, 1H), 7.69 (s, 1H), 7.68 (ddt, J=8.6, 2.6, 0.7 Hz, 1H), 6.65
(t, J.sub.HF=71.9 Hz, 1H), 3.83 (q, J=7.0 Hz, 1H), 3.29 (s, 3H),
1.88 (s, 3H), 1.25 (d, J=7.0 Hz, 3H).
[0287] The fourth-eluting isomer from the supercritical fluid
chromatography provided 13. Yield: 7.7 mg, 16.7 .mu.mol, 5%. LCMS
m/z 461.3 [M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
10.39 (br s, 1H), 8.49 (dd, J=2.7, 0.5 Hz, 1H), 8.32 (dd, J=8.6,
0.6 Hz, 1H), 7.71 (s, 1H), 7.68 (br dd, J=8.6, 2.7 Hz, 1H), 6.66
(t, J.sub.HF=72.0 Hz, 1H), 3.84 (q, J=7.0 Hz, 1H), 3.31 (s, 3H),
1.90 (s, 3H), 1.31 (d, J=7.0 Hz, 3H).
[0288] The indicated relative and absolute stereochemistries were
assigned on the basis of NMR work and biological activity. From the
.sup.1H NMR spectra, 10 and 11 are enantiomers of one another; 12
and 13 are also enantiomers of one another. NOE studies revealed
that irradiation of the methine adjacent to the sulfonyl group
results in an enhancement of the quaternary methyl group signal for
both 12 and 13, but similar irradiation has no effect on the
quaternary methyl group resonance in 10 and 11. This established
the relative stereochemistry of the vicinal methyl groups.
Examination of the biological activity of these four compounds (see
Table 7) allowed assignment of the absolute stereochemistry, in
accordance with Examples 3 and 4.
Examples 14, 15, 16, and 17
N-{2-[(5R,6S)-3-Amino-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,-
4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carboxa-
mide (14),
N-{2-[(5S,6R)-3-Amino-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihy-
dro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridin-
e-2-carboxamide (15),
N-{2-[(5R,6R)-3-Amino-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2-
,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carbox-
amide (16), and
N-{2-[(5S,6S)-3-Amino-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2-
,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carbox-
amide (17)
##STR00025##
[0289] Step 1. Synthesis of
N-[5-(4-amino-1,3-thiazol-2-yl)-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihy-
dro-2H-1,2,4-thiadiazin-3-yl]benzamide (C53)
[0290] Trifluoroacetic acid (0.38 mL, 4.9 mmol) was added in a
drop-wise manner to a 0.degree. C. solution of C52
[N-(5-{4-[(2,4-dimethoxybenzyl)amino]-1,3-thiazol-2-yl}-6-ethyl-2,5-dimet-
hyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-3-yl)benzamide;
this material was prepared in analogous fashion to P3, by utilizing
propane-1-sulfonyl chloride in place of cyclopropylmethanesulfonyl
chloride] (140 mg, 0.251 mmol) in dichloromethane (4 mL) The
reaction mixture was stirred at 0.degree. C. for 1 hour. Analysis
of the reaction mixture by LCMS at the end of the reaction
indicated a major peak consistent with the molecular weight of the
product: LCMS m/z 408.3 [M+H].sup.+. The reaction mixture was
diluted with additional dichloromethane and saturated aqueous
sodium bicarbonate solution. The aqueous layer was extracted twice
with dichloromethane, and the combined organic layers were dried
over sodium sulfate, filtered, and concentrated under reduced
pressure to provide the product as an orange solid (100 mg). This
material was used directly in the following step.
Step 2. Synthesis of
N-{2-[3-(benzoylamino)-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,-
2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carbo-
xamide (C54)
[0291] Reaction of C53 (from the previous step; 100 mg, 50.245
mmol) with P6 to provide the product was effected using the method
described for synthesis of C43 from P2 in Example 2. In this case,
no chromatographic purification was carried out; the product was
isolated as a yellow solid (130 mg), which was used directly in the
following step.
Step 3. Synthesis of
N-{2-[(5R,6S)-3-amino-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2-
,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carbox-
amide (14),
N-{2-[(5S,6R)-3-amino-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2-
,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carbox-
amide (15),
N-{2-[(5R,6R)-3-amino-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2-
,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carbox-
amide (16), and
N-{2-[(5S,6S)-3-amino-6-ethyl-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2-
,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carbox-
amide (17)
[0292] 1,8-Diazabicyclo[5.4.0]undec-7-ene (33.9 .mu.L, 0.227 mmol)
was added to a solution of C54 (130 mg, 50.225 mmol) in methanol
(2.2 mL). The reaction mixture was heated to 60.degree. C. for 16
hours, whereupon it was concentrated under reduced pressure. The
residue was dissolved in dichloromethane (10 mL) and adsorbed on
silica gel; chromatography on silica gel (Gradient: 20% to 100%
ethyl acetate in heptane) provided a mixture of the products (45
mg, 95 .mu.mol, 38% over 3 steps). This material was separated into
its four component isomers using supercritical fluid chromatography
[Column: Phenomenex Lux Cellulose-2, 5 .mu.m; Mobile phase: 45:55
carbon dioxide/(methanol containing 0.2% ammonium hydroxide)]. In
order of elution:
[0293] 14: Yield: 6.2 mg, 14% for the separation. LCMS m/z 475.3
[M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.41 (br s,
1H), 8.50 (dd, J=2.7, 0.5 Hz, 1H), 8.32 (dd, J=8.6, 0.5 Hz, 1H),
7.79 (s, 1H), 7.68 (br dd, J=8.6, 2.6 Hz, 1H), 6.66 (t,
J.sub.HF=71.9 Hz, 1H), 3.83-3.76 (m, 1H), 3.33 (s, 3H), 2.23-2.12
(m, 2H), 1.83 (s, 3H), 1.17 (t, J=7.5 Hz, 3H).
[0294] 15: Yield: 17.5 mg, 39% for the separation. LCMS m/z 475.3
[M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.40 (br s,
1H), 8.50 (d, J=2.3 Hz, 1H), 8.32 (d, J=8.6 Hz, 1H), 7.78 (s, 1H),
7.68 (br dd, J=8.6, 2.6 Hz, 1H), 6.66 (t, J.sub.HF=71.9 Hz, 1H),
3.78-3.71 (m, 1H), 3.32 (s, 3H), 2.28-2.11 (m, 2H), 1.81 (s, 3H),
1.17 (t, J=7.4 Hz, 3H).
[0295] 16: Yield: 1.2 mg, 3% for the separation. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 10.39 (br s, 1H), 8.50 (dd, J=2.7, 0.5 Hz,
1H), 8.32 (dd, J=8.6, 0.6 Hz, 1H), 7.74 (s, 1H), 7.68 (br dd,
J=8.6, 2.7 Hz, 1H), 6.66 (t, J.sub.HF=71.9 Hz, 1H), 3.63 (dd,
J=7.7, 3.2 Hz, 1H), 3.31 (s, 3H), 2.02-1.9 (m, 2H), 1.89 (s, 3H),
1.12 (t, J=7.5 Hz, 3H).
[0296] 17: Yield: 9.4 mg, 21% for the separation. LCMS m/z 475.3
[M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.39 (br s,
1H), 8.50 (br d, J=2.5 Hz, 1H), 8.32 (dd, J=8.6, 0.5 Hz, 1H), 7.75
(s, 1H), 7.68 (br dd, J=8.7, 2.7 Hz, 1H), 6.66 (t, J.sub.HF=71.9
Hz, 1H), 3.62 (dd, J=7.8, 3.4 Hz, 1H), 3.30 (s, 3H), 2.09-1.9 (m,
2H), 1.89 (s, 3H), 1.14 (t, J=7.3 Hz, 3H).
[0297] The indicated relative and absolute stereochemistries were
assigned on the basis of NMR work and biological activity. From the
.sup.1H NMR spectra, 14 and 15 are enantiomers of one another; 16
and 17 are also enantiomers of one another. NOE studies revealed
that irradiation of the methine adjacent to the sulfonyl group
results in an enhancement of the quaternary methyl group signal for
both 16 and 17, but has no effect on that resonance in 15. This
established the relative stereochemistry of the vicinal methyl and
ethyl groups. Examination of the biological activity of these four
compounds (see Table 7) allowed assignment of the absolute
stereochemistries, in accordance with Examples 3 and 4.
TABLE-US-00006 TABLE 6 Method of Preparation, Structure, and
Physicochemical Properties for Examples 18-28. Method of
Preparation; .sup.1H NMR (400 MHz, CHCl.sub.3) .delta.; Example
Non-commercial Mass spectrum, observed ion m/z number starting
materials Structure [M + H].sup.+ (unless otherwise indicated) 18
Example 2; P2 ##STR00026## 10.26 (br s, 1H), 9.43 (s, 1H), 8.78 (s,
1H), 7.75 (s, 1H), 5.67 (d, JHF = 46.4 Hz, 2H), 4.13 (d, J = 13.7
Hz, 1H), 3.69 (d, J = 13.7 Hz, 1H), 3.30 (s, 3H), 1.80 (s, 3H);
414.1 19 Example 2; P2 ##STR00027## 9.50 (s, 1H), 8.94 (s, 1H),
7.76 (s, 1H), 6.79 (t, J.sub.HF = 54.4 Hz, 1H), 4.15 (d, J = 13.7
Hz, 1H), 3.66 (br d, J = 13.7 Hz, 1H), 3.28-3.23 (m, 3H), 1.79 (br
s, 3H); 432.1 20 Example 2; P2 ##STR00028## 10.40 (br s, 1H), 8.59
(d, J = 2.0 Hz, 1H), 8.23 (d, J = 8.6 Hz, 1H), 7.89 (dd, J = 8.2,
2.3 Hz, 1H), 7.72 (s, 1H), 4.13 (d, J = 14.0 Hz, 1H), 3.70 (d, J =
13.7 Hz, 1H), 3.30 (s, 3H), 1.81 (s, 3H); 415.0 (chlorine isotope
pattern observed) 21 Example 2; P2, P9 ##STR00029## By .sup.1H NMR
analysis, judged to be a mixture of rotamers; [9.40 (br s) and 9.37
(br s), total 1H], [8.37 (d, J = 1.3 Hz) and 8.36 (d, J = 1.4 Hz),
total 1H], [7.72 (br s) and 7.69- 7.66 (m), total 1H], 5.44 (d,
J.sub.HF = 47.1 Hz, 2H), 4.27-4.16 (m, 1H), 3.76 (br d, J = 14 Hz,
1H), 3.35 (s, 3H), [1.95 (br s) and 1.85 (s), total 3H]; 403.1 22
Example 1.sup.1,2; P1 ##STR00030## 10.11 (br s, 1H), 9.00 (d, J =
1.3 Hz, 1H), 8.29 (d, J = 1.3 Hz, 1H), 7.72 (s, 1H), 4.62 (t,
J.sub.HF = 11.9 Hz, 2H), 4.16 (d, J = 13.8 Hz, 1H), 3.72 (d, J =
13.8 Hz, 1H), 3.32 (s, 3H), 1.83 (s, 3H), 1.79 (t, J.sub.HF = 18.6
Hz, 3H); 476.1 23 Example 1.sup.3,2; P1 ##STR00031## By .sup.1H NMR
analysis, judged to be a mixture of rotamers; [10.14 (br s) and
10.10 (br s), total 1H], 9.02 (s, 1H), 8.23 (s, 1H), [7.78 (br s)
and 7.70-7.68 (m), total 1H], 5.08- 5.03 (m, 2H), 4.06 (br d, J =
14 Hz, 1H), 3.70-3.62 (m, 1H), [3.35 (br s) and 3.29-3.26 (m),
total 3H], [1.96 (br s) and 1.78 (br s), total 3H], 1.92-1.88 (m,
3H); 450.1 24 Example 1.sup.2; P1, P10 ##STR00032## This is likely
a mixture of rotamers. Only peaks for the predominant rotamer were
tabulated: 10.41 (br s, 1H), 8.34 (d, J = 2.7 Hz, 1H), 8.22 (d, J =
8.6 Hz, 1H), 7.70 (s, 1H), 7.44 (dd, J = 8.7, 2.8 Hz, 1H),
4.81-4.77 (m, 2H), 4.14 (d, J = 13.8 Hz, 1H), 3.73 (d, J = 13.8 Hz,
1H), 3.31 (s, 3H), 1.88 (t, J = 2.1 Hz, 3H), 1.83 (s, 3H); 449.2 25
Example 2; P2, P8 ##STR00033## 10.35 (br s, 1H), 8.45-8.41 (m, 1H),
7.72 (s, 1H), 7.71-7.67 (m, 1H), 6.67 (t, J.sub.HF = 71.3 Hz, 1H),
4.00 (d, J = 13.6 Hz, 1H), 3.65 (d, J = 13.7 Hz, 1H), 3.26 (s, 3H),
1.75 (s, 3H); 481.0 26 Example 1; P1 ##STR00034## 10.43 (br s, 1H),
8.92 (br d, J = 1 Hz, 1H), 8.41 (br d, half of AB quartet, J = 8.2
Hz, 1H), 8.21 (dd, J = 8.2, 2.0 Hz, 1H), 7.73 (s, 1H), 4.05 (d, J =
13.7 Hz, 1H), 3.63 (d, J = 13.7 Hz, 1H), 3.26 (s, 3H), 1.75 (s,
3H); 406.0 27 Example 1; P1 ##STR00035## 10.58 (br s, 1H),
8.76-8.73 (m, 1H), 7.97-7.94 (m, 1H), 7.69 (s, 1H), 4.46-4.12 (br
s, 2H), 4.04 (d, J = 13.7 Hz, 1H), 3.63 (d, J = 13.7 Hz, 1H), 3.26
(s, 3H), 2.87 (br s, 3H), 1.75 (s, 3H); LCMS m/z 442.0 [M +
Na.sup.+] 28 Example 1; P1 ##STR00036## 10.33 (br s, 1H), 8.80 (d,
J = 1.6 Hz, 1H), 8.18 (d, J = 1.8 Hz, 1H), 7.74 (s, 1H), 4.03 (d, J
= 13.6 Hz, 1H), 3.62 (d, J = 13.7 Hz, 1H), 3.26 (s, 3H), 1.74 (s,
3H); 439.9 (chlorine isotope pattern observed) 29 ##STR00037## 30
##STR00038## 31 ##STR00039## 32 ##STR00040## 33 ##STR00041##
.sup.1Methyl 5-chloropyrazine-2-carboxylate was reacted with cesium
carbonate and 2,2-difluoropropan-1-ol to provide methyl
5-(2,2-difluoropropoxy)pyrazine-2-carboxylate; ester hydrolysis was
effected with lithium hydroxide to afford the requisite
5-(2,2-difluoropropoxy)pyrazine-2-carboxylic acid. .sup.2In this
case, 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane
2,4,6-trioxide was used in place of
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate. .sup.3.Reaction of methyl
5-chloropyrazine-2-carboxylate with but-2-yn-1-ol and potassium
tert-butoxide, followed by ester hydrolysis with lithium hydroxide,
afforded the requisite 5-(but-2-yn-1-yloxy)pyrazine-2-carboxylic
acid.
BIOLOGICAL ASSAYS
[0298] BACE1 Cell-Free Assay:
[0299] Beta-secretase (BACE) is one of the enzymes involved in the
generation of the amyloid beta peptide found in the amyloid plaques
of Alzheimer's disease patients. This assay measures the inhibition
of the beta-secretase enzyme as it cleaves a non-native
peptide.
[0300] A synthetic APP substrate that can be cleaved by
beta-secretase having N-terminal biotin and made fluorescent by the
covalent attachment of Oregon Green at the Cys residue is used to
assay beta-secretase activity in the presence or absence of the
inhibitory compounds. The substrate is Biotin-GLTNIKTEEISEISY
EVEFR-C[Oregon Green]KK-OH. The BACE1 enzyme is affinity purified
material from conditioned media of CHO-K1 cells that have been
transfected with a soluble BACE construct (BACE1deltaTM96His).
Compounds are incubated in a 1/2 log dose response curve from a top
concentration of 100 .mu.M with BACE1 enzyme and the biotinylated
fluorescent peptide in 384-well black plates (Thermo Scientific
#4318). BACE1 is at a final concentration of 0.1 nM with a final
concentration of peptide substrate of 150 nM in a reaction volume
of 30 .mu.L assay buffer [100 mM sodium acetate, pH 4.5 (brought to
pH with acetic acid), and 0.001% Tween-20]. Plates are covered and
incubated for 3 hours at 37.degree. C. The reaction is stopped with
the addition of 30 .mu.L of 1.5 .mu.M Streptavidin (Pierce,
#21125). After a 10 minute incubation at room temperature, plates
are read on a PerkinElmer EnVision for fluorescence polarization
(Ex485 nm/Em530 nm). The activity of the beta-secretase enzyme is
detected by changes in the fluorescence polarization that occur
when the substrate is cleaved by the enzyme. Incubation in the
presence of compound inhibitor demonstrates specific inhibition of
beta-secretase enzymatic cleavage of the synthetic APP
substrate.
TABLE-US-00007 TABLE 7 Biological activity and IUPAC name for
Examples 1-28 BACE1 Cell-free Example Assay IC.sub.50 number
(.mu.M).sup.a IUPAC Name 1 0.060.sup.b
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-
dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-
5-(difluoromethoxy)pyridine-2-carboxamide 2 0.019
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-
dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-
1-(difluoromethyl)-1H-pyrazole-3-carboxamide 3 31.2
N-{2-[(5R,6S)-3-amino-6-cyclopropyl-2,5-dimethyl-
1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl]-
1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2- carboxamide 4
0.103 N-{2-[(5S,6R)-3-amino-6-cyclopropyl-2,5-dimethyl-
1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl]-
1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2- carboxamide 5
0.051 N-{2-[(5S,6S)-3-amino-6-cyclopropyl-2,5-dimethyl-
1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl]-
1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2- carboxamide 6
0.185.sup.c N-[2-(3-amino-2,5,6,6-tetramethyl-1,1-dioxido-5,6-
dihydro-2H-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]-
5-(difluoromethoxy)pyridine-2-carboxamide 7 4.40
N-{2-[(5R)-3-amino-2,5,6,6-tetramethyl-1,1-dioxido-
5,6-dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-
yl}-5-(difluoromethoxy)pyridine-2-carboxamide 8 0.078
N-{2-[(5S)-3-amino-2,5,6,6-tetramethyl-1,1-dioxido-
5,6-dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-
yl}-5-(difluoromethoxy)pyridine-2-carboxamide 9 0.029.sup.b
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-
dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-
5-(difluoromethoxy)-3-methylpyridine-2-carboxamide, methanesulfonic
acid salt 10 18.0
N-{2-[(5R,6S)-3-amino-2,5,6-trimethyl-1,1-dioxido-
5,6-dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-
yl}-5-(difluoromethoxy)pyridine-2-carboxamide 11 0.136
N-{2-[(5S,6R)-3-amino-2,5,6-trimethyl-1,1-dioxido-
5,6-dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-
yl}-5-(difluoromethoxy)pyridine-2-carboxamide 12 0.088
N-{2-[(5S,6S)-3-amino-2,5,6-trimethyl-1,1-dioxido-
5,6-dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-
yl}-5-(difluoromethoxy)pyridine-2-carboxamide 13 33.8
N-{2-[(5R,6R)-3-amino-2,5,6-trimethyl-1,1-dioxido-
5,6-dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-
yl}-5-(difluoromethoxy)pyridine-2-carboxamide 14 14.2
N-{2-[(5R,6S)-3-amino-6-ethyl-2,5-dimethyl-1,1-
dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-
thiazol-4-yl}-5-(difluoromethoxy)pyridine-2- carboxamide 15 0.371
N-{2-[(5S,6R)-3-amino-6-ethyl-2,5-dimethyl-1,1-
dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-
thiazol-4-yl}-5-(difluoromethoxy)pyridine-2- carboxamide 16
3.92.sup.c N-{2-[(5R,6R)-3-amino-6-ethyl-2,5-dimethyl-1,1-
dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-
thiazol-4-yl}-5-(difluoromethoxy)pyridine-2- carboxamide 17 0.200
N-{2-[(5S,6S)-3-amino-6-ethyl-2,5-dimethyl-1,1-
dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-
thiazol-4-yl}-5-(difluoromethoxy)pyridine-2- carboxamide 18 0.246
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-
dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-
5-(fluoromethyl)pyrazine-2-carboxamide 19 0.172
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-
dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-
5-(difluoromethyl)pyrazine-2-carboxamide 20 0.042
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-
dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-
5-chloropyridine-2-carboxamide 21 0.011
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-
dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-
2-(fluoromethyl)-1,3-oxazole-4-carboxamide 22 0.134
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-
dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-
5-(2,2-difluoropropoxy)pyrazine-2-carboxamide 23 0.013
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-
dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-
5-(but-2-yn-1-yloxy)pyrazine-2-carboxamide 24 0.013
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-
dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-
5-(but-2-yn-1-yloxy)pyridine-2-carboxamide 25 0.023
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-
dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-
3-chloro-5-(difluoromethoxy)pyridine-2-carboxamide 26 0.045.sup.c
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-
dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-
5-cyanopyridine-2-carboxamide 27 0.009
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-
dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-
5-cyano-3-methylpyridine-2-carboxamide 28 N.D..sup.d
N-{2-[(5S)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-
dihydro-2H-1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-
3-chloro-5-cyanopyridine-2-carboxamide 29
N-(2-{(5S,6R)-3-amino-6-[(1R)-2,2-
dimethylcyclopropyl]-2,5-dimethyl-1,1-dioxido-5,6-
dihydro-2H-1,2,4-thiadiazin-5-yl}-1,3-thiazol-4-yl)-5-
(difluoromethoxy)-3-methylpyridine-2-carboxamide 30
N-{2-[(5S,6R)-3-amino-2,5-dimethyl-6-(1-
methylcyclopropyl)-1,1-dioxido-5,6-dihydro-2H-
1,2,4-thiadiazin-5-yl]-1,3-thiazol-4-yl}-5-
(difluoromethoxy)pyridine-2-carboxamide 31
N-{2-[(8S)-6-amino-5,8-dimethyl-4,4-dioxido-4-thia-
5,7-diazaspiro[2.5]oct-6-en-8-yl]-1,3-thiazol-4-
yl}-5-(difluoromethoxy) pyridine-2-carboxamide 32
N-{2-[(9S)-7-amino-6,9-dimethyl-5,5-dioxido-5-thia-
6,8-diazaspiro[3.5]non-7-en-9-yl]-1,3-thiazol-4-
yl}-5-(difluoromethoxy) pyridine-2-carboxamide 33
N-{2-[(10S)-8-amino-7,10-dimethyl-6,6-dioxido-6-
thia-7,9-diazaspiro[4.5]dec-8-en-10-yl]-1,3-thiazol-
4-yl}-5-(difluoromethoxy)pyridine-2-carboxamide .sup.aReported
IC.sub.50 values are the geometric mean of 2-4 determinations,
unless otherwise indicated. .sup.bThe reported IC.sub.50 value is
the geometric mean of .gtoreq.5 determinations. .sup.cThe IC.sub.50
value is from a single determination. .sup.dNot determined
* * * * *